{
  "symbol": "BIIB",
  "frequency": "annual",
  "timestamp": "2025-09-19T15:18:57.574311",
  "data": {
    "cik": "875045",
    "data": [
      {
        "accessNumber": "0000875045-25-000009",
        "symbol": "BIIB",
        "cik": "875045",
        "year": 2024,
        "quarter": 0,
        "form": "10-K",
        "startDate": "2024-01-01 00:00:00",
        "endDate": "2024-12-31 00:00:00",
        "filedDate": "2025-02-12 00:00:00",
        "acceptedDate": "2025-02-12 17:28:51",
        "report": {
          "bs": [
            {
              "concept": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
              "unit": "usd",
              "label": "Cash and cash equivalents",
              "value": 2375000000.0
            },
            {
              "concept": "us-gaap_AccountsReceivableNetCurrent",
              "unit": "usd",
              "label": "Accounts receivable, net of allowance for doubtful accounts of $2.2 and $2.4, respectively",
              "value": 1404800000
            },
            {
              "concept": "biib_DueFromUnconsolidatedJointBusiness",
              "unit": "usd",
              "label": "Due from anti-CD20 therapeutic programs",
              "value": 464000000
            },
            {
              "concept": "us-gaap_InventoryNet",
              "unit": "usd",
              "label": "Inventory",
              "value": 2460500000.0
            },
            {
              "concept": "us-gaap_OtherAssetsCurrent",
              "unit": "usd",
              "label": "Other current assets",
              "value": 752500000
            },
            {
              "concept": "us-gaap_AssetsCurrent",
              "unit": "usd",
              "label": "Total current assets",
              "value": 7456800000
            },
            {
              "concept": "us-gaap_PropertyPlantAndEquipmentNet",
              "unit": "usd",
              "label": "Property, plant and equipment, net",
              "value": 3181300000.0
            },
            {
              "concept": "us-gaap_OperatingLeaseRightOfUseAsset",
              "unit": "usd",
              "label": "Operating lease assets",
              "value": 356400000.0
            },
            {
              "concept": "us-gaap_IntangibleAssetsNetExcludingGoodwill",
              "unit": "usd",
              "label": "Intangible assets, net",
              "value": 9691200000.0
            },
            {
              "concept": "us-gaap_Goodwill",
              "unit": "usd",
              "label": "Goodwill",
              "value": 6478900000.0
            },
            {
              "concept": "us-gaap_DeferredIncomeTaxAssetsNet",
              "unit": "usd",
              "label": "Deferred tax asset",
              "value": 324200000
            },
            {
              "concept": "us-gaap_OtherAssetsNoncurrent",
              "unit": "usd",
              "label": "Investments and other assets",
              "value": 560500000
            },
            {
              "concept": "us-gaap_Assets",
              "unit": "usd",
              "label": "Total assets",
              "value": 28049300000
            },
            {
              "concept": "us-gaap_DebtCurrent",
              "unit": "usd",
              "label": "Current portion of notes payable and term loan",
              "value": 1748600000
            },
            {
              "concept": "us-gaap_TaxesPayableCurrent",
              "unit": "usd",
              "label": "Taxes payable",
              "value": 548300000
            },
            {
              "concept": "us-gaap_AccountsPayableCurrent",
              "unit": "usd",
              "label": "Accounts payable",
              "value": 424200000
            },
            {
              "concept": "us-gaap_OtherLiabilitiesCurrent",
              "unit": "usd",
              "label": "Accrued expense and other",
              "value": 2807700000.0
            },
            {
              "concept": "us-gaap_LiabilitiesCurrent",
              "unit": "usd",
              "label": "Total current liabilities",
              "value": 5528800000
            },
            {
              "concept": "us-gaap_LongTermNotesPayable",
              "unit": "usd",
              "label": "Notes payable and term loan",
              "value": 4547200000
            },
            {
              "concept": "us-gaap_DeferredIncomeTaxLiabilitiesNet",
              "unit": "usd",
              "label": "Deferred tax liability",
              "value": 190500000
            },
            {
              "concept": "us-gaap_OperatingLeaseLiabilityNoncurrent",
              "unit": "usd",
              "label": "Long-term operating lease liabilities",
              "value": 334500000.0
            },
            {
              "concept": "us-gaap_OtherLiabilitiesNoncurrent",
              "unit": "usd",
              "label": "Other long-term liabilities",
              "value": 732300000.0
            },
            {
              "concept": "us-gaap_Liabilities",
              "unit": "usd",
              "label": "Total liabilities",
              "value": 11333300000
            },
            {
              "concept": "us-gaap_PreferredStockValueOutstanding",
              "unit": "usd",
              "label": "Preferred stock, par value $0.001 per share",
              "value": 0
            },
            {
              "concept": "us-gaap_CommonStockValueOutstanding",
              "unit": "usd",
              "label": "Common stock, par value $0.0005 per share",
              "value": 100000
            },
            {
              "concept": "us-gaap_AdditionalPaidInCapital",
              "unit": "usd",
              "label": "Additional paid-in capital",
              "value": 569400000
            },
            {
              "concept": "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax",
              "unit": "usd",
              "label": "Accumulated other comprehensive income (loss)",
              "value": -136200000
            },
            {
              "concept": "us-gaap_RetainedEarningsAccumulatedDeficit",
              "unit": "usd",
              "label": "Retained earnings",
              "value": 19259800000
            },
            {
              "concept": "us-gaap_TreasuryStockValue",
              "unit": "usd",
              "label": "Treasury stock, at cost; 23.8 million and 23.8 million shares, respectively",
              "value": 2977100000
            },
            {
              "concept": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
              "unit": "usd",
              "label": "Total equity",
              "value": 16716000000.0
            },
            {
              "concept": "us-gaap_LiabilitiesAndStockholdersEquity",
              "unit": "usd",
              "label": "Total liabilities and equity",
              "value": 28049300000
            }
          ],
          "ic": [
            {
              "concept": "us-gaap_Revenues",
              "unit": "usd",
              "label": "Revenues",
              "value": 9675900000.0
            },
            {
              "concept": "us-gaap_CostOfGoodsAndServicesSold",
              "unit": "usd",
              "label": "Cost of sales, excluding amortization and impairment of acquired intangible assets",
              "value": 2310400000
            },
            {
              "concept": "us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
              "unit": "usd",
              "label": "Research and development",
              "value": 2041800000
            },
            {
              "concept": "us-gaap_SellingGeneralAndAdministrativeExpense",
              "unit": "usd",
              "label": "Selling, general and administrative",
              "value": 2403700000
            },
            {
              "concept": "biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets",
              "unit": "usd",
              "label": "Amortization and impairment of acquired intangible assets",
              "value": 446700000.0
            },
            {
              "concept": "biib_CollaborationProfitLossSharing",
              "unit": "usd",
              "label": "Collaboration profit sharing/(loss reimbursement)",
              "value": 254400000
            },
            {
              "concept": "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings",
              "unit": "usd",
              "label": "(Gain) loss on fair value remeasurement of contingent consideration",
              "value": -27700000.0
            },
            {
              "concept": "us-gaap_RestructuringCharges",
              "unit": "usd",
              "label": "Restructuring charges",
              "value": 30200000
            },
            {
              "concept": "us-gaap_GainLossOnDispositionOfIntangibleAssets",
              "unit": "usd",
              "label": "Gain on sale of priority review voucher, net",
              "value": 88600000.0
            },
            {
              "concept": "us-gaap_GainLossOnSaleOfPropertyPlantEquipment",
              "unit": "usd",
              "label": "Gain on sale of building, net",
              "value": 0.0
            },
            {
              "concept": "us-gaap_NonoperatingIncomeExpense",
              "unit": "usd",
              "label": "Other (income) expense, net",
              "value": -343600000.0
            },
            {
              "concept": "us-gaap_CostsAndExpenses",
              "unit": "usd",
              "label": "Total cost and expense",
              "value": 7769900000
            },
            {
              "concept": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
              "unit": "usd",
              "label": "Income before income tax (benefit) expense and equity in (income) loss of investee, net of tax",
              "value": 1906000000.0
            },
            {
              "concept": "us-gaap_IncomeTaxExpenseBenefit",
              "unit": "usd",
              "label": "Income tax (benefit) expense",
              "value": 273800000.0
            },
            {
              "concept": "biib_IncomeLossFromEquityMethodInvestmentsNetOfTax",
              "unit": "usd",
              "label": "Equity in (income) loss of investee, net of tax",
              "value": 0
            },
            {
              "concept": "us-gaap_ProfitLoss",
              "unit": "usd",
              "label": "Net income",
              "value": 1632200000.0
            },
            {
              "concept": "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest",
              "unit": "usd",
              "label": "Net income (loss) attributable to noncontrolling interests, net of tax",
              "value": 0
            },
            {
              "concept": "us-gaap_NetIncomeLoss",
              "unit": "usd",
              "label": "Net income attributable to Biogen Inc.",
              "value": 1632200000.0
            },
            {
              "concept": "us-gaap_EarningsPerShareBasic",
              "unit": "usd/share",
              "label": "Basic earnings per share attributable to Biogen Inc. (in dollars per share)",
              "value": 11
            },
            {
              "concept": "us-gaap_EarningsPerShareDiluted",
              "unit": "usd/share",
              "label": "Diluted earnings per share attributable to Biogen Inc. (in dollars per share)",
              "value": 11
            },
            {
              "concept": "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic",
              "unit": "shares",
              "label": "Weighted-average number of common shares outstanding (in shares)",
              "value": 145600000.0
            },
            {
              "concept": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
              "unit": "shares",
              "label": "Diluted earnings per share attributable to Biogen Inc. (in shares)",
              "value": 145900000.0
            },
            {
              "concept": "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax",
              "unit": "usd",
              "label": "Unrealized gains (losses) on securities available for sale, net of tax",
              "value": 0
            },
            {
              "concept": "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent",
              "unit": "usd",
              "label": "Unrealized gains (losses) on cash flow hedges, net of tax",
              "value": 76600000
            },
            {
              "concept": "us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAfterAdjustmentsAndTax",
              "unit": "usd",
              "label": "Gains (losses) on net investment hedges, net of tax",
              "value": 0
            },
            {
              "concept": "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax",
              "unit": "usd",
              "label": "Unrealized gains (losses) on pension benefit obligation, net of tax",
              "value": 14000000
            },
            {
              "concept": "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
              "unit": "usd",
              "label": "Currency translation adjustments, net of tax",
              "value": -45100000
            },
            {
              "concept": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
              "unit": "usd",
              "label": "Total other comprehensive income (loss), net of tax",
              "value": 17500000
            },
            {
              "concept": "us-gaap_ComprehensiveIncomeNetOfTax",
              "unit": "usd",
              "label": "Comprehensive income (loss) attributable to Biogen Inc.",
              "value": 1649700000
            },
            {
              "concept": "us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest",
              "unit": "usd",
              "label": "Comprehensive income (loss) attributable to noncontrolling interests, net of tax",
              "value": 0
            },
            {
              "concept": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
              "unit": "usd",
              "label": "Comprehensive income (loss)",
              "value": 1649700000
            }
          ],
          "cf": [
            {
              "concept": "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings",
              "unit": "usd",
              "label": "(Gain) loss on fair value remeasurement of contingent consideration",
              "value": -27700000.0
            },
            {
              "concept": "us-gaap_GainLossOnDispositionOfIntangibleAssets",
              "unit": "usd",
              "label": "Gain on sale of priority review voucher, net",
              "value": 88600000.0
            },
            {
              "concept": "us-gaap_GainLossOnSaleOfPropertyPlantEquipment",
              "unit": "usd",
              "label": "Gain on sale of building, net",
              "value": 0.0
            },
            {
              "concept": "us-gaap_ProfitLoss",
              "unit": "usd",
              "label": "Net income",
              "value": 1632200000.0
            },
            {
              "concept": "us-gaap_DepreciationDepletionAndAmortization",
              "unit": "usd",
              "label": "Depreciation and amortization",
              "value": 673200000
            },
            {
              "concept": "us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill",
              "unit": "usd",
              "label": "Impairment of intangible assets",
              "value": 60200000
            },
            {
              "concept": "us-gaap_InventoryWriteDown",
              "unit": "usd",
              "label": "Excess and obsolescence charges related to inventory",
              "value": 101900000.0
            },
            {
              "concept": "biib_AmortizationOfInventoryStepUp",
              "unit": "usd",
              "label": "Amortization of acquired inventory step-up",
              "value": 230000000
            },
            {
              "concept": "us-gaap_ShareBasedCompensation",
              "unit": "usd",
              "label": "Share-based compensation",
              "value": 291200000
            },
            {
              "concept": "us-gaap_DeferredIncomeTaxExpenseBenefit",
              "unit": "usd",
              "label": "Deferred income taxes",
              "value": -158100000.0
            },
            {
              "concept": "us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi",
              "unit": "usd",
              "label": "(Gain) loss on strategic investments",
              "value": -101400000
            },
            {
              "concept": "us-gaap_IncomeLossFromEquityMethodInvestments",
              "unit": "usd",
              "label": "(Gain) loss on equity method investment",
              "value": 0
            },
            {
              "concept": "us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal",
              "unit": "usd",
              "label": "Gain on sale of equity interest in Samsung Bioepis",
              "value": 0.0
            },
            {
              "concept": "us-gaap_OtherNoncashIncomeExpense",
              "unit": "usd",
              "label": "Other",
              "value": -159600000
            },
            {
              "concept": "us-gaap_IncreaseDecreaseInAccountsReceivable",
              "unit": "usd",
              "label": "Accounts receivable",
              "value": -222300000
            },
            {
              "concept": "us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet",
              "unit": "usd",
              "label": "Due from anti-CD20 therapeutic programs",
              "value": 28100000
            },
            {
              "concept": "us-gaap_IncreaseDecreaseInInventories",
              "unit": "usd",
              "label": "Inventory",
              "value": 273800000
            },
            {
              "concept": "us-gaap_IncreaseDecreaseInAccruedLiabilities",
              "unit": "usd",
              "label": "Accrued expense and other current liabilities",
              "value": 24600000
            },
            {
              "concept": "us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable",
              "unit": "usd",
              "label": "Income tax assets and liabilities",
              "value": 78500000
            },
            {
              "concept": "us-gaap_IncreaseDecreaseInOtherOperatingLiabilities",
              "unit": "usd",
              "label": "Other changes in operating assets and liabilities, net",
              "value": -178700000
            },
            {
              "concept": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
              "unit": "usd",
              "label": "Net cash flow provided by (used in) operating activities",
              "value": 2875500000
            },
            {
              "concept": "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment",
              "unit": "usd",
              "label": "Purchases of property, plant and equipment",
              "value": 153700000
            },
            {
              "concept": "us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities",
              "unit": "usd",
              "label": "Proceeds from sales and maturities of marketable securities",
              "value": 0
            },
            {
              "concept": "us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt",
              "unit": "usd",
              "label": "Purchases of marketable securities",
              "value": 0
            },
            {
              "concept": "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired",
              "unit": "usd",
              "label": "Acquisition, net of cash acquired",
              "value": 1074800000
            },
            {
              "concept": "us-gaap_ProceedsFromDivestitureOfInterestInConsolidatedSubsidiaries",
              "unit": "usd",
              "label": "Proceeds from sale of equity interest in Samsung Bioepis",
              "value": 406800000
            },
            {
              "concept": "us-gaap_PaymentsToAcquireBusinessTwoNetOfCashAcquired",
              "unit": "usd",
              "label": "Proceeds from sale of building",
              "value": 0
            },
            {
              "concept": "us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment",
              "unit": "usd",
              "label": "Proceeds from sale of priority review voucher, net",
              "value": 88600000
            },
            {
              "concept": "us-gaap_PaymentsToAcquireIntangibleAssets",
              "unit": "usd",
              "label": "Acquisitions of intangible assets",
              "value": 206100000
            },
            {
              "concept": "us-gaap_ProceedsFromSaleOfEquityMethodInvestments",
              "unit": "usd",
              "label": "Proceeds from sales of strategic investments",
              "value": 144700000
            },
            {
              "concept": "us-gaap_PaymentsForProceedsFromOtherInvestingActivities",
              "unit": "usd",
              "label": "Other",
              "value": 4700000
            },
            {
              "concept": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
              "unit": "usd",
              "label": "Net cash flow provided by (used in) investing activities",
              "value": -799200000
            },
            {
              "concept": "us-gaap_PaymentsForRepurchaseOfCommonStock",
              "unit": "usd",
              "label": "Purchase of treasury stock",
              "value": 0
            },
            {
              "concept": "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation",
              "unit": "usd",
              "label": "Payments related to issuance of stock for share-based compensation arrangements, net",
              "value": 31300000
            },
            {
              "concept": "biib_RepaymentsOfDebtIncludingPremiumsPaid",
              "unit": "usd",
              "label": "Repayments of borrowings and premiums paid",
              "value": 650000000
            },
            {
              "concept": "us-gaap_ProceedsFromIssuanceOfLongTermDebt",
              "unit": "usd",
              "label": "Proceeds from borrowings",
              "value": 0
            },
            {
              "concept": "us-gaap_ProceedsFromPaymentsToMinorityShareholders",
              "unit": "usd",
              "label": "Net (distribution) contribution to noncontrolling interest",
              "value": 0
            },
            {
              "concept": "us-gaap_ProceedsFromPaymentsForOtherFinancingActivities",
              "unit": "usd",
              "label": "Other",
              "value": -2200000
            },
            {
              "concept": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
              "unit": "usd",
              "label": "Net cash flow provided by (used in) financing activities",
              "value": -683500000
            },
            {
              "concept": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
              "unit": "usd",
              "label": "Net increase (decrease) in cash and cash equivalents",
              "value": 1392800000
            },
            {
              "concept": "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
              "unit": "usd",
              "label": "Effect of exchange rate changes on cash and cash equivalents",
              "value": -67700000
            }
          ]
        }
      },
      {
        "accessNumber": "0000875045-24-000009",
        "symbol": "BIIB",
        "cik": "875045",
        "year": 2023,
        "quarter": 0,
        "form": "10-K",
        "startDate": "2023-01-01 00:00:00",
        "endDate": "2023-12-31 00:00:00",
        "filedDate": "2024-02-14 00:00:00",
        "acceptedDate": "2024-02-13 17:40:44",
        "report": {
          "bs": [
            {
              "concept": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
              "unit": "usd",
              "label": "Cash and cash equivalents",
              "value": 1049900000.0
            },
            {
              "concept": "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent",
              "unit": "usd",
              "label": "Marketable securities",
              "value": 0
            },
            {
              "concept": "us-gaap_AccountsReceivableNetCurrent",
              "unit": "usd",
              "label": "Accounts receivable, net of allowance for doubtful accounts of $2.4 and $2.3, respectively",
              "value": 1664100000
            },
            {
              "concept": "biib_DueFromUnconsolidatedJointBusiness",
              "unit": "usd",
              "label": "Due from anti-CD20 therapeutic programs",
              "value": 435900000
            },
            {
              "concept": "us-gaap_InventoryNet",
              "unit": "usd",
              "label": "Inventory",
              "value": 2527400000.0
            },
            {
              "concept": "us-gaap_OtherAssetsCurrent",
              "unit": "usd",
              "label": "Other current assets",
              "value": 1182000000
            },
            {
              "concept": "us-gaap_AssetsCurrent",
              "unit": "usd",
              "label": "Total current assets",
              "value": 6859300000
            },
            {
              "concept": "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent",
              "unit": "usd",
              "label": "Marketable securities",
              "value": 0
            },
            {
              "concept": "us-gaap_PropertyPlantAndEquipmentNet",
              "unit": "usd",
              "label": "Property, plant and equipment, net",
              "value": 3309700000.0
            },
            {
              "concept": "us-gaap_OperatingLeaseRightOfUseAsset",
              "unit": "usd",
              "label": "Operating lease assets",
              "value": 420000000.0
            },
            {
              "concept": "us-gaap_IntangibleAssetsNetExcludingGoodwill",
              "unit": "usd",
              "label": "Intangible assets, net",
              "value": 8363000000.0
            },
            {
              "concept": "us-gaap_Goodwill",
              "unit": "usd",
              "label": "Goodwill",
              "value": 6219200000.0
            },
            {
              "concept": "us-gaap_DeferredIncomeTaxAssetsNet",
              "unit": "usd",
              "label": "Deferred tax asset",
              "value": 928600000
            },
            {
              "concept": "us-gaap_OtherAssetsNoncurrent",
              "unit": "usd",
              "label": "Investments and other assets",
              "value": 745000000
            },
            {
              "concept": "us-gaap_Assets",
              "unit": "usd",
              "label": "Total assets",
              "value": 26844800000
            },
            {
              "concept": "us-gaap_DebtCurrent",
              "unit": "usd",
              "label": "Current portion of term loan",
              "value": 150000000
            },
            {
              "concept": "us-gaap_TaxesPayableCurrent",
              "unit": "usd",
              "label": "Taxes payable",
              "value": 257400000
            },
            {
              "concept": "us-gaap_AccountsPayableCurrent",
              "unit": "usd",
              "label": "Accounts payable",
              "value": 403300000
            },
            {
              "concept": "us-gaap_OtherLiabilitiesCurrent",
              "unit": "usd",
              "label": "Accrued expense and other",
              "value": 2623600000.0
            },
            {
              "concept": "us-gaap_LiabilitiesCurrent",
              "unit": "usd",
              "label": "Total current liabilities",
              "value": 3434300000
            },
            {
              "concept": "us-gaap_LongTermNotesPayable",
              "unit": "usd",
              "label": "Notes payable and term loan",
              "value": 6788200000
            },
            {
              "concept": "us-gaap_DeferredIncomeTaxLiabilitiesNet",
              "unit": "usd",
              "label": "Deferred tax liability",
              "value": 641800000
            },
            {
              "concept": "us-gaap_OperatingLeaseLiabilityNoncurrent",
              "unit": "usd",
              "label": "Long-term operating lease liabilities",
              "value": 400000000.0
            },
            {
              "concept": "us-gaap_OtherLiabilitiesNoncurrent",
              "unit": "usd",
              "label": "Other long-term liabilities",
              "value": 781100000.0
            },
            {
              "concept": "us-gaap_Liabilities",
              "unit": "usd",
              "label": "Total liabilities",
              "value": 12045400000
            },
            {
              "concept": "us-gaap_PreferredStockValueOutstanding",
              "unit": "usd",
              "label": "Preferred stock, par value $0.001 per share",
              "value": 0
            },
            {
              "concept": "us-gaap_CommonStockValueOutstanding",
              "unit": "usd",
              "label": "Common stock, par value $0.0005 per share",
              "value": 100000
            },
            {
              "concept": "us-gaap_AdditionalPaidInCapital",
              "unit": "usd",
              "label": "Additional paid-in capital",
              "value": 302500000
            },
            {
              "concept": "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax",
              "unit": "usd",
              "label": "Accumulated other comprehensive income (loss)",
              "value": -153700000
            },
            {
              "concept": "us-gaap_RetainedEarningsAccumulatedDeficit",
              "unit": "usd",
              "label": "Retained earnings",
              "value": 17627600000
            },
            {
              "concept": "us-gaap_TreasuryStockValue",
              "unit": "usd",
              "label": "Treasury stock, at cost; 23.8 million and 23.8 million shares, respectively",
              "value": 2977100000
            },
            {
              "concept": "us-gaap_StockholdersEquity",
              "unit": "usd",
              "label": "Total Biogen Inc. shareholders\u2019 equity",
              "value": 14799400000
            },
            {
              "concept": "us-gaap_MinorityInterest",
              "unit": "usd",
              "label": "Noncontrolling interests",
              "value": 0
            },
            {
              "concept": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
              "unit": "usd",
              "label": "Total equity",
              "value": 14799400000.0
            },
            {
              "concept": "us-gaap_LiabilitiesAndStockholdersEquity",
              "unit": "usd",
              "label": "Total liabilities and equity",
              "value": 26844800000
            }
          ],
          "ic": [
            {
              "concept": "us-gaap_Revenues",
              "unit": "usd",
              "label": "Revenues",
              "value": 9835600000.0
            },
            {
              "concept": "us-gaap_CostOfGoodsAndServicesSold",
              "unit": "usd",
              "label": "Cost of sales, excluding amortization and impairment of acquired intangible assets",
              "value": 2533400000
            },
            {
              "concept": "us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
              "unit": "usd",
              "label": "Research and development",
              "value": 2462000000
            },
            {
              "concept": "us-gaap_SellingGeneralAndAdministrativeExpense",
              "unit": "usd",
              "label": "Selling, general and administrative",
              "value": 2549700000
            },
            {
              "concept": "biib_AmortizationandImpairmentofAcquiredIntangibleAssets",
              "unit": "usd",
              "label": "Amortization and impairment of acquired intangible assets",
              "value": 240600000.0
            },
            {
              "concept": "biib_CollaborationProfitLossSharing",
              "unit": "usd",
              "label": "Collaboration profit sharing/(loss reimbursement)",
              "value": 218800000
            },
            {
              "concept": "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings",
              "unit": "usd",
              "label": "(Gain) loss on fair value remeasurement of contingent consideration",
              "value": 0.0
            },
            {
              "concept": "biib_AcquiredInProcessResearchAndDevelopment",
              "unit": "usd",
              "label": "Acquired in-process research and development",
              "value": 0
            },
            {
              "concept": "us-gaap_RestructuringCharges",
              "unit": "usd",
              "label": "Restructuring charges",
              "value": 218800000
            },
            {
              "concept": "us-gaap_GainLossOnSaleOfPropertyPlantEquipment",
              "unit": "usd",
              "label": "Gain on sale of building",
              "value": 0.0
            },
            {
              "concept": "us-gaap_NonoperatingIncomeExpense",
              "unit": "usd",
              "label": "Other (income) expense, net",
              "value": -315500000.0
            },
            {
              "concept": "us-gaap_CostsAndExpenses",
              "unit": "usd",
              "label": "Total cost and expense",
              "value": 8538800000
            },
            {
              "concept": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
              "unit": "usd",
              "label": "Income before income tax (benefit) expense and equity in loss of investee, net of tax",
              "value": 1296800000.0
            },
            {
              "concept": "us-gaap_IncomeTaxExpenseBenefit",
              "unit": "usd",
              "label": "Income tax (benefit) expense",
              "value": 135300000.0
            },
            {
              "concept": "biib_IncomeLossFromEquityMethodInvestmentsNetOfTax",
              "unit": "usd",
              "label": "Equity in (income) loss of investee, net of tax",
              "value": 0
            },
            {
              "concept": "us-gaap_ProfitLoss",
              "unit": "usd",
              "label": "Net income",
              "value": 1161500000.0
            },
            {
              "concept": "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest",
              "unit": "usd",
              "label": "Net income (loss) attributable to noncontrolling interests, net of tax",
              "value": 400000
            },
            {
              "concept": "us-gaap_NetIncomeLoss",
              "unit": "usd",
              "label": "Net income attributable to Biogen Inc.",
              "value": 1161100000.0
            },
            {
              "concept": "us-gaap_EarningsPerShareBasic",
              "unit": "usd/share",
              "label": "Basic earnings per share attributable to Biogen Inc. (in dollars per share)",
              "value": 8
            },
            {
              "concept": "us-gaap_EarningsPerShareDiluted",
              "unit": "usd/share",
              "label": "Diluted earnings per share attributable to Biogen Inc. (in dollars per share)",
              "value": 7
            },
            {
              "concept": "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic",
              "unit": "shares",
              "label": "Weighted average number of common shares outstanding (in shares)",
              "value": 144700000.0
            },
            {
              "concept": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
              "unit": "shares",
              "label": "Diluted earnings per share attributable to Biogen Inc. (in shares)",
              "value": 145600000.0
            },
            {
              "concept": "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax",
              "unit": "usd",
              "label": "Unrealized gains (losses) on securities available for sale, net of tax",
              "value": 15700000
            },
            {
              "concept": "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent",
              "unit": "usd",
              "label": "Unrealized gains (losses) on cash flow hedges, net of tax",
              "value": -40100000
            },
            {
              "concept": "us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAfterAdjustmentsAndTax",
              "unit": "usd",
              "label": "Gains (losses) on net investment hedges, net of tax",
              "value": 0
            },
            {
              "concept": "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax",
              "unit": "usd",
              "label": "Unrealized gains (losses) on pension benefit obligation, net of tax",
              "value": 1500000
            },
            {
              "concept": "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
              "unit": "usd",
              "label": "Currency translation adjustment",
              "value": 37100000
            },
            {
              "concept": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
              "unit": "usd",
              "label": "Total other comprehensive income (loss), net of tax",
              "value": 11200000
            },
            {
              "concept": "us-gaap_ComprehensiveIncomeNetOfTax",
              "unit": "usd",
              "label": "Comprehensive income (loss) attributable to Biogen Inc.",
              "value": 1172300000
            },
            {
              "concept": "us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest",
              "unit": "usd",
              "label": "Comprehensive income (loss) attributable to noncontrolling interests, net of tax",
              "value": 400000
            },
            {
              "concept": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
              "unit": "usd",
              "label": "Comprehensive income (loss)",
              "value": 1172700000
            }
          ],
          "cf": [
            {
              "concept": "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings",
              "unit": "usd",
              "label": "(Gain) loss on fair value remeasurement of contingent consideration",
              "value": 0.0
            },
            {
              "concept": "us-gaap_GainLossOnSaleOfPropertyPlantEquipment",
              "unit": "usd",
              "label": "Gain on sale of building",
              "value": 0.0
            },
            {
              "concept": "us-gaap_ProfitLoss",
              "unit": "usd",
              "label": "Net income",
              "value": 1161500000.0
            },
            {
              "concept": "us-gaap_DepreciationDepletionAndAmortization",
              "unit": "usd",
              "label": "Depreciation and amortization",
              "value": 494800000
            },
            {
              "concept": "us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill",
              "unit": "usd",
              "label": "Impairment of intangible assets",
              "value": 0
            },
            {
              "concept": "us-gaap_InventoryWriteDown",
              "unit": "usd",
              "label": "Excess and obsolescence charges related to inventory",
              "value": 124400000.0
            },
            {
              "concept": "biib_AmortizationOfInventoryStepUp",
              "unit": "usd",
              "label": "Amortization of inventory step-up",
              "value": 31500000
            },
            {
              "concept": "biib_PaymentsToAcquireInProcessResearchAndDevelopmentOperatingActivities",
              "unit": "usd",
              "label": "Acquired in-process research and development",
              "value": 0
            },
            {
              "concept": "us-gaap_ShareBasedCompensation",
              "unit": "usd",
              "label": "Share-based compensation",
              "value": 264200000
            },
            {
              "concept": "us-gaap_DeferredIncomeTaxExpenseBenefit",
              "unit": "usd",
              "label": "Deferred income taxes",
              "value": -305800000.0
            },
            {
              "concept": "us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi",
              "unit": "usd",
              "label": "(Gain) loss on strategic investments",
              "value": -277100000
            },
            {
              "concept": "us-gaap_IncomeLossFromEquityMethodInvestments",
              "unit": "usd",
              "label": "(Gain) loss on equity method investment",
              "value": 0
            },
            {
              "concept": "us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal",
              "unit": "usd",
              "label": "Gain on sale of equity interest in Samsung Bioepis",
              "value": 0.0
            },
            {
              "concept": "us-gaap_OtherNoncashIncomeExpense",
              "unit": "usd",
              "label": "Other",
              "value": -148200000
            },
            {
              "concept": "us-gaap_IncreaseDecreaseInAccountsReceivable",
              "unit": "usd",
              "label": "Accounts receivable",
              "value": -61300000
            },
            {
              "concept": "us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet",
              "unit": "usd",
              "label": "Due from anti-CD20 therapeutic programs",
              "value": 4600000
            },
            {
              "concept": "us-gaap_IncreaseDecreaseInInventories",
              "unit": "usd",
              "label": "Inventory",
              "value": 130900000
            },
            {
              "concept": "us-gaap_IncreaseDecreaseInAccruedLiabilities",
              "unit": "usd",
              "label": "Accrued expense and other current liabilities",
              "value": -201600000
            },
            {
              "concept": "us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable",
              "unit": "usd",
              "label": "Income tax assets and liabilities",
              "value": -299000000
            },
            {
              "concept": "us-gaap_IncreaseDecreaseInOtherOperatingLiabilities",
              "unit": "usd",
              "label": "Other changes in operating assets and liabilities, net",
              "value": -73900000
            },
            {
              "concept": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
              "unit": "usd",
              "label": "Net cash flow provided by (used in) operating activities",
              "value": 1547200000
            },
            {
              "concept": "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment",
              "unit": "usd",
              "label": "Purchases of property, plant and equipment",
              "value": 277000000
            },
            {
              "concept": "us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities",
              "unit": "usd",
              "label": "Proceeds from sales and maturities of marketable securities",
              "value": 7380800000.0
            },
            {
              "concept": "us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt",
              "unit": "usd",
              "label": "Purchases of marketable securities",
              "value": 5140700000
            },
            {
              "concept": "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired",
              "unit": "usd",
              "label": "Proceeds from sale of building",
              "value": 6926100000
            },
            {
              "concept": "us-gaap_ProceedsFromDivestitureOfInterestInConsolidatedSubsidiaries",
              "unit": "usd",
              "label": "Proceeds from sale of equity interest in Samsung Bioepis",
              "value": 788100000
            },
            {
              "concept": "us-gaap_PaymentsToAcquireBusinessTwoNetOfCashAcquired",
              "unit": "usd",
              "label": "Proceeds from sale of building",
              "value": 0
            },
            {
              "concept": "us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment",
              "unit": "usd",
              "label": "Proceeds from divestiture of Hiller\u00f8d, Denmark manufacturing operations",
              "value": 0
            },
            {
              "concept": "us-gaap_PaymentsToAcquireIntangibleAssets",
              "unit": "usd",
              "label": "Acquisitions of intangible assets",
              "value": 34400000
            },
            {
              "concept": "us-gaap_ProceedsFromSaleOfEquityMethodInvestments",
              "unit": "usd",
              "label": "Proceeds from sales of strategic investments",
              "value": 119600000
            },
            {
              "concept": "us-gaap_PaymentsForProceedsFromOtherInvestingActivities",
              "unit": "usd",
              "label": "Other",
              "value": 11300000
            },
            {
              "concept": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
              "unit": "usd",
              "label": "Net cash flow provided by (used in) investing activities",
              "value": -4101000000
            },
            {
              "concept": "us-gaap_PaymentsForRepurchaseOfCommonStock",
              "unit": "usd",
              "label": "Purchase of treasury stock",
              "value": 0
            },
            {
              "concept": "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation",
              "unit": "usd",
              "label": "Payments related to issuance of stock for share-based compensation arrangements, net",
              "value": 44300000
            },
            {
              "concept": "biib_RepaymentsOfDebtIncludingPremiumsPaid",
              "unit": "usd",
              "label": "Repayments of borrowings and premiums paid",
              "value": 809900000
            },
            {
              "concept": "us-gaap_ProceedsFromIssuanceOfLongTermDebt",
              "unit": "usd",
              "label": "Proceeds from borrowings",
              "value": 997200000
            },
            {
              "concept": "us-gaap_ProceedsFromPaymentsToMinorityShareholders",
              "unit": "usd",
              "label": "Net (distribution) contribution to noncontrolling interest",
              "value": 12300000
            },
            {
              "concept": "us-gaap_ProceedsFromPaymentsForOtherFinancingActivities",
              "unit": "usd",
              "label": "Other",
              "value": -6000000
            },
            {
              "concept": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
              "unit": "usd",
              "label": "Net cash flow provided by (used in) financing activities",
              "value": 149300000
            },
            {
              "concept": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
              "unit": "usd",
              "label": "Net increase (decrease) in cash and cash equivalents",
              "value": -2404500000
            },
            {
              "concept": "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
              "unit": "usd",
              "label": "Effect of exchange rate changes on cash and cash equivalents",
              "value": 35100000
            }
          ]
        }
      },
      {
        "accessNumber": "0000875045-23-000009",
        "symbol": "BIIB",
        "cik": "875045",
        "year": 2022,
        "quarter": 0,
        "form": "10-K",
        "startDate": "2022-01-01 00:00:00",
        "endDate": "2022-12-31 00:00:00",
        "filedDate": "2023-02-15 00:00:00",
        "acceptedDate": "2023-02-15 16:24:20",
        "report": {
          "bs": [
            {
              "concept": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
              "unit": "usd",
              "label": "Cash and cash equivalents",
              "value": 3419300000.0
            },
            {
              "concept": "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent",
              "unit": "usd",
              "label": "Marketable securities",
              "value": 1473500000
            },
            {
              "concept": "us-gaap_AccountsReceivableNetCurrent",
              "unit": "usd",
              "label": "Accounts receivable, net",
              "value": 1705000000
            },
            {
              "concept": "biib_DueFromUnconsolidatedJointBusiness",
              "unit": "usd",
              "label": "Due from anti-CD20 therapeutic programs",
              "value": 431400000
            },
            {
              "concept": "us-gaap_InventoryNet",
              "unit": "usd",
              "label": "Inventory",
              "value": 1344400000.0
            },
            {
              "concept": "us-gaap_OtherAssetsCurrent",
              "unit": "usd",
              "label": "Other current assets",
              "value": 1417600000
            },
            {
              "concept": "us-gaap_AssetsCurrent",
              "unit": "usd",
              "label": "Total current assets",
              "value": 9791200000
            },
            {
              "concept": "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent",
              "unit": "usd",
              "label": "Marketable securities",
              "value": 705700000
            },
            {
              "concept": "us-gaap_PropertyPlantAndEquipmentNet",
              "unit": "usd",
              "label": "Property, plant and equipment, net",
              "value": 3298600000.0
            },
            {
              "concept": "us-gaap_OperatingLeaseRightOfUseAsset",
              "unit": "usd",
              "label": "Operating lease assets",
              "value": 403900000.0
            },
            {
              "concept": "us-gaap_IntangibleAssetsNetExcludingGoodwill",
              "unit": "usd",
              "label": "Intangible assets, net",
              "value": 1850100000.0
            },
            {
              "concept": "us-gaap_Goodwill",
              "unit": "usd",
              "label": "Goodwill",
              "value": 5749000000.0
            },
            {
              "concept": "us-gaap_DeferredIncomeTaxAssetsNet",
              "unit": "usd",
              "label": "Deferred tax asset",
              "value": 1226400000
            },
            {
              "concept": "us-gaap_OtherAssetsNoncurrent",
              "unit": "usd",
              "label": "Investments and other assets",
              "value": 1529200000
            },
            {
              "concept": "us-gaap_Assets",
              "unit": "usd",
              "label": "Total assets",
              "value": 24554100000
            },
            {
              "concept": "us-gaap_DebtCurrent",
              "unit": "usd",
              "label": "Current portion of notes payable",
              "value": 0
            },
            {
              "concept": "us-gaap_TaxesPayableCurrent",
              "unit": "usd",
              "label": "Taxes payable",
              "value": 259900000
            },
            {
              "concept": "us-gaap_AccountsPayableCurrent",
              "unit": "usd",
              "label": "Accounts payable",
              "value": 491500000
            },
            {
              "concept": "us-gaap_OtherLiabilitiesCurrent",
              "unit": "usd",
              "label": "Accrued expense and other",
              "value": 2521400000.0
            },
            {
              "concept": "us-gaap_LiabilitiesCurrent",
              "unit": "usd",
              "label": "Total current liabilities",
              "value": 3272800000
            },
            {
              "concept": "us-gaap_LongTermDebt",
              "unit": "usd",
              "label": "Notes payable",
              "value": 6281000000.0
            },
            {
              "concept": "us-gaap_DeferredIncomeTaxLiabilitiesNet",
              "unit": "usd",
              "label": "Deferred tax liability",
              "value": 334700000
            },
            {
              "concept": "us-gaap_OperatingLeaseLiabilityNoncurrent",
              "unit": "usd",
              "label": "Long-term operating lease liabilities",
              "value": 333000000.0
            },
            {
              "concept": "us-gaap_OtherLiabilitiesNoncurrent",
              "unit": "usd",
              "label": "Other long-term liabilities",
              "value": 944200000.0
            },
            {
              "concept": "us-gaap_Liabilities",
              "unit": "usd",
              "label": "Total liabilities",
              "value": 11165700000
            },
            {
              "concept": "us-gaap_PreferredStockValue",
              "unit": "usd",
              "label": "Preferred stock, par value $0.001 per share",
              "value": 0
            },
            {
              "concept": "us-gaap_CommonStockValue",
              "unit": "usd",
              "label": "Common stock, par value $0.0005 per share",
              "value": 100000
            },
            {
              "concept": "us-gaap_AdditionalPaidInCapital",
              "unit": "usd",
              "label": "Additional paid-in capital",
              "value": 73300000
            },
            {
              "concept": "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax",
              "unit": "usd",
              "label": "Accumulated other comprehensive loss",
              "value": -164900000
            },
            {
              "concept": "us-gaap_RetainedEarningsAccumulatedDeficit",
              "unit": "usd",
              "label": "Retained earnings",
              "value": 16466500000
            },
            {
              "concept": "us-gaap_TreasuryStockValue",
              "unit": "usd",
              "label": "Treasury stock, at cost; 23.8 million and 23.8 million shares, respectively",
              "value": 2977100000
            },
            {
              "concept": "us-gaap_StockholdersEquity",
              "unit": "usd",
              "label": "Total Biogen Inc. shareholders\u2019 equity",
              "value": 13397900000
            },
            {
              "concept": "us-gaap_MinorityInterest",
              "unit": "usd",
              "label": "Noncontrolling interests",
              "value": -9500000
            },
            {
              "concept": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
              "unit": "usd",
              "label": "Total equity",
              "value": 13388400000.0
            },
            {
              "concept": "us-gaap_LiabilitiesAndStockholdersEquity",
              "unit": "usd",
              "label": "Total liabilities and equity",
              "value": 24554100000
            }
          ],
          "ic": [
            {
              "concept": "us-gaap_Revenues",
              "unit": "usd",
              "label": "Revenues",
              "value": 10173400000.0
            },
            {
              "concept": "us-gaap_CostOfGoodsAndServicesSold",
              "unit": "usd",
              "label": "Cost of sales, excluding amortization and impairment of acquired intangible assets",
              "value": 2278300000
            },
            {
              "concept": "us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
              "unit": "usd",
              "label": "Research and development",
              "value": 2231100000
            },
            {
              "concept": "us-gaap_SellingGeneralAndAdministrativeExpense",
              "unit": "usd",
              "label": "Selling, general and administrative",
              "value": 2403600000
            },
            {
              "concept": "biib_AmortizationandImpairmentofAcquiredIntangibleAssets",
              "unit": "usd",
              "label": "Amortization and impairment of acquired intangible assets",
              "value": 365900000.0
            },
            {
              "concept": "biib_CollaborationProfitSharing",
              "unit": "usd",
              "label": "Collaboration profit (loss) sharing",
              "value": -7400000
            },
            {
              "concept": "us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown",
              "unit": "usd",
              "label": "(Gain) loss on divestiture of Hiller\u00f8d, Denmark manufacturing operations",
              "value": 0
            },
            {
              "concept": "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings",
              "unit": "usd",
              "label": "(Gain) loss on fair value remeasurement of contingent consideration",
              "value": 209100000.0
            },
            {
              "concept": "us-gaap_ResearchAndDevelopmentInProcess",
              "unit": "usd",
              "label": "Acquired in-process research and development",
              "value": 0.0
            },
            {
              "concept": "us-gaap_RestructuringCharges",
              "unit": "usd",
              "label": "Restructuring charges",
              "value": 131100000.0
            },
            {
              "concept": "us-gaap_GainLossOnSaleOfPropertyPlantEquipment",
              "unit": "usd",
              "label": "Gain on sale of building",
              "value": 503700000.0
            },
            {
              "concept": "us-gaap_NonoperatingIncomeExpense",
              "unit": "usd",
              "label": "Other (income) expense, net",
              "value": 108200000.0
            },
            {
              "concept": "us-gaap_CostsAndExpenses",
              "unit": "usd",
              "label": "Total cost and expense",
              "value": 6581600000
            },
            {
              "concept": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
              "unit": "usd",
              "label": "Income before income tax expense and equity in loss of investee, net of tax",
              "value": 3591800000.0
            },
            {
              "concept": "us-gaap_IncomeTaxExpenseBenefit",
              "unit": "usd",
              "label": "Income tax (benefit) expense",
              "value": 632800000.0
            },
            {
              "concept": "biib_IncomeLossFromEquityMethodInvestmentsNetOfTax",
              "unit": "usd",
              "label": "Equity in (income) loss of investee, net of tax",
              "value": 2600000
            },
            {
              "concept": "us-gaap_ProfitLoss",
              "unit": "usd",
              "label": "Net income",
              "value": 2961600000.0
            },
            {
              "concept": "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest",
              "unit": "usd",
              "label": "Net income (loss) attributable to noncontrolling interests, net of tax",
              "value": -85300000
            },
            {
              "concept": "us-gaap_NetIncomeLoss",
              "unit": "usd",
              "label": "Net income attributable to Biogen Inc.",
              "value": 3046900000.0
            },
            {
              "concept": "us-gaap_EarningsPerShareBasic",
              "unit": "usd/share",
              "label": "Basic earnings per share attributable to Biogen Inc. (in dollars per share)",
              "value": 20
            },
            {
              "concept": "us-gaap_EarningsPerShareDiluted",
              "unit": "usd/share",
              "label": "Diluted earnings per share attributable to Biogen Inc. (in dollars per share)",
              "value": 20
            },
            {
              "concept": "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic",
              "unit": "shares",
              "label": "Weighted average number of common shares outstanding (in shares)",
              "value": 145300000.0
            },
            {
              "concept": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
              "unit": "shares",
              "label": "Diluted earnings per share attributable to Biogen Inc. (in shares)",
              "value": 146000000.0
            },
            {
              "concept": "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax",
              "unit": "usd",
              "label": "Unrealized gains (losses) on securities available for sale, net of tax",
              "value": -13500000
            },
            {
              "concept": "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent",
              "unit": "usd",
              "label": "Unrealized gains (losses) on cash flow hedges, net of tax",
              "value": -38700000
            },
            {
              "concept": "us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAfterAdjustmentsAndTax",
              "unit": "usd",
              "label": "Gains (losses) on net investment hedges, net of tax",
              "value": -25500000
            },
            {
              "concept": "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax",
              "unit": "usd",
              "label": "Unrealized gains (losses) on pension benefit obligation, net of tax",
              "value": -43700000
            },
            {
              "concept": "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
              "unit": "usd",
              "label": "Currency translation adjustment",
              "value": -24200000
            },
            {
              "concept": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
              "unit": "usd",
              "label": "Total other comprehensive income (loss), net of tax",
              "value": -58200000.0
            },
            {
              "concept": "us-gaap_ComprehensiveIncomeNetOfTax",
              "unit": "usd",
              "label": "Comprehensive income (loss) attributable to Biogen Inc.",
              "value": 2988700000
            },
            {
              "concept": "us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest",
              "unit": "usd",
              "label": "Comprehensive income (loss) attributable to noncontrolling interests, net of tax",
              "value": -85300000
            },
            {
              "concept": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
              "unit": "usd",
              "label": "Comprehensive income (loss)",
              "value": 2903400000
            }
          ],
          "cf": [
            {
              "concept": "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings",
              "unit": "usd",
              "label": "(Gain) loss on fair value remeasurement of contingent consideration",
              "value": 209100000.0
            },
            {
              "concept": "us-gaap_ResearchAndDevelopmentInProcess",
              "unit": "usd",
              "label": "Acquired in-process research and development",
              "value": 0.0
            },
            {
              "concept": "us-gaap_GainLossOnSaleOfPropertyPlantEquipment",
              "unit": "usd",
              "label": "Gain on sale of building",
              "value": 503700000.0
            },
            {
              "concept": "us-gaap_ProfitLoss",
              "unit": "usd",
              "label": "Net income",
              "value": 2961600000.0
            },
            {
              "concept": "us-gaap_DepreciationDepletionAndAmortization",
              "unit": "usd",
              "label": "Depreciation and amortization",
              "value": 518400000
            },
            {
              "concept": "us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill",
              "unit": "usd",
              "label": "Impairment of intangible assets",
              "value": 119600000
            },
            {
              "concept": "us-gaap_InventoryWriteDown",
              "unit": "usd",
              "label": "Excess and obsolescence charges related to inventory",
              "value": 336200000.0
            },
            {
              "concept": "us-gaap_ShareBasedCompensation",
              "unit": "usd",
              "label": "Share-based compensation",
              "value": 254100000
            },
            {
              "concept": "us-gaap_IncomeLossFromIndividuallySignificantComponentDisposedOfOrHeldForSaleExcludingDiscontinuedOperationsAttributableToParentBeforeIncomeTax",
              "unit": "usd",
              "label": "(Gain)/loss on divestiture of Hiller\u00f8d, Denmark manufacturing operations",
              "value": 0
            },
            {
              "concept": "us-gaap_DeferredIncomeTaxExpenseBenefit",
              "unit": "usd",
              "label": "Deferred income taxes",
              "value": -168600000.0
            },
            {
              "concept": "us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi",
              "unit": "usd",
              "label": "(Gain) loss on strategic investments",
              "value": -265900000
            },
            {
              "concept": "us-gaap_IncomeLossFromEquityMethodInvestments",
              "unit": "usd",
              "label": "(Gain) loss on equity method investment",
              "value": 2600000
            },
            {
              "concept": "us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal",
              "unit": "usd",
              "label": "Gain on sale of equity interest in Samsung Bioepis",
              "value": 1505400000.0
            },
            {
              "concept": "us-gaap_OtherNoncashIncomeExpense",
              "unit": "usd",
              "label": "Other",
              "value": -208200000
            },
            {
              "concept": "us-gaap_IncreaseDecreaseInAccountsReceivable",
              "unit": "usd",
              "label": "Accounts receivable",
              "value": 203400000
            },
            {
              "concept": "us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet",
              "unit": "usd",
              "label": "Due from anti-CD20 therapeutic programs",
              "value": 19000000
            },
            {
              "concept": "us-gaap_IncreaseDecreaseInInventories",
              "unit": "usd",
              "label": "Inventory",
              "value": 320200000
            },
            {
              "concept": "us-gaap_IncreaseDecreaseInAccruedLiabilities",
              "unit": "usd",
              "label": "Accrued expense and other current liabilities",
              "value": -113400000
            },
            {
              "concept": "us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable",
              "unit": "usd",
              "label": "Income tax assets and liabilities",
              "value": -142300000
            },
            {
              "concept": "us-gaap_IncreaseDecreaseInOtherOperatingLiabilities",
              "unit": "usd",
              "label": "Other changes in operating assets and liabilities, net",
              "value": -92000000
            },
            {
              "concept": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
              "unit": "usd",
              "label": "Net cash flow provided by (used in) operating activities",
              "value": 1384300000
            },
            {
              "concept": "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment",
              "unit": "usd",
              "label": "Purchases of property, plant and equipment",
              "value": 240300000
            },
            {
              "concept": "us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities",
              "unit": "usd",
              "label": "Proceeds from sales and maturities of marketable securities",
              "value": 3671000000.0
            },
            {
              "concept": "us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt",
              "unit": "usd",
              "label": "Purchases of marketable securities",
              "value": 3448500000
            },
            {
              "concept": "us-gaap_ProceedsFromDivestitureOfInterestInConsolidatedSubsidiaries",
              "unit": "usd",
              "label": "Proceeds from sale of equity interest in Samsung Bioepis",
              "value": 990300000
            },
            {
              "concept": "us-gaap_PaymentsToAcquireBusinessTwoNetOfCashAcquired",
              "unit": "usd",
              "label": "Proceeds from sale of building",
              "value": -582600000
            },
            {
              "concept": "us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates",
              "unit": "usd",
              "label": "Purchase of subsidiaries and affiliates",
              "value": 0.0
            },
            {
              "concept": "us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment",
              "unit": "usd",
              "label": "Proceeds from divestiture of Hiller\u00f8d, Denmark manufacturing operations",
              "value": 0
            },
            {
              "concept": "us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment",
              "unit": "usd",
              "label": "Acquired in-process research and development",
              "value": 0
            },
            {
              "concept": "us-gaap_PaymentsToAcquireIntangibleAssets",
              "unit": "usd",
              "label": "Acquisitions of intangible assets",
              "value": 2900000
            },
            {
              "concept": "us-gaap_ProceedsFromSaleOfEquityMethodInvestments",
              "unit": "usd",
              "label": "Proceeds from sales of strategic investments",
              "value": 0
            },
            {
              "concept": "us-gaap_PaymentsForProceedsFromOtherInvestingActivities",
              "unit": "usd",
              "label": "Other",
              "value": -24400000
            },
            {
              "concept": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
              "unit": "usd",
              "label": "Net cash flow provided by (used in) investing activities",
              "value": 1576600000
            },
            {
              "concept": "us-gaap_PaymentsForRepurchaseOfCommonStock",
              "unit": "usd",
              "label": "Purchase of treasury stock",
              "value": 750000000
            },
            {
              "concept": "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation",
              "unit": "usd",
              "label": "Payments related to issuance of stock for share-based compensation arrangements, net",
              "value": 1900000
            },
            {
              "concept": "biib_RepaymentsOfDebtIncludingPremiumsPaid",
              "unit": "usd",
              "label": "Repayments of borrowings and premiums paid on debt exchange",
              "value": 1002200000
            },
            {
              "concept": "us-gaap_ProceedsFromIssuanceOfLongTermDebt",
              "unit": "usd",
              "label": "Proceeds from borrowings",
              "value": 0
            },
            {
              "concept": "us-gaap_RepaymentsOfDebt",
              "unit": "usd",
              "label": "Repayments of borrowings",
              "value": 0
            },
            {
              "concept": "us-gaap_ProceedsFromPaymentsToMinorityShareholders",
              "unit": "usd",
              "label": "Net (distribution) contribution to noncontrolling interest",
              "value": 12400000
            },
            {
              "concept": "us-gaap_ProceedsFromPaymentsForOtherFinancingActivities",
              "unit": "usd",
              "label": "Other",
              "value": -5600000
            },
            {
              "concept": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
              "unit": "usd",
              "label": "Net cash flow provided by (used in) financing activities",
              "value": -1747300000
            },
            {
              "concept": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
              "unit": "usd",
              "label": "Net increase (decrease) in cash and cash equivalents",
              "value": 1213600000
            },
            {
              "concept": "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
              "unit": "usd",
              "label": "Effect of exchange rate changes on cash and cash equivalents",
              "value": -55700000
            }
          ]
        }
      },
      {
        "accessNumber": "0000875045-22-000007",
        "symbol": "BIIB",
        "cik": "875045",
        "year": 2021,
        "quarter": 0,
        "form": "10-K",
        "startDate": "2021-01-01 00:00:00",
        "endDate": "2021-12-31 00:00:00",
        "filedDate": "2022-02-03 00:00:00",
        "acceptedDate": "2022-02-03 17:24:29",
        "report": {
          "bs": [
            {
              "concept": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
              "unit": "usd",
              "label": "Cash and cash equivalents",
              "value": 2261400000.0
            },
            {
              "concept": "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent",
              "unit": "usd",
              "label": "Marketable securities",
              "value": 1541100000.0
            },
            {
              "concept": "us-gaap_AccountsReceivableNetCurrent",
              "unit": "usd",
              "label": "Accounts receivable, net",
              "value": 1549400000.0
            },
            {
              "concept": "biib_DueFromUnconsolidatedJointBusiness",
              "unit": "usd",
              "label": "Due from anti-CD20 therapeutic programs",
              "value": 412300000.0
            },
            {
              "concept": "us-gaap_InventoryNet",
              "unit": "usd",
              "label": "Inventory",
              "value": 1351500000.0
            },
            {
              "concept": "us-gaap_OtherAssetsCurrent",
              "unit": "usd",
              "label": "Other current assets",
              "value": 740800000.0
            },
            {
              "concept": "us-gaap_AssetsCurrent",
              "unit": "usd",
              "label": "Total current assets",
              "value": 7856500000.0
            },
            {
              "concept": "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent",
              "unit": "usd",
              "label": "Marketable securities",
              "value": 892000000.0
            },
            {
              "concept": "us-gaap_PropertyPlantAndEquipmentNet",
              "unit": "usd",
              "label": "Property, plant and equipment, net",
              "value": 3416400000.0
            },
            {
              "concept": "us-gaap_OperatingLeaseRightOfUseAsset",
              "unit": "usd",
              "label": "Operating lease assets",
              "value": 375400000.0
            },
            {
              "concept": "us-gaap_IntangibleAssetsNetExcludingGoodwill",
              "unit": "usd",
              "label": "Intangible assets, net",
              "value": 2221300000.0
            },
            {
              "concept": "us-gaap_Goodwill",
              "unit": "usd",
              "label": "Goodwill",
              "value": 5761100000.0
            },
            {
              "concept": "us-gaap_DeferredIncomeTaxAssetsNet",
              "unit": "usd",
              "label": "Deferred tax asset",
              "value": 1415100000.0
            },
            {
              "concept": "us-gaap_OtherAssetsNoncurrent",
              "unit": "usd",
              "label": "Investments and other assets",
              "value": 1939500000.0
            },
            {
              "concept": "us-gaap_Assets",
              "unit": "usd",
              "label": "Total assets",
              "value": 23877300000.0
            },
            {
              "concept": "us-gaap_DebtCurrent",
              "unit": "usd",
              "label": "Current portion of notes payable",
              "value": 999100000.0
            },
            {
              "concept": "us-gaap_TaxesPayableCurrent",
              "unit": "usd",
              "label": "Taxes payable",
              "value": 174700000.0
            },
            {
              "concept": "us-gaap_AccountsPayableCurrent",
              "unit": "usd",
              "label": "Accounts payable",
              "value": 589200000.0
            },
            {
              "concept": "us-gaap_OtherLiabilitiesCurrent",
              "unit": "usd",
              "label": "Accrued expense and other",
              "value": 2535200000.0
            },
            {
              "concept": "us-gaap_LiabilitiesCurrent",
              "unit": "usd",
              "label": "Total current liabilities",
              "value": 4298200000.0
            },
            {
              "concept": "us-gaap_LongTermDebt",
              "unit": "usd",
              "label": "Notes payable",
              "value": 6274000000.0
            },
            {
              "concept": "us-gaap_DeferredIncomeTaxLiabilitiesNet",
              "unit": "usd",
              "label": "Deferred tax liability",
              "value": 694500000.0
            },
            {
              "concept": "us-gaap_OperatingLeaseLiabilityNoncurrent",
              "unit": "usd",
              "label": "Long-term operating lease liabilities",
              "value": 330400000.0
            },
            {
              "concept": "us-gaap_OtherLiabilitiesNoncurrent",
              "unit": "usd",
              "label": "Other long-term liabilities",
              "value": 1320500000.0
            },
            {
              "concept": "us-gaap_Liabilities",
              "unit": "usd",
              "label": "Total liabilities",
              "value": 12917600000.0
            },
            {
              "concept": "us-gaap_PreferredStockValue",
              "unit": "usd",
              "label": "Preferred stock, par value $0.001 per share",
              "value": 0.0
            },
            {
              "concept": "us-gaap_CommonStockValue",
              "unit": "usd",
              "label": "Common stock, par value $0.0005 per share",
              "value": 100000.0
            },
            {
              "concept": "us-gaap_AdditionalPaidInCapital",
              "unit": "usd",
              "label": "Additional paid-in capital",
              "value": 68200000.0
            },
            {
              "concept": "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax",
              "unit": "usd",
              "label": "Accumulated other comprehensive loss",
              "value": -106700000.0
            },
            {
              "concept": "us-gaap_RetainedEarningsAccumulatedDeficit",
              "unit": "usd",
              "label": "Retained earnings",
              "value": 13911700000.0
            },
            {
              "concept": "us-gaap_TreasuryStockValue",
              "unit": "usd",
              "label": "Treasury stock, at cost; 23.8 million and 23.8 million shares, respectively",
              "value": 2977100000.0
            },
            {
              "concept": "us-gaap_StockholdersEquity",
              "unit": "usd",
              "label": "Total Biogen Inc. shareholders\u2019 equity",
              "value": 10896200000.0
            },
            {
              "concept": "us-gaap_MinorityInterest",
              "unit": "usd",
              "label": "Noncontrolling interests",
              "value": 63500000.0
            },
            {
              "concept": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
              "unit": "usd",
              "label": "Total equity",
              "value": 10959700000.0
            },
            {
              "concept": "us-gaap_LiabilitiesAndStockholdersEquity",
              "unit": "usd",
              "label": "Total liabilities and equity",
              "value": 23877300000.0
            }
          ],
          "ic": [
            {
              "concept": "us-gaap_Revenues",
              "unit": "usd",
              "label": "Revenues",
              "value": 10981700000.0
            },
            {
              "concept": "us-gaap_CostOfGoodsAndServicesSold",
              "unit": "usd",
              "label": "Cost of sales, excluding amortization and impairment of acquired intangible assets",
              "value": 2109700000.0
            },
            {
              "concept": "us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
              "unit": "usd",
              "label": "Research and development",
              "value": 2501200000.0
            },
            {
              "concept": "us-gaap_SellingGeneralAndAdministrativeExpense",
              "unit": "usd",
              "label": "Selling, general and administrative",
              "value": 2674300000.0
            },
            {
              "concept": "biib_AmortizationandImpairmentofAcquiredIntangibleAssets",
              "unit": "usd",
              "label": "Amortization and impairment of acquired intangible assets",
              "value": 881300000.0
            },
            {
              "concept": "biib_CollaborationProfitSharing",
              "unit": "usd",
              "label": "Collaboration profit (loss) sharing",
              "value": 7200000.0
            },
            {
              "concept": "us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown",
              "unit": "usd",
              "label": "(Gain) loss on divestiture of Hiller\u00f8d, Denmark manufacturing operations",
              "value": 0.0
            },
            {
              "concept": "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings",
              "unit": "usd",
              "label": "(Gain) loss on fair value remeasurement of contingent consideration",
              "value": 50700000.0
            },
            {
              "concept": "us-gaap_ResearchAndDevelopmentInProcess",
              "unit": "usd",
              "label": "Acquired in-process research and development",
              "value": 18000000.0
            },
            {
              "concept": "us-gaap_RestructuringCharges",
              "unit": "usd",
              "label": "Restructuring charges",
              "value": 0.0
            },
            {
              "concept": "us-gaap_CostsAndExpenses",
              "unit": "usd",
              "label": "Total cost and expense",
              "value": 8141000000.0
            },
            {
              "concept": "us-gaap_OperatingIncomeLoss",
              "unit": "usd",
              "label": "Income from operations",
              "value": 2840700000.0
            },
            {
              "concept": "us-gaap_NonoperatingIncomeExpense",
              "unit": "usd",
              "label": "Other income (expense), net",
              "value": -1095500000.0
            },
            {
              "concept": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
              "unit": "usd",
              "label": "Income before income tax expense and equity in loss of investee, net of tax",
              "value": 1745200000.0
            },
            {
              "concept": "us-gaap_IncomeTaxExpenseBenefit",
              "unit": "usd",
              "label": "Income tax (benefit) expense",
              "value": 52500000.0
            },
            {
              "concept": "biib_IncomeLossFromEquityMethodInvestmentsNetOfTax",
              "unit": "usd",
              "label": "Equity in (income) loss of investee, net of tax",
              "value": 34900000.0
            },
            {
              "concept": "us-gaap_ProfitLoss",
              "unit": "usd",
              "label": "Net income",
              "value": 1727600000.0
            },
            {
              "concept": "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest",
              "unit": "usd",
              "label": "Net income (loss) attributable to noncontrolling interests, net of tax",
              "value": 171500000.0
            },
            {
              "concept": "us-gaap_NetIncomeLoss",
              "unit": "usd",
              "label": "Net income attributable to Biogen Inc.",
              "value": 1556100000.0
            },
            {
              "concept": "us-gaap_EarningsPerShareBasic",
              "unit": "usd/share",
              "label": "Basic earnings per share attributable to Biogen Inc. (in dollars per share)",
              "value": 10.44
            },
            {
              "concept": "us-gaap_EarningsPerShareDiluted",
              "unit": "usd/share",
              "label": "Diluted earnings per share attributable to Biogen Inc. (in dollars per share)",
              "value": 10.4
            },
            {
              "concept": "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic",
              "unit": "shares",
              "label": "Weighted average number of common shares outstanding (in shares)",
              "value": 149100000.0
            },
            {
              "concept": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
              "unit": "shares",
              "label": "Diluted earnings per share attributable to Biogen Inc. (in shares)",
              "value": 149600000.0
            },
            {
              "concept": "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax",
              "unit": "usd",
              "label": "Unrealized gains (losses) on securities available for sale, net of tax",
              "value": -3600000.0
            },
            {
              "concept": "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent",
              "unit": "usd",
              "label": "Unrealized gains (losses) on cash flow hedges, net of tax",
              "value": 232800000.0
            },
            {
              "concept": "us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAfterAdjustmentsAndTax",
              "unit": "usd",
              "label": "Gains (losses) on net investment hedges, net of tax",
              "value": 34000000.0
            },
            {
              "concept": "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax",
              "unit": "usd",
              "label": "Unrealized gains (losses) on pension benefit obligation, net of tax",
              "value": -21500000.0
            },
            {
              "concept": "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
              "unit": "usd",
              "label": "Currency translation adjustment",
              "value": -92400000.0
            },
            {
              "concept": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
              "unit": "usd",
              "label": "Total other comprehensive income (loss), net of tax",
              "value": 192300000.0
            },
            {
              "concept": "us-gaap_ComprehensiveIncomeNetOfTax",
              "unit": "usd",
              "label": "Comprehensive income attributable to Biogen Inc.",
              "value": 1748400000.0
            },
            {
              "concept": "us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest",
              "unit": "usd",
              "label": "Comprehensive income (loss) attributable to noncontrolling interests, net of tax",
              "value": 172100000.0
            },
            {
              "concept": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
              "unit": "usd",
              "label": "Comprehensive income",
              "value": 1920500000.0
            }
          ],
          "cf": [
            {
              "concept": "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings",
              "unit": "usd",
              "label": "(Gain) loss on fair value remeasurement of contingent consideration",
              "value": 50700000.0
            },
            {
              "concept": "us-gaap_ResearchAndDevelopmentInProcess",
              "unit": "usd",
              "label": "Acquired in-process research and development",
              "value": 18000000.0
            },
            {
              "concept": "us-gaap_ProfitLoss",
              "unit": "usd",
              "label": "Net income",
              "value": 1727600000.0
            },
            {
              "concept": "us-gaap_DepreciationDepletionAndAmortization",
              "unit": "usd",
              "label": "Depreciation and amortization",
              "value": 487700000.0
            },
            {
              "concept": "us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill",
              "unit": "usd",
              "label": "Impairment of intangible assets",
              "value": 629300000.0
            },
            {
              "concept": "us-gaap_InventoryWriteDown",
              "unit": "usd",
              "label": "Excess and obsolescence charges related to inventory",
              "value": 167600000.0
            },
            {
              "concept": "us-gaap_ShareBasedCompensation",
              "unit": "usd",
              "label": "Share-based compensation",
              "value": 238600000.0
            },
            {
              "concept": "us-gaap_IncomeLossFromIndividuallySignificantComponentDisposedOfOrHeldForSaleExcludingDiscontinuedOperationsAttributableToParentBeforeIncomeTax",
              "unit": "usd",
              "label": "(Gain)/loss on divestiture of Hiller\u00f8d, Denmark manufacturing operations",
              "value": 0.0
            },
            {
              "concept": "us-gaap_DeferredIncomeTaxExpenseBenefit",
              "unit": "usd",
              "label": "Deferred income taxes",
              "value": -426800000.0
            },
            {
              "concept": "us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi",
              "unit": "usd",
              "label": "(Gain) loss on strategic investments",
              "value": -826800000.0
            },
            {
              "concept": "us-gaap_IncomeLossFromEquityMethodInvestments",
              "unit": "usd",
              "label": "(Gain) loss on equity method investment",
              "value": 34900000.0
            },
            {
              "concept": "us-gaap_OtherNoncashIncomeExpense",
              "unit": "usd",
              "label": "Other",
              "value": -202200000.0
            },
            {
              "concept": "us-gaap_IncreaseDecreaseInAccountsReceivable",
              "unit": "usd",
              "label": "Accounts receivable",
              "value": -324800000.0
            },
            {
              "concept": "us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet",
              "unit": "usd",
              "label": "Due from anti-CD20 therapeutic programs",
              "value": -1200000.0
            },
            {
              "concept": "us-gaap_IncreaseDecreaseInInventories",
              "unit": "usd",
              "label": "Inventory",
              "value": 462400000.0
            },
            {
              "concept": "us-gaap_IncreaseDecreaseInAccruedLiabilities",
              "unit": "usd",
              "label": "Accrued expense and other current liabilities",
              "value": -95400000.0
            },
            {
              "concept": "us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable",
              "unit": "usd",
              "label": "Income tax assets and liabilities",
              "value": 230800000.0
            },
            {
              "concept": "us-gaap_IncreaseDecreaseInOtherOperatingLiabilities",
              "unit": "usd",
              "label": "Other changes in operating assets and liabilities, net",
              "value": -144500000.0
            },
            {
              "concept": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
              "unit": "usd",
              "label": "Net cash flow provided by operating activities",
              "value": 3639900000.0
            },
            {
              "concept": "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment",
              "unit": "usd",
              "label": "Purchases of property, plant and equipment",
              "value": 258100000.0
            },
            {
              "concept": "us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities",
              "unit": "usd",
              "label": "Proceeds from sales and maturities of marketable securities",
              "value": 3405400000.0
            },
            {
              "concept": "us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt",
              "unit": "usd",
              "label": "Purchases of marketable securities",
              "value": 3808700000.0
            },
            {
              "concept": "us-gaap_PaymentsToAcquireOtherProductiveAssets",
              "unit": "usd",
              "label": "Contingent consideration paid related to Fumapharm AG acquisition",
              "value": 0.0
            },
            {
              "concept": "us-gaap_PaymentsToAcquireBusinessTwoNetOfCashAcquired",
              "unit": "usd",
              "label": "Acquisition of Nightstar Therapeutics plc, net of cash acquired",
              "value": 0.0
            },
            {
              "concept": "us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates",
              "unit": "usd",
              "label": "Purchase of subsidiaries and affiliates",
              "value": 0.0
            },
            {
              "concept": "us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment",
              "unit": "usd",
              "label": "Proceeds from divestiture of Hiller\u00f8d, Denmark manufacturing operations",
              "value": 28100000.0
            },
            {
              "concept": "us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment",
              "unit": "usd",
              "label": "Acquired in-process research and development",
              "value": 18000000.0
            },
            {
              "concept": "us-gaap_PaymentsToAcquireIntangibleAssets",
              "unit": "usd",
              "label": "Acquisitions of intangible assets",
              "value": 18800000.0
            },
            {
              "concept": "us-gaap_ProceedsFromSaleOfEquityMethodInvestments",
              "unit": "usd",
              "label": "Proceeds from sales of strategic investments",
              "value": 93500000.0
            },
            {
              "concept": "us-gaap_PaymentsForProceedsFromOtherInvestingActivities",
              "unit": "usd",
              "label": "Other",
              "value": -12900000.0
            },
            {
              "concept": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
              "unit": "usd",
              "label": "Net cash flow (used in) provided by investing activities",
              "value": -563700000.0
            },
            {
              "concept": "us-gaap_PaymentsForRepurchaseOfCommonStock",
              "unit": "usd",
              "label": "Purchase of treasury stock",
              "value": 1800000000.0
            },
            {
              "concept": "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation",
              "unit": "usd",
              "label": "Payments related to issuance of stock for share-based compensation arrangements, net",
              "value": 700000.0
            },
            {
              "concept": "biib_RepaymentsOfDebtIncludingPremiumsPaid",
              "unit": "usd",
              "label": "Repayments of borrowings and premiums paid on debt exchange",
              "value": 170000000.0
            },
            {
              "concept": "us-gaap_ProceedsFromIssuanceOfLongTermDebt",
              "unit": "usd",
              "label": "Proceeds from borrowings",
              "value": 0.0
            },
            {
              "concept": "us-gaap_RepaymentsOfDebt",
              "unit": "usd",
              "label": "Repayments of borrowings",
              "value": 0.0
            },
            {
              "concept": "us-gaap_ProceedsFromPaymentsToMinorityShareholders",
              "unit": "usd",
              "label": "Net (distribution) contribution to noncontrolling interest",
              "value": -94400000.0
            },
            {
              "concept": "us-gaap_ProceedsFromPaymentsForOtherFinancingActivities",
              "unit": "usd",
              "label": "Other",
              "value": -21100000.0
            },
            {
              "concept": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
              "unit": "usd",
              "label": "Net cash flow used in financing activities",
              "value": -2086200000.0
            },
            {
              "concept": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
              "unit": "usd",
              "label": "Net increase (decrease) in cash and cash equivalents",
              "value": 990000000.0
            },
            {
              "concept": "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
              "unit": "usd",
              "label": "Effect of exchange rate changes on cash and cash equivalents",
              "value": -59800000.0
            }
          ]
        }
      },
      {
        "accessNumber": "0000875045-21-000010",
        "symbol": "BIIB",
        "cik": "875045",
        "year": 2020,
        "quarter": 0,
        "form": "10-K",
        "startDate": "2020-01-01 00:00:00",
        "endDate": "2020-12-31 00:00:00",
        "filedDate": "2021-02-03 00:00:00",
        "acceptedDate": "2021-02-03 16:30:07",
        "report": {
          "bs": [
            {
              "concept": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
              "unit": "usd",
              "label": "Cash and cash equivalents",
              "value": 1331200000.0
            },
            {
              "concept": "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent",
              "unit": "usd",
              "label": "Marketable securities",
              "value": 1278900000.0
            },
            {
              "concept": "us-gaap_AccountsReceivableNetCurrent",
              "unit": "usd",
              "label": "Accounts receivable, net",
              "value": 1913800000.0
            },
            {
              "concept": "biib_DueFromUnconsolidatedJointBusiness",
              "unit": "usd",
              "label": "Due from anti-CD20 therapeutic programs",
              "value": 413500000.0
            },
            {
              "concept": "us-gaap_InventoryNet",
              "unit": "usd",
              "label": "Inventory",
              "value": 1068600000.0
            },
            {
              "concept": "us-gaap_OtherAssetsCurrent",
              "unit": "usd",
              "label": "Other current assets",
              "value": 881100000.0
            },
            {
              "concept": "us-gaap_AssetsCurrent",
              "unit": "usd",
              "label": "Total current assets",
              "value": 6887100000.0
            },
            {
              "concept": "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent",
              "unit": "usd",
              "label": "Marketable securities",
              "value": 772100000.0
            },
            {
              "concept": "us-gaap_PropertyPlantAndEquipmentNet",
              "unit": "usd",
              "label": "Property, plant and equipment, net",
              "value": 3411500000.0
            },
            {
              "concept": "us-gaap_OperatingLeaseRightOfUseAsset",
              "unit": "usd",
              "label": "Operating lease assets",
              "value": 433300000.0
            },
            {
              "concept": "us-gaap_IntangibleAssetsNetExcludingGoodwill",
              "unit": "usd",
              "label": "Intangible assets, net",
              "value": 3084300000.0
            },
            {
              "concept": "us-gaap_Goodwill",
              "unit": "usd",
              "label": "Goodwill",
              "value": 5762100000.0
            },
            {
              "concept": "us-gaap_DeferredIncomeTaxAssetsNet",
              "unit": "usd",
              "label": "Deferred tax asset",
              "value": 1369500000.0
            },
            {
              "concept": "us-gaap_OtherAssetsNoncurrent",
              "unit": "usd",
              "label": "Investments and other assets",
              "value": 2899000000.0
            },
            {
              "concept": "us-gaap_Assets",
              "unit": "usd",
              "label": "Total assets",
              "value": 24618900000.0
            },
            {
              "concept": "us-gaap_DebtCurrent",
              "unit": "usd",
              "label": "Current portion of notes payable",
              "value": 0.0
            },
            {
              "concept": "us-gaap_TaxesPayableCurrent",
              "unit": "usd",
              "label": "Taxes payable",
              "value": 142000000.0
            },
            {
              "concept": "us-gaap_AccountsPayableCurrent",
              "unit": "usd",
              "label": "Accounts payable",
              "value": 454900000.0
            },
            {
              "concept": "us-gaap_OtherLiabilitiesCurrent",
              "unit": "usd",
              "label": "Accrued expenses and other",
              "value": 3145300000.0
            },
            {
              "concept": "us-gaap_LiabilitiesCurrent",
              "unit": "usd",
              "label": "Total current liabilities",
              "value": 3742200000.0
            },
            {
              "concept": "us-gaap_LongTermDebt",
              "unit": "usd",
              "label": "Notes payable",
              "value": 7426200000.0
            },
            {
              "concept": "us-gaap_DeferredIncomeTaxLiabilitiesNet",
              "unit": "usd",
              "label": "Deferred tax liability",
              "value": 1032800000.0
            },
            {
              "concept": "us-gaap_OperatingLeaseLiabilityNoncurrent",
              "unit": "usd",
              "label": "Long-term operating lease liabilities",
              "value": 402000000.0
            },
            {
              "concept": "us-gaap_OtherLiabilitiesNoncurrent",
              "unit": "usd",
              "label": "Other long-term liabilities",
              "value": 1329600000.0
            },
            {
              "concept": "us-gaap_Liabilities",
              "unit": "usd",
              "label": "Total liabilities",
              "value": 13932800000.0
            },
            {
              "concept": "us-gaap_PreferredStockValue",
              "unit": "usd",
              "label": "Preferred stock, par value $0.001 per share",
              "value": 0.0
            },
            {
              "concept": "us-gaap_CommonStockValue",
              "unit": "usd",
              "label": "Common stock, par value $0.0005 per share",
              "value": 100000.0
            },
            {
              "concept": "us-gaap_AdditionalPaidInCapital",
              "unit": "usd",
              "label": "Additional paid-in capital",
              "value": 0.0
            },
            {
              "concept": "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax",
              "unit": "usd",
              "label": "Accumulated other comprehensive loss",
              "value": -299000000.0
            },
            {
              "concept": "us-gaap_RetainedEarningsAccumulatedDeficit",
              "unit": "usd",
              "label": "Retained earnings",
              "value": 13976300000.0
            },
            {
              "concept": "us-gaap_TreasuryStockValue",
              "unit": "usd",
              "label": "Treasury stock, at cost; 23.8 million and 23.8 million shares, respectively",
              "value": 2977100000.0
            },
            {
              "concept": "us-gaap_StockholdersEquity",
              "unit": "usd",
              "label": "Total Biogen Inc. shareholders\u2019 equity",
              "value": 10700300000.0
            },
            {
              "concept": "us-gaap_MinorityInterest",
              "unit": "usd",
              "label": "Noncontrolling interests",
              "value": -14200000.0
            },
            {
              "concept": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
              "unit": "usd",
              "label": "Total equity",
              "value": 10686100000.0
            },
            {
              "concept": "us-gaap_LiabilitiesAndStockholdersEquity",
              "unit": "usd",
              "label": "Total liabilities and equity",
              "value": 24618900000.0
            }
          ],
          "ic": [
            {
              "concept": "us-gaap_Revenues",
              "unit": "usd",
              "label": "Total revenues",
              "value": 13444600000.0
            },
            {
              "concept": "us-gaap_CostOfGoodsAndServicesSold",
              "unit": "usd",
              "label": "Cost of sales, excluding amortization and impairment of acquired intangible assets",
              "value": 1805200000.0
            },
            {
              "concept": "us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
              "unit": "usd",
              "label": "Research and development",
              "value": 3990900000.0
            },
            {
              "concept": "us-gaap_SellingGeneralAndAdministrativeExpense",
              "unit": "usd",
              "label": "Selling, general and administrative",
              "value": 2504500000.0
            },
            {
              "concept": "biib_AmortizationandImpairmentofAcquiredIntangibleAssets",
              "unit": "usd",
              "label": "Amortization and impairment of acquired intangible assets",
              "value": 464800000.0
            },
            {
              "concept": "biib_CollaborationProfitSharing",
              "unit": "usd",
              "label": "Collaboration profit (loss) sharing",
              "value": 232900000.0
            },
            {
              "concept": "us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown",
              "unit": "usd",
              "label": "(Gain) loss on divestiture of Hiller\u00f8d, Denmark manufacturing operations",
              "value": -92500000.0
            },
            {
              "concept": "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings",
              "unit": "usd",
              "label": "(Gain) loss on fair value remeasurement of contingent consideration",
              "value": 86300000.0
            },
            {
              "concept": "us-gaap_ResearchAndDevelopmentInProcess",
              "unit": "usd",
              "label": "Acquired in-process research and development",
              "value": 75000000.0
            },
            {
              "concept": "us-gaap_RestructuringCharges",
              "unit": "usd",
              "label": "Restructuring charges",
              "value": 0.0
            },
            {
              "concept": "us-gaap_CostsAndExpenses",
              "unit": "usd",
              "label": "Total cost and expenses",
              "value": 8894500000.0
            },
            {
              "concept": "us-gaap_OperatingIncomeLoss",
              "unit": "usd",
              "label": "Income from operations",
              "value": 4550100000.0
            },
            {
              "concept": "us-gaap_NonoperatingIncomeExpense",
              "unit": "usd",
              "label": "Other income (expense), net",
              "value": 497400000.0
            },
            {
              "concept": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
              "unit": "usd",
              "label": "Income before income tax expense and equity in loss of investee, net of tax",
              "value": 5047500000.0
            },
            {
              "concept": "us-gaap_IncomeTaxExpenseBenefit",
              "unit": "usd",
              "label": "Income tax expense",
              "value": 992300000.0
            },
            {
              "concept": "biib_IncomeLossFromEquityMethodInvestmentsNetOfTax",
              "unit": "usd",
              "label": "Equity in (income) loss of investee, net of tax",
              "value": 5300000.0
            },
            {
              "concept": "us-gaap_ProfitLoss",
              "unit": "usd",
              "label": "Net income",
              "value": 4060500000.0
            },
            {
              "concept": "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest",
              "unit": "usd",
              "label": "Net income (loss) attributable to noncontrolling interests, net of tax",
              "value": 59900000.0
            },
            {
              "concept": "us-gaap_NetIncomeLoss",
              "unit": "usd",
              "label": "Net income attributable to Biogen Inc.",
              "value": 4000600000.0
            },
            {
              "concept": "us-gaap_EarningsPerShareBasic",
              "unit": "usd/share",
              "label": "Basic earnings per share attributable to Biogen Inc. (in dollars per share)",
              "value": 24.86
            },
            {
              "concept": "us-gaap_EarningsPerShareDiluted",
              "unit": "usd/share",
              "label": "Diluted earnings per share attributable to Biogen Inc. (in dollars per share)",
              "value": 24.8
            },
            {
              "concept": "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic",
              "unit": "shares",
              "label": "Basic earnings per share attributable to Biogen Inc. (in shares)",
              "value": 160900000.0
            },
            {
              "concept": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
              "unit": "shares",
              "label": "Diluted earnings per share attributable to Biogen Inc. (in shares)",
              "value": 161300000.0
            },
            {
              "concept": "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax",
              "unit": "usd",
              "label": "Unrealized gains (losses) on securities available for sale, net of tax",
              "value": -2800000.0
            },
            {
              "concept": "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent",
              "unit": "usd",
              "label": "Unrealized gains (losses) on cash flow hedges, net of tax",
              "value": -186800000.0
            },
            {
              "concept": "us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAfterAdjustmentsAndTax",
              "unit": "usd",
              "label": "Gains (losses) on net investment hedges, net of tax",
              "value": -33600000.0
            },
            {
              "concept": "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax",
              "unit": "usd",
              "label": "Unrealized gains (losses) on pension benefit obligation, net of tax",
              "value": 33500000.0
            },
            {
              "concept": "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
              "unit": "usd",
              "label": "Currency translation adjustment",
              "value": 92900000.0
            },
            {
              "concept": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
              "unit": "usd",
              "label": "Total other comprehensive income (loss), net of tax",
              "value": -163800000.0
            },
            {
              "concept": "us-gaap_ComprehensiveIncomeNetOfTax",
              "unit": "usd",
              "label": "Comprehensive income attributable to Biogen Inc.",
              "value": 3836800000.0
            },
            {
              "concept": "us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest",
              "unit": "usd",
              "label": "Comprehensive income (loss) attributable to noncontrolling interests, net of tax",
              "value": 60900000.0
            },
            {
              "concept": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
              "unit": "usd",
              "label": "Comprehensive income",
              "value": 3897700000.0
            }
          ],
          "cf": [
            {
              "concept": "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings",
              "unit": "usd",
              "label": "(Gain) loss on fair value remeasurement of contingent consideration",
              "value": 86300000.0
            },
            {
              "concept": "us-gaap_ResearchAndDevelopmentInProcess",
              "unit": "usd",
              "label": "Acquired in-process research and development",
              "value": 75000000.0
            },
            {
              "concept": "us-gaap_ProfitLoss",
              "unit": "usd",
              "label": "Net income",
              "value": 4060500000.0
            },
            {
              "concept": "us-gaap_DepreciationDepletionAndAmortization",
              "unit": "usd",
              "label": "Depreciation and amortization",
              "value": 457200000.0
            },
            {
              "concept": "us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill",
              "unit": "usd",
              "label": "Impairment of intangible assets",
              "value": 209700000.0
            },
            {
              "concept": "us-gaap_ShareBasedCompensation",
              "unit": "usd",
              "label": "Share-based compensation",
              "value": 198300000.0
            },
            {
              "concept": "us-gaap_IncomeLossFromIndividuallySignificantComponentDisposedOfOrHeldForSaleExcludingDiscontinuedOperationsAttributableToParentBeforeIncomeTax",
              "unit": "usd",
              "label": "(Gain)/loss on divestiture of Hillerod, Denmark manufactuing operations",
              "value": 92500000.0
            },
            {
              "concept": "us-gaap_DeferredIncomeTaxExpenseBenefit",
              "unit": "usd",
              "label": "Deferred income taxes",
              "value": 149000000.0
            },
            {
              "concept": "us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi",
              "unit": "usd",
              "label": "Unrealized (gain) loss on strategic investments",
              "value": 681800000.0
            },
            {
              "concept": "us-gaap_IncomeLossFromEquityMethodInvestments",
              "unit": "usd",
              "label": "Loss on equity method investment",
              "value": 3300000.0
            },
            {
              "concept": "us-gaap_OtherNoncashIncomeExpense",
              "unit": "usd",
              "label": "Other",
              "value": -131200000.0
            },
            {
              "concept": "us-gaap_IncreaseDecreaseInAccountsReceivable",
              "unit": "usd",
              "label": "Accounts receivable",
              "value": -2800000.0
            },
            {
              "concept": "us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet",
              "unit": "usd",
              "label": "Due from anti-CD20 therapeutic programs",
              "value": -176700000.0
            },
            {
              "concept": "us-gaap_IncreaseDecreaseInInventories",
              "unit": "usd",
              "label": "Inventory",
              "value": 316300000.0
            },
            {
              "concept": "us-gaap_IncreaseDecreaseInAccruedLiabilities",
              "unit": "usd",
              "label": "Accrued expenses and other current liabilities",
              "value": 154200000.0
            },
            {
              "concept": "us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable",
              "unit": "usd",
              "label": "Income tax assets and liabilities",
              "value": -67500000.0
            },
            {
              "concept": "us-gaap_IncreaseDecreaseInOtherOperatingLiabilities",
              "unit": "usd",
              "label": "Other changes in operating assets and liabilities, net",
              "value": -137100000.0
            },
            {
              "concept": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
              "unit": "usd",
              "label": "Net cash flows provided by operating activities",
              "value": 4229800000.0
            },
            {
              "concept": "us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities",
              "unit": "usd",
              "label": "Proceeds from sales and maturities of marketable securities",
              "value": 7299400000.0
            },
            {
              "concept": "us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt",
              "unit": "usd",
              "label": "Purchases of marketable securities",
              "value": 6397700000.0
            },
            {
              "concept": "us-gaap_PaymentsToAcquireOtherProductiveAssets",
              "unit": "usd",
              "label": "Contingent consideration paid related to Fumapharm AG acquisition",
              "value": 0.0
            },
            {
              "concept": "us-gaap_PaymentsToAcquireBusinessTwoNetOfCashAcquired",
              "unit": "usd",
              "label": "Acquisition of Nightstar Therapeutics plc, net of cash acquired",
              "value": 0.0
            },
            {
              "concept": "us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment",
              "unit": "usd",
              "label": "Proceeds from divesiture of Hillerod, Denmark manufacturing operations",
              "value": 0.0
            },
            {
              "concept": "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment",
              "unit": "usd",
              "label": "Purchases of property, plant and equipment",
              "value": 424800000.0
            },
            {
              "concept": "us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment",
              "unit": "usd",
              "label": "Acquired in-process research and development",
              "value": 75000000.0
            },
            {
              "concept": "us-gaap_PaymentsToAcquireIntangibleAssets",
              "unit": "usd",
              "label": "Acquisitions of intangible assets",
              "value": 52000000.0
            },
            {
              "concept": "us-gaap_PaymentsToAcquireEquityMethodInvestments",
              "unit": "usd",
              "label": "Investment in Samsung Bioepis",
              "value": 0.0
            },
            {
              "concept": "us-gaap_ProceedsFromSaleOfEquityMethodInvestments",
              "unit": "usd",
              "label": "Proceeds from sales of strategic investments",
              "value": 74900000.0
            },
            {
              "concept": "us-gaap_PaymentsForProceedsFromOtherInvestingActivities",
              "unit": "usd",
              "label": "Other",
              "value": 26900000.0
            },
            {
              "concept": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
              "unit": "usd",
              "label": "Net cash flows provided by (used in) investing activities",
              "value": -608600000.0
            },
            {
              "concept": "us-gaap_PaymentsForRepurchaseOfCommonStock",
              "unit": "usd",
              "label": "Purchase of treasury stock",
              "value": 6679100000.0
            },
            {
              "concept": "us-gaap_PaymentsToMinorityShareholders",
              "unit": "usd",
              "label": "Payments related to issuance of stock for share-based compensation arrangements, net",
              "value": 4600000.0
            },
            {
              "concept": "us-gaap_ProceedsFromIssuanceOfLongTermDebt",
              "unit": "usd",
              "label": "Proceeds from borrowings",
              "value": 2967400000.0
            },
            {
              "concept": "us-gaap_RepaymentsOfDebt",
              "unit": "usd",
              "label": "Repayments of borrowings",
              "value": 1500000000.0
            },
            {
              "concept": "us-gaap_PaymentsOfCapitalDistribution",
              "unit": "usd",
              "label": "Net contribution (distribution) to noncontrolling interest",
              "value": 71000000.0
            },
            {
              "concept": "us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities",
              "unit": "usd",
              "label": "Contingent consideration payments",
              "value": 0.0
            },
            {
              "concept": "us-gaap_ProceedsFromPaymentsForOtherFinancingActivities",
              "unit": "usd",
              "label": "Other",
              "value": 14600000.0
            },
            {
              "concept": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
              "unit": "usd",
              "label": "Net cash flows (used in) financing activities",
              "value": -5272700000.0
            },
            {
              "concept": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
              "unit": "usd",
              "label": "Net increase (decrease) in cash and cash equivalents",
              "value": -1651500000.0
            },
            {
              "concept": "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
              "unit": "usd",
              "label": "Effect of exchange rate changes on cash and cash equivalents",
              "value": 69000000.0
            }
          ]
        }
      },
      {
        "accessNumber": "0000875045-20-000005",
        "symbol": "BIIB",
        "cik": "875045",
        "year": 2019,
        "quarter": 0,
        "form": "10-K",
        "startDate": "2019-01-01 00:00:00",
        "endDate": "2019-12-31 00:00:00",
        "filedDate": "2020-02-06 00:00:00",
        "acceptedDate": "2020-02-06 16:32:39",
        "report": {
          "bs": [
            {
              "concept": "us-gaap_CashAndCashEquivalentsAtCarryingValue",
              "unit": "usd",
              "label": "Cash and cash equivalents, end of the year",
              "value": 2913700000.0
            },
            {
              "concept": "us-gaap_AvailableForSaleSecuritiesCurrent",
              "unit": "usd",
              "label": "Marketable securities",
              "value": 1562200000
            },
            {
              "concept": "us-gaap_AccountsReceivableNetCurrent",
              "unit": "usd",
              "label": "Accounts receivable, net",
              "value": 1880500000
            },
            {
              "concept": "biib_DueFromUnconsolidatedJointBusiness",
              "unit": "usd",
              "label": "Due from anti-CD20 therapeutic programs",
              "value": 590200000
            },
            {
              "concept": "us-gaap_InventoryNet",
              "unit": "usd",
              "label": "Inventory",
              "value": 804200000.0
            },
            {
              "concept": "us-gaap_OtherAssetsCurrent",
              "unit": "usd",
              "label": "Other current assets",
              "value": 631000000
            },
            {
              "concept": "us-gaap_AssetsCurrent",
              "unit": "usd",
              "label": "Total current assets",
              "value": 8381800000
            },
            {
              "concept": "us-gaap_AvailableForSaleSecuritiesNoncurrent",
              "unit": "usd",
              "label": "Marketable securities",
              "value": 1408100000
            },
            {
              "concept": "us-gaap_PropertyPlantAndEquipmentNet",
              "unit": "usd",
              "label": "Property, plant and equipment, net",
              "value": 3247300000.0
            },
            {
              "concept": "us-gaap_OperatingLeaseRightOfUseAsset",
              "unit": "usd",
              "label": "Operating lease assets",
              "value": 427000000
            },
            {
              "concept": "us-gaap_IntangibleAssetsNetExcludingGoodwill",
              "unit": "usd",
              "label": "Intangible assets, net",
              "value": 3527400000.0
            },
            {
              "concept": "us-gaap_Goodwill",
              "unit": "usd",
              "label": "Goodwill",
              "value": 5757800000.0
            },
            {
              "concept": "us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent",
              "unit": "usd",
              "label": "Deferred tax asset",
              "value": 3232100000
            },
            {
              "concept": "us-gaap_OtherAssetsNoncurrent",
              "unit": "usd",
              "label": "Investments and other assets",
              "value": 1252800000
            },
            {
              "concept": "us-gaap_Assets",
              "unit": "usd",
              "label": "Total assets",
              "value": 27234300000
            },
            {
              "concept": "us-gaap_DebtCurrent",
              "unit": "usd",
              "label": "Current portion of notes payable",
              "value": 1495800000.0
            },
            {
              "concept": "us-gaap_TaxesPayableCurrent",
              "unit": "usd",
              "label": "Taxes payable",
              "value": 71400000
            },
            {
              "concept": "us-gaap_AccountsPayableCurrent",
              "unit": "usd",
              "label": "Accounts payable",
              "value": 530800000
            },
            {
              "concept": "us-gaap_OtherLiabilitiesCurrent",
              "unit": "usd",
              "label": "Accrued expenses and other",
              "value": 2765800000.0
            },
            {
              "concept": "us-gaap_LiabilitiesCurrent",
              "unit": "usd",
              "label": "Total current liabilities",
              "value": 4863800000
            },
            {
              "concept": "us-gaap_LongTermDebt",
              "unit": "usd",
              "label": "Notes payable",
              "value": 4459000000.0
            },
            {
              "concept": "us-gaap_DeferredTaxLiabilitiesNoncurrent",
              "unit": "usd",
              "label": "Deferred tax liability",
              "value": 2810800000
            },
            {
              "concept": "us-gaap_OperatingLeaseLiabilityNoncurrent",
              "unit": "usd",
              "label": "Operating lease liability, noncurrent",
              "value": 412700000
            },
            {
              "concept": "us-gaap_OtherLiabilitiesNoncurrent",
              "unit": "usd",
              "label": "Other long-term liabilities",
              "value": 1348900000.0
            },
            {
              "concept": "us-gaap_Liabilities",
              "unit": "usd",
              "label": "Total liabilities",
              "value": 13895200000
            },
            {
              "concept": "us-gaap_PreferredStockValue",
              "unit": "usd",
              "label": "Preferred stock, par value $0.001 per share",
              "value": 0
            },
            {
              "concept": "us-gaap_CommonStockValue",
              "unit": "usd",
              "label": "Common stock, par value $0.0005 per share",
              "value": 100000
            },
            {
              "concept": "us-gaap_AdditionalPaidInCapital",
              "unit": "usd",
              "label": "Additional paid-in capital",
              "value": 0
            },
            {
              "concept": "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax",
              "unit": "usd",
              "label": "Accumulated other comprehensive loss",
              "value": -135200000.0
            },
            {
              "concept": "us-gaap_RetainedEarningsAccumulatedDeficit",
              "unit": "usd",
              "label": "Retained earnings",
              "value": 16455400000
            },
            {
              "concept": "us-gaap_TreasuryStockValue",
              "unit": "usd",
              "label": "Treasury stock, at cost; 23.8 million and 23.8 million shares, respectively",
              "value": 2977100000
            },
            {
              "concept": "us-gaap_StockholdersEquity",
              "unit": "usd",
              "label": "Total Biogen Inc. shareholders\u2019 equity",
              "value": 13343200000.0
            },
            {
              "concept": "us-gaap_MinorityInterest",
              "unit": "usd",
              "label": "Noncontrolling interests",
              "value": -4100000
            },
            {
              "concept": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
              "unit": "usd",
              "label": "Total equity",
              "value": 13339100000.0
            },
            {
              "concept": "us-gaap_LiabilitiesAndStockholdersEquity",
              "unit": "usd",
              "label": "Total liabilities and equity",
              "value": 27234300000
            }
          ],
          "ic": [
            {
              "concept": "us-gaap_Revenues",
              "unit": "usd",
              "label": "Total Revenues",
              "value": 14377900000.0
            },
            {
              "concept": "us-gaap_CostOfGoodsAndServicesSold",
              "unit": "usd",
              "label": "Cost of Sales",
              "value": 1955400000
            },
            {
              "concept": "us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
              "unit": "usd",
              "label": "Research and development",
              "value": 2280600000
            },
            {
              "concept": "us-gaap_SellingGeneralAndAdministrativeExpense",
              "unit": "usd",
              "label": "Selling, general and administrative",
              "value": 2374700000
            },
            {
              "concept": "biib_AmortizationandImpairmentofAcquiredIntangibleAssets",
              "unit": "usd",
              "label": "Amortization and impairment of acquired intangible assets",
              "value": 489900000.0
            },
            {
              "concept": "biib_CollaborationProfitSharing",
              "unit": "usd",
              "label": "Collaboration profit (loss) sharing",
              "value": 241600000
            },
            {
              "concept": "us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown",
              "unit": "usd",
              "label": "Loss on divestiture of Hiller\u00f8d, Denmark manufacturing operations",
              "value": 55300000
            },
            {
              "concept": "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings",
              "unit": "usd",
              "label": "Loss (gain) on fair value remeasurement of contingent consideration",
              "value": 63700000.0
            },
            {
              "concept": "us-gaap_ResearchAndDevelopmentInProcess",
              "unit": "usd",
              "label": "Acquired in-process research and development",
              "value": 0.0
            },
            {
              "concept": "us-gaap_RestructuringCharges",
              "unit": "usd",
              "label": "Restructuring Charges",
              "value": 1500000
            },
            {
              "concept": "us-gaap_CostsAndExpenses",
              "unit": "usd",
              "label": "Costs and expenses",
              "value": 7335300000
            },
            {
              "concept": "us-gaap_OperatingIncomeLoss",
              "unit": "usd",
              "label": "Income from operations",
              "value": 7042600000
            },
            {
              "concept": "us-gaap_NonoperatingIncomeExpense",
              "unit": "usd",
              "label": "Total other income (expense), net",
              "value": 83300000.0
            },
            {
              "concept": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
              "unit": "usd",
              "label": "Income before income tax expense and equity in loss of investee, net of tax",
              "value": 7125900000.0
            },
            {
              "concept": "us-gaap_IncomeTaxExpenseBenefit",
              "unit": "usd",
              "label": "Total income tax expense",
              "value": 1158000000.0
            },
            {
              "concept": "us-gaap_IncomeLossFromEquityMethodInvestments",
              "unit": "usd",
              "label": "Equity in loss of investee, net of tax",
              "value": -79400000
            },
            {
              "concept": "us-gaap_ProfitLoss",
              "unit": "usd",
              "label": "Net income",
              "value": 5888500000.0
            },
            {
              "concept": "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest",
              "unit": "usd",
              "label": "Net income (loss) attributable to noncontrolling interests, net of tax",
              "value": 0
            },
            {
              "concept": "us-gaap_NetIncomeLoss",
              "unit": "usd",
              "label": "Net income attributable to Biogen Inc.",
              "value": 5888500000.0
            },
            {
              "concept": "us-gaap_EarningsPerShareBasic",
              "unit": "usd/share",
              "label": "Basic earnings per share attributable to Biogen Inc.",
              "value": 31.47
            },
            {
              "concept": "us-gaap_EarningsPerShareDiluted",
              "unit": "usd/share",
              "label": "Diluted earnings per share attributable to Biogen Inc.",
              "value": 31.42
            },
            {
              "concept": "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic",
              "unit": "shares",
              "label": "Weighted average number of common shares outstanding",
              "value": 187100000.0
            },
            {
              "concept": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
              "unit": "shares",
              "label": "Shares used in calculating diluted earnings per share",
              "value": 187400000.0
            },
            {
              "concept": "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
              "unit": "usd",
              "label": "Unrealized gains (losses) recognized during the period, net of tax",
              "value": 11800000
            },
            {
              "concept": "us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax",
              "unit": "usd",
              "label": "Less: reclassification adjustment for (gains) losses included in net income, net of tax",
              "value": 3600000
            },
            {
              "concept": "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax",
              "unit": "usd",
              "label": "Unrealized gains (losses) on securities available for sale, net of tax",
              "value": 8200000
            },
            {
              "concept": "us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax",
              "unit": "usd",
              "label": "Unrealized gains (losses) recognized during the period, net of tax",
              "value": 88100000
            },
            {
              "concept": "us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesNetOfTax",
              "unit": "usd",
              "label": "Less: reclassification adjustment for (gains) losses included in net income, net of tax",
              "value": 115000000
            },
            {
              "concept": "us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax",
              "unit": "usd",
              "label": "Unrealized gains (losses) on cash flow hedges, net of tax",
              "value": -26900000
            },
            {
              "concept": "us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax",
              "unit": "usd",
              "label": "Gains (Losses) on net investment hedge recognized during period",
              "value": 28600000
            },
            {
              "concept": "us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAdjustmentsAfterTax",
              "unit": "usd",
              "label": "Less: Reclassification of net investment hedge forward points amortization",
              "value": 7000000
            },
            {
              "concept": "us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAfterAdjustmentsAndTax",
              "unit": "usd",
              "label": "Gains (losses) on net investment hedges",
              "value": 21600000
            },
            {
              "concept": "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax",
              "unit": "usd",
              "label": "Unrealized gains (losses) on pension benefit obligation, net of tax",
              "value": 1500000
            },
            {
              "concept": "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
              "unit": "usd",
              "label": "Currency translation adjustment",
              "value": 103800000
            },
            {
              "concept": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
              "unit": "usd",
              "label": "Total other comprehensive income (loss), net of tax",
              "value": 105200000.0
            },
            {
              "concept": "us-gaap_ComprehensiveIncomeNetOfTax",
              "unit": "usd",
              "label": "Comprehensive income attributable to Biogen Inc.",
              "value": 5993700000
            },
            {
              "concept": "us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest",
              "unit": "usd",
              "label": "Comprehensive income (loss) attributable to noncontrolling interests, net of tax",
              "value": -400000
            },
            {
              "concept": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
              "unit": "usd",
              "label": "Comprehensive income",
              "value": 5993300000
            }
          ],
          "cf": [
            {
              "concept": "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings",
              "unit": "usd",
              "label": "Loss (gain) on fair value remeasurement of contingent consideration",
              "value": 63700000.0
            },
            {
              "concept": "us-gaap_ResearchAndDevelopmentInProcess",
              "unit": "usd",
              "label": "Acquired in-process research and development",
              "value": 0.0
            },
            {
              "concept": "us-gaap_ProfitLoss",
              "unit": "usd",
              "label": "Net income",
              "value": 5888500000.0
            },
            {
              "concept": "us-gaap_DepreciationDepletionAndAmortization",
              "unit": "usd",
              "label": "Depreciation, amortization and impairments",
              "value": 680600000
            },
            {
              "concept": "us-gaap_ShareBasedCompensation",
              "unit": "usd",
              "label": "Share-based compensation",
              "value": 182300000
            },
            {
              "concept": "us-gaap_DeferredIncomeTaxExpenseBenefit",
              "unit": "usd",
              "label": "Deferred income taxes",
              "value": 67100000.0
            },
            {
              "concept": "us-gaap_IncomeLossFromIndividuallySignificantComponentDisposedOfOrHeldForSaleExcludingDiscontinuedOperationsAttributableToParentBeforeIncomeTax",
              "unit": "usd",
              "label": "Income (Loss) from Individually Significant Component Disposed of or Held-for-sale, Excluding Discontinued Operations, Attributable to Parent, before Income Tax",
              "value": -55300000
            },
            {
              "concept": "us-gaap_OtherNoncashIncomeExpense",
              "unit": "usd",
              "label": "Other",
              "value": -69200000
            },
            {
              "concept": "us-gaap_IncreaseDecreaseInAccountsReceivable",
              "unit": "usd",
              "label": "Accounts receivable",
              "value": -68800000
            },
            {
              "concept": "us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet",
              "unit": "usd",
              "label": "Due from anti-CD20 therapeutic programs",
              "value": 63300000
            },
            {
              "concept": "us-gaap_IncreaseDecreaseInInventories",
              "unit": "usd",
              "label": "Inventory",
              "value": 19200000
            },
            {
              "concept": "us-gaap_IncreaseDecreaseInAccruedLiabilities",
              "unit": "usd",
              "label": "Accrued expenses and other current liabilities",
              "value": 240200000
            },
            {
              "concept": "us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable",
              "unit": "usd",
              "label": "Income tax assets and liabilities",
              "value": 16100000
            },
            {
              "concept": "us-gaap_IncreaseDecreaseInOtherOperatingLiabilities",
              "unit": "usd",
              "label": "Other liabilities",
              "value": -43300000
            },
            {
              "concept": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
              "unit": "usd",
              "label": "Net cash flows provided by operating activities",
              "value": 7078600000
            },
            {
              "concept": "us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities",
              "unit": "usd",
              "label": "Proceeds from sales and maturities of marketable securities",
              "value": 6007000000.0
            },
            {
              "concept": "us-gaap_PaymentsToAcquireAvailableForSaleSecurities",
              "unit": "usd",
              "label": "Purchases of marketable securities",
              "value": 5252600000
            },
            {
              "concept": "us-gaap_PaymentsToAcquireOtherProductiveAssets",
              "unit": "usd",
              "label": "Contingent consideration related to Fumapharm AG acquisition",
              "value": 300000000
            },
            {
              "concept": "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired",
              "unit": "usd",
              "label": "Payments to Acquire Businesses, Net of Cash Acquired",
              "value": 744400000
            },
            {
              "concept": "us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment",
              "unit": "usd",
              "label": "Proceeds from Sale of Property, Plant, and Equipment",
              "value": 923700000
            },
            {
              "concept": "us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment",
              "unit": "usd",
              "label": "Payments to Acquire in Process Research and Development",
              "value": 0
            },
            {
              "concept": "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment",
              "unit": "usd",
              "label": "Purchases of property, plant and equipment",
              "value": 514500000
            },
            {
              "concept": "us-gaap_PaymentsToAcquireIntangibleAssets",
              "unit": "usd",
              "label": "Acquisitions of intangible assets",
              "value": 155000000
            },
            {
              "concept": "us-gaap_PaymentsToAcquireOtherInvestments",
              "unit": "usd",
              "label": "Payments to Acquire Other Investments",
              "value": 0
            },
            {
              "concept": "us-gaap_PaymentsToAcquireEquityMethodInvestments",
              "unit": "usd",
              "label": "Payments to increase investment in Samsung Bioepis",
              "value": 0
            },
            {
              "concept": "us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity",
              "unit": "usd",
              "label": "Proceeds from Sale of Available-for-sale Securities, Equity",
              "value": 479300000
            },
            {
              "concept": "us-gaap_PaymentsForProceedsFromOtherInvestingActivities",
              "unit": "usd",
              "label": "Other",
              "value": -27000000
            },
            {
              "concept": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
              "unit": "usd",
              "label": "Net cash flows provided by (used in) investing activities",
              "value": 470500000
            },
            {
              "concept": "us-gaap_PaymentsForRepurchaseOfCommonStock",
              "unit": "usd",
              "label": "Purchases of treasury stock",
              "value": 5868300000
            },
            {
              "concept": "us-gaap_PaymentsToMinorityShareholders",
              "unit": "usd",
              "label": "Payments to Noncontrolling Interests",
              "value": -4300000
            },
            {
              "concept": "us-gaap_RepaymentsOfDebt",
              "unit": "usd",
              "label": "Repayments of borrowings",
              "value": 0
            },
            {
              "concept": "us-gaap_PaymentsOfCapitalDistribution",
              "unit": "usd",
              "label": "Net cash contribution to Bioverativ, Inc.",
              "value": 0
            },
            {
              "concept": "us-gaap_PaymentsToAcquireProductiveAssets",
              "unit": "usd",
              "label": "Contingent consideration payments",
              "value": 0
            },
            {
              "concept": "us-gaap_ProceedsFromPaymentsForOtherFinancingActivities",
              "unit": "usd",
              "label": "Other",
              "value": 3600000
            },
            {
              "concept": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
              "unit": "usd",
              "label": "Net cash flows used in financing activities",
              "value": -5860400000
            },
            {
              "concept": "us-gaap_CashAndCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
              "unit": "usd",
              "label": "Net increase (decrease) in cash and cash equivalents",
              "value": 1688700000
            },
            {
              "concept": "us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents",
              "unit": "usd",
              "label": "Effect of exchange rate changes on cash and cash equivalents",
              "value": 400000
            }
          ]
        }
      },
      {
        "accessNumber": "0000875045-19-000006",
        "symbol": "BIIB",
        "cik": "875045",
        "year": 2018,
        "quarter": 0,
        "form": "10-K",
        "startDate": "2018-01-01 00:00:00",
        "endDate": "2018-12-31 00:00:00",
        "filedDate": "2019-02-06 00:00:00",
        "acceptedDate": "2019-02-06 17:21:15",
        "report": {
          "bs": [
            {
              "concept": "biib_DueFromUnconsolidatedJointBusiness",
              "unit": "usd",
              "label": "Due from anti-CD20 therapeutic programs",
              "value": 526900000
            },
            {
              "concept": "us-gaap_AccountsPayableCurrent",
              "unit": "usd",
              "label": "Accounts payable",
              "value": 370500000
            },
            {
              "concept": "us-gaap_AccountsReceivableNetCurrent",
              "unit": "usd",
              "label": "Accounts receivable, net",
              "value": 1958500000
            },
            {
              "concept": "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax",
              "unit": "usd",
              "label": "Accumulated other comprehensive loss",
              "value": -240400000
            },
            {
              "concept": "us-gaap_AdditionalPaidInCapital",
              "unit": "usd",
              "label": "Additional paid-in capital",
              "value": 0
            },
            {
              "concept": "us-gaap_Assets",
              "unit": "usd",
              "label": "Total assets",
              "value": 25288900000
            },
            {
              "concept": "us-gaap_AssetsCurrent",
              "unit": "usd",
              "label": "Total current assets",
              "value": 7640900000
            },
            {
              "concept": "us-gaap_AvailableForSaleSecuritiesCurrent",
              "unit": "usd",
              "label": "Marketable securities",
              "value": 2313400000
            },
            {
              "concept": "us-gaap_AvailableForSaleSecuritiesNoncurrent",
              "unit": "usd",
              "label": "Marketable securities",
              "value": 1375900000
            },
            {
              "concept": "us-gaap_CashAndCashEquivalentsAtCarryingValue",
              "unit": "usd",
              "label": "Cash and cash equivalents",
              "value": 1224600000
            },
            {
              "concept": "us-gaap_CommonStockValue",
              "unit": "usd",
              "label": "Common stock, par value $0.0005 per share",
              "value": 100000
            },
            {
              "concept": "us-gaap_DebtCurrent",
              "unit": "usd",
              "label": "Current portion of notes payable",
              "value": 0
            },
            {
              "concept": "us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent",
              "unit": "usd",
              "label": "Deferred tax asset",
              "value": 2153900000
            },
            {
              "concept": "us-gaap_DeferredTaxLiabilitiesNoncurrent",
              "unit": "usd",
              "label": "Deferred tax liability",
              "value": 1636200000
            },
            {
              "concept": "us-gaap_Goodwill",
              "unit": "usd",
              "label": "Goodwill, end of period",
              "value": 5706400000
            },
            {
              "concept": "us-gaap_IntangibleAssetsNetExcludingGoodwill",
              "unit": "usd",
              "label": "Intangible assets, net",
              "value": 3120000000
            },
            {
              "concept": "us-gaap_InventoryNet",
              "unit": "usd",
              "label": "Inventory, current",
              "value": 929900000
            },
            {
              "concept": "us-gaap_Liabilities",
              "unit": "usd",
              "label": "Total liabilities",
              "value": 12257300000
            },
            {
              "concept": "us-gaap_LiabilitiesAndStockholdersEquity",
              "unit": "usd",
              "label": "Total liabilities and equity",
              "value": 25288900000
            },
            {
              "concept": "us-gaap_LiabilitiesCurrent",
              "unit": "usd",
              "label": "Total current liabilities",
              "value": 3295200000
            },
            {
              "concept": "us-gaap_LongTermDebt",
              "unit": "usd",
              "label": "Notes payable",
              "value": 5936500000
            },
            {
              "concept": "us-gaap_MinorityInterest",
              "unit": "usd",
              "label": "Noncontrolling interests",
              "value": -8000000
            },
            {
              "concept": "us-gaap_OtherAssetsCurrent",
              "unit": "usd",
              "label": "Other current assets",
              "value": 687600000
            },
            {
              "concept": "us-gaap_OtherAssetsNoncurrent",
              "unit": "usd",
              "label": "Investments and other assets",
              "value": 1690600000
            },
            {
              "concept": "us-gaap_OtherLiabilitiesCurrent",
              "unit": "usd",
              "label": "Accrued expenses and other",
              "value": 2861200000
            },
            {
              "concept": "us-gaap_OtherLiabilitiesNoncurrent",
              "unit": "usd",
              "label": "Other long-term liabilities",
              "value": 1389400000
            },
            {
              "concept": "us-gaap_PreferredStockValue",
              "unit": "usd",
              "label": "Preferred stock, par value $0.001 per share",
              "value": 0
            },
            {
              "concept": "us-gaap_PropertyPlantAndEquipmentNet",
              "unit": "usd",
              "label": "Property, plant and equipment, net",
              "value": 3601200000
            },
            {
              "concept": "us-gaap_RetainedEarningsAccumulatedDeficit",
              "unit": "usd",
              "label": "Retained earnings",
              "value": 16257000000
            },
            {
              "concept": "us-gaap_StockholdersEquity",
              "unit": "usd",
              "label": "Total Biogen Inc. shareholders\u2019 equity",
              "value": 13039600000
            },
            {
              "concept": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
              "unit": "usd",
              "label": "Total equity",
              "value": 13031600000
            },
            {
              "concept": "us-gaap_TaxesPayableCurrent",
              "unit": "usd",
              "label": "Taxes payable",
              "value": 63500000
            },
            {
              "concept": "us-gaap_TreasuryStockValue",
              "unit": "usd",
              "label": "Treasury stock, at cost; 23.8 million and 23.8 million shares, respectively",
              "value": 2977100000
            }
          ],
          "ic": [
            {
              "concept": "biib_AmortizationandImpairmentofAcquiredIntangibleAssets",
              "unit": "usd",
              "label": "Amortization and impairment of acquired intangible assets",
              "value": 747300000
            },
            {
              "concept": "biib_CollaborationProfitSharing",
              "unit": "usd",
              "label": "Collaboration profit (loss) sharing",
              "value": 185000000
            },
            {
              "concept": "us-gaap_ComprehensiveIncomeNetOfTax",
              "unit": "usd",
              "label": "Comprehensive income attributable to Biogen Inc.",
              "value": 4507200000
            },
            {
              "concept": "us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest",
              "unit": "usd",
              "label": "Comprehensive income (loss) attributable to noncontrolling interests, net of tax",
              "value": 42900000
            },
            {
              "concept": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
              "unit": "usd",
              "label": "Comprehensive income",
              "value": 4550100000
            },
            {
              "concept": "us-gaap_CostOfGoodsAndServicesSold",
              "unit": "usd",
              "label": "Cost of sales, excluding amortization and impairment of acquired intangible assets",
              "value": 1816300000
            },
            {
              "concept": "us-gaap_CostsAndExpenses",
              "unit": "usd",
              "label": "Total cost and expenses",
              "value": 7564300000
            },
            {
              "concept": "us-gaap_EarningsPerShareBasic",
              "unit": "usd/share",
              "label": "Basic earnings per share attributable to Biogen Inc.",
              "value": 21
            },
            {
              "concept": "us-gaap_EarningsPerShareDiluted",
              "unit": "usd/share",
              "label": "Diluted earnings per share attributable to Biogen Inc.",
              "value": 21
            },
            {
              "concept": "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings",
              "unit": "usd",
              "label": "Loss (gain) on fair value remeasurement of contingent consideration",
              "value": 12300000
            },
            {
              "concept": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
              "unit": "usd",
              "label": "Income before income tax expense and equity in loss of investee, net of tax",
              "value": 5899600000
            },
            {
              "concept": "us-gaap_IncomeLossFromEquityMethodInvestments",
              "unit": "usd",
              "label": "Equity in loss of investee, net of tax",
              "value": 0
            },
            {
              "concept": "us-gaap_IncomeTaxExpenseBenefit",
              "unit": "usd",
              "label": "Total income tax expense",
              "value": 1425600000
            },
            {
              "concept": "us-gaap_LitigationSettlementExpense",
              "unit": "usd",
              "label": "TECFIDERA litigation settlement charge",
              "value": 0
            },
            {
              "concept": "us-gaap_NetIncomeLoss",
              "unit": "usd",
              "label": "Net income attributable to Biogen Inc.",
              "value": 4430700000
            },
            {
              "concept": "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest",
              "unit": "usd",
              "label": "Net income (loss) attributable to noncontrolling interests, net of tax",
              "value": 43300000
            },
            {
              "concept": "us-gaap_NonoperatingIncomeExpense",
              "unit": "usd",
              "label": "Total other income (expense), net",
              "value": 11000000
            },
            {
              "concept": "us-gaap_OperatingIncomeLoss",
              "unit": "usd",
              "label": "Income from operations",
              "value": 5888600000
            },
            {
              "concept": "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax",
              "unit": "usd",
              "label": "Unrealized gains (losses) on securities available for sale, net of tax",
              "value": -3900000
            },
            {
              "concept": "us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAdjustmentsAfterTax",
              "unit": "usd",
              "label": "Less: Reclassification of net investment hedge forward points amortization",
              "value": 1500000
            },
            {
              "concept": "us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAfterAdjustmentsAndTax",
              "unit": "usd",
              "label": "Gains (losses) on net investment hedges",
              "value": 3500000
            },
            {
              "concept": "us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax",
              "unit": "usd",
              "label": "Gains (Losses) on net investment hedge recognized during period",
              "value": 5000000
            },
            {
              "concept": "us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax",
              "unit": "usd",
              "label": "Unrealized gains (losses) on cash flow hedges, net of tax",
              "value": 139200000
            },
            {
              "concept": "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
              "unit": "usd",
              "label": "Currency translation adjustment",
              "value": -67800000
            },
            {
              "concept": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
              "unit": "usd",
              "label": "Net current period other comprehensive income (loss)",
              "value": 76500000
            },
            {
              "concept": "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax",
              "unit": "usd",
              "label": "Unrealized gains (losses) on pension benefit obligation, net of tax",
              "value": -5500000
            },
            {
              "concept": "us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax",
              "unit": "usd",
              "label": "Less: reclassification adjustment for (gains) losses included in net income, net of tax",
              "value": -6700000
            },
            {
              "concept": "us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesNetOfTax",
              "unit": "usd",
              "label": "Less: reclassification adjustment for (gains) losses included in net income, net of tax",
              "value": -41800000
            },
            {
              "concept": "us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax",
              "unit": "usd",
              "label": "Unrealized gains (losses) recognized during the period, net of tax",
              "value": 97400000
            },
            {
              "concept": "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
              "unit": "usd",
              "label": "Unrealized gains (losses) recognized during the period, net of tax",
              "value": -10600000
            },
            {
              "concept": "us-gaap_ProfitLoss",
              "unit": "usd",
              "label": "Net income",
              "value": 4474000000
            },
            {
              "concept": "us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
              "unit": "usd",
              "label": "Research and development",
              "value": 2597200000
            },
            {
              "concept": "us-gaap_ResearchAndDevelopmentInProcess",
              "unit": "usd",
              "label": "Acquired in-process research and development",
              "value": 112500000
            },
            {
              "concept": "us-gaap_RestructuringCharges",
              "unit": "usd",
              "label": "Restructuring charges",
              "value": 12000000
            },
            {
              "concept": "us-gaap_Revenues",
              "unit": "usd",
              "label": "Total Revenues",
              "value": 13452900000
            },
            {
              "concept": "us-gaap_SellingGeneralAndAdministrativeExpense",
              "unit": "usd",
              "label": "Selling, general and administrative",
              "value": 2106300000
            },
            {
              "concept": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
              "unit": "shares",
              "label": "Shares used in calculating diluted earnings per share",
              "value": 205300000
            },
            {
              "concept": "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic",
              "unit": "shares",
              "label": "Weighted average number of common shares outstanding",
              "value": 204900000
            }
          ],
          "cf": [
            {
              "concept": "us-gaap_CashAndCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
              "unit": "usd",
              "label": "Net increase (decrease) in cash and cash equivalents",
              "value": -330600000
            },
            {
              "concept": "us-gaap_DeferredIncomeTaxExpenseBenefit",
              "unit": "usd",
              "label": "Total",
              "value": 108300000
            },
            {
              "concept": "us-gaap_DepreciationDepletionAndAmortization",
              "unit": "usd",
              "label": "Depreciation, amortization and impairments",
              "value": 1016600000
            },
            {
              "concept": "us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents",
              "unit": "usd",
              "label": "Effect of exchange rate changes on cash and cash equivalents",
              "value": -18600000
            },
            {
              "concept": "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings",
              "unit": "usd",
              "label": "Loss (gain) on fair value remeasurement of contingent consideration",
              "value": 12300000
            },
            {
              "concept": "us-gaap_IncreaseDecreaseInAccountsReceivable",
              "unit": "usd",
              "label": "Accounts receivable",
              "value": 205200000
            },
            {
              "concept": "us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable",
              "unit": "usd",
              "label": "Income tax assets and liabilities",
              "value": 321700000
            },
            {
              "concept": "us-gaap_IncreaseDecreaseInAccruedLiabilities",
              "unit": "usd",
              "label": "Accrued expenses and other current liabilities",
              "value": 465500000
            },
            {
              "concept": "us-gaap_IncreaseDecreaseInInventories",
              "unit": "usd",
              "label": "Inventory",
              "value": 52100000
            },
            {
              "concept": "us-gaap_IncreaseDecreaseInOtherOperatingAssets",
              "unit": "usd",
              "label": "Other assets",
              "value": 119100000
            },
            {
              "concept": "us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet",
              "unit": "usd",
              "label": "Due from anti-CD20 therapeutic programs",
              "value": -5700000
            },
            {
              "concept": "us-gaap_IncreaseDecreaseInOtherOperatingLiabilities",
              "unit": "usd",
              "label": "Other liabilities",
              "value": -16300000
            },
            {
              "concept": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
              "unit": "usd",
              "label": "Net cash flows used in financing activities",
              "value": -4472000000
            },
            {
              "concept": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
              "unit": "usd",
              "label": "Net cash flows used in investing activities",
              "value": -2046300000
            },
            {
              "concept": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
              "unit": "usd",
              "label": "Net cash flows provided by operating activities",
              "value": 6187700000
            },
            {
              "concept": "us-gaap_OtherNoncashIncomeExpense",
              "unit": "usd",
              "label": "Other",
              "value": 69100000
            },
            {
              "concept": "us-gaap_PaymentsForProceedsFromOtherInvestingActivities",
              "unit": "usd",
              "label": "Other",
              "value": -400000
            },
            {
              "concept": "us-gaap_PaymentsForRepurchaseOfCommonStock",
              "unit": "usd",
              "label": "Purchases of treasury stock",
              "value": 4352600000
            },
            {
              "concept": "us-gaap_PaymentsOfCapitalDistribution",
              "unit": "usd",
              "label": "Net cash contribution to Bioverativ, Inc.",
              "value": 0
            },
            {
              "concept": "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation",
              "unit": "usd",
              "label": "Payments related to issuance of stock for share-based compensation arrangements, net",
              "value": 2100000
            },
            {
              "concept": "us-gaap_PaymentsToAcquireAvailableForSaleSecurities",
              "unit": "usd",
              "label": "Purchases of marketable securities",
              "value": 7694800000
            },
            {
              "concept": "us-gaap_PaymentsToAcquireEquityMethodInvestments",
              "unit": "usd",
              "label": "Payments to Acquire Equity Method Investments",
              "value": 676600000
            },
            {
              "concept": "us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment",
              "unit": "usd",
              "label": "Payments to Acquire in Process Research and Development",
              "value": 112500000
            },
            {
              "concept": "us-gaap_PaymentsToAcquireIntangibleAssets",
              "unit": "usd",
              "label": "Acquisitions of intangible assets",
              "value": 3000000
            },
            {
              "concept": "us-gaap_PaymentsToAcquireOtherInvestments",
              "unit": "usd",
              "label": "Payments to Acquire Other Investments",
              "value": 462900000
            },
            {
              "concept": "us-gaap_PaymentsToAcquireOtherProductiveAssets",
              "unit": "usd",
              "label": "Contingent consideration related to Fumapharm AG acquisition",
              "value": 1500000000
            },
            {
              "concept": "us-gaap_PaymentsToAcquireProductiveAssets",
              "unit": "usd",
              "label": "Contingent consideration payments",
              "value": 58200000
            },
            {
              "concept": "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment",
              "unit": "usd",
              "label": "Purchases of property, plant and equipment",
              "value": 770600000
            },
            {
              "concept": "us-gaap_PaymentsToMinorityShareholders",
              "unit": "usd",
              "label": "Payments to Noncontrolling Interests",
              "value": 36400000
            },
            {
              "concept": "us-gaap_ProceedsFromPaymentsForOtherFinancingActivities",
              "unit": "usd",
              "label": "Other",
              "value": -19500000
            },
            {
              "concept": "us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities",
              "unit": "usd",
              "label": "Proceeds from sales and maturities of marketable securities",
              "value": 9173700000
            },
            {
              "concept": "us-gaap_ProfitLoss",
              "unit": "usd",
              "label": "Net income",
              "value": 4474000000
            },
            {
              "concept": "us-gaap_RepaymentsOfDebt",
              "unit": "usd",
              "label": "Repayments of borrowings",
              "value": 3200000
            },
            {
              "concept": "us-gaap_ResearchAndDevelopmentInProcess",
              "unit": "usd",
              "label": "Acquired in-process research and development",
              "value": 112500000
            },
            {
              "concept": "us-gaap_ShareBasedCompensation",
              "unit": "usd",
              "label": "Share-based compensation",
              "value": 157500000
            }
          ]
        }
      },
      {
        "accessNumber": "0000875045-18-000005",
        "symbol": "BIIB",
        "cik": "875045",
        "year": 2017,
        "quarter": 0,
        "form": "10-K",
        "startDate": "2017-01-01 00:00:00",
        "endDate": "2017-12-31 00:00:00",
        "filedDate": "2018-02-01 00:00:00",
        "acceptedDate": "2018-02-01 16:35:03",
        "report": {
          "bs": [
            {
              "concept": "biib_DueFromUnconsolidatedJointBusiness",
              "unit": "usd",
              "label": "Due from anti-CD20 therapeutic programs",
              "value": 532600000
            },
            {
              "concept": "us-gaap_AccountsPayableCurrent",
              "unit": "usd",
              "label": "Accounts payable",
              "value": 395500000
            },
            {
              "concept": "us-gaap_AccountsReceivableNetCurrent",
              "unit": "usd",
              "label": "Accounts receivable, net",
              "value": 1787000000
            },
            {
              "concept": "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax",
              "unit": "usd",
              "label": "Accumulated other comprehensive income (loss), net of tax ending balance",
              "value": -318400000
            },
            {
              "concept": "us-gaap_AdditionalPaidInCapital",
              "unit": "usd",
              "label": "Additional paid-in capital",
              "value": 97800000
            },
            {
              "concept": "us-gaap_Assets",
              "unit": "usd",
              "label": "Total assets",
              "value": 23652600000
            },
            {
              "concept": "us-gaap_AssetsCurrent",
              "unit": "usd",
              "label": "Total current assets",
              "value": 7873300000
            },
            {
              "concept": "us-gaap_AvailableForSaleSecuritiesCurrent",
              "unit": "usd",
              "label": "Marketable securities",
              "value": 2115200000
            },
            {
              "concept": "us-gaap_AvailableForSaleSecuritiesNoncurrent",
              "unit": "usd",
              "label": "Marketable securities",
              "value": 3057300000
            },
            {
              "concept": "us-gaap_CashAndCashEquivalentsAtCarryingValue",
              "unit": "usd",
              "label": "Cash and cash equivalents, end of the year",
              "value": 1573800000
            },
            {
              "concept": "us-gaap_CommonStockValue",
              "unit": "usd",
              "label": "Common stock, par value $0.0005 per share",
              "value": 100000
            },
            {
              "concept": "us-gaap_DebtCurrent",
              "unit": "usd",
              "label": "Current portion of notes payable and other financing arrangements",
              "value": 3200000
            },
            {
              "concept": "us-gaap_DeferredTaxLiabilitiesNoncurrent",
              "unit": "usd",
              "label": "Deferred tax liability",
              "value": 122600000
            },
            {
              "concept": "us-gaap_Goodwill",
              "unit": "usd",
              "label": "Goodwill, end of period",
              "value": 4632500000
            },
            {
              "concept": "us-gaap_IntangibleAssetsNetExcludingGoodwill",
              "unit": "usd",
              "label": "Intangible assets, net",
              "value": 3879600000
            },
            {
              "concept": "us-gaap_InventoryNet",
              "unit": "usd",
              "label": "Inventory, current",
              "value": 902700000
            },
            {
              "concept": "us-gaap_Liabilities",
              "unit": "usd",
              "label": "Total liabilities",
              "value": 11054500000
            },
            {
              "concept": "us-gaap_LiabilitiesAndStockholdersEquity",
              "unit": "usd",
              "label": "Total liabilities and equity",
              "value": 23652600000
            },
            {
              "concept": "us-gaap_LiabilitiesCurrent",
              "unit": "usd",
              "label": "Total current liabilities",
              "value": 3368200000
            },
            {
              "concept": "us-gaap_LongTermDebt",
              "unit": "usd",
              "label": "Non-current portion of notes payable and other financing arrangements",
              "value": 5935000000
            },
            {
              "concept": "us-gaap_MinorityInterest",
              "unit": "usd",
              "label": "Ending Balance",
              "value": -14700000
            },
            {
              "concept": "us-gaap_OtherAssetsCurrent",
              "unit": "usd",
              "label": "Other current assets",
              "value": 962000000
            },
            {
              "concept": "us-gaap_OtherAssetsNoncurrent",
              "unit": "usd",
              "label": "Prepaid research and development",
              "value": 1027500000
            },
            {
              "concept": "us-gaap_OtherLiabilitiesCurrent",
              "unit": "usd",
              "label": "Accrued expenses and other",
              "value": 2901300000
            },
            {
              "concept": "us-gaap_OtherLiabilitiesNoncurrent",
              "unit": "usd",
              "label": "Other long-term liabilities",
              "value": 1628700000
            },
            {
              "concept": "us-gaap_PreferredStockValue",
              "unit": "usd",
              "label": "Preferred stock, par value $0.001 per share",
              "value": 0
            },
            {
              "concept": "us-gaap_PropertyPlantAndEquipmentNet",
              "unit": "usd",
              "label": "Total property, plant and equipment, net",
              "value": 3182400000
            },
            {
              "concept": "us-gaap_RetainedEarningsAccumulatedDeficit",
              "unit": "usd",
              "label": "Retained earnings",
              "value": 15810400000
            },
            {
              "concept": "us-gaap_StockholdersEquity",
              "unit": "usd",
              "label": "Ending Balance",
              "value": 12612800000
            },
            {
              "concept": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
              "unit": "usd",
              "label": "Ending Balance",
              "value": 12598100000
            },
            {
              "concept": "us-gaap_TaxesPayableCurrent",
              "unit": "usd",
              "label": "Taxes payable",
              "value": 68200000
            },
            {
              "concept": "us-gaap_TreasuryStockValue",
              "unit": "usd",
              "label": "Treasury stock, at cost; 23.8 million and 22.6 million shares, respectively",
              "value": 2977100000
            }
          ],
          "ic": [
            {
              "concept": "biib_CollaborationProfitSharing",
              "unit": "usd",
              "label": "Collaboration profit (loss) sharing",
              "value": 112300000
            },
            {
              "concept": "biib_RevenuesfromantiCD20therapeuticprograms",
              "unit": "usd",
              "label": "Total revenues from anti-CD20 therapeutic programs",
              "value": 1559200000
            },
            {
              "concept": "us-gaap_AmortizationOfIntangibleAssets",
              "unit": "usd",
              "label": "Amortization of acquired intangible assets",
              "value": 814700000
            },
            {
              "concept": "us-gaap_ComprehensiveIncomeNetOfTax",
              "unit": "usd",
              "label": "Comprehensive income attributable to Biogen Inc.",
              "value": 2540600000
            },
            {
              "concept": "us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest",
              "unit": "usd",
              "label": "Comprehensive income (loss) attributable to noncontrolling interests, net of tax",
              "value": -131000000
            },
            {
              "concept": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
              "unit": "usd",
              "label": "Comprehensive income",
              "value": 2671600000
            },
            {
              "concept": "us-gaap_CostOfGoodsSold",
              "unit": "usd",
              "label": "Cost of sales, excluding amortization of acquired intangible assets",
              "value": 1630000000
            },
            {
              "concept": "us-gaap_CostsAndExpenses",
              "unit": "usd",
              "label": "Total cost and expenses",
              "value": 6929700000
            },
            {
              "concept": "us-gaap_EarningsPerShareBasic",
              "unit": "usd/share",
              "label": "Basic earnings per share attributable to Biogen Inc.",
              "value": 11
            },
            {
              "concept": "us-gaap_EarningsPerShareDiluted",
              "unit": "usd/share",
              "label": "Diluted earnings per share attributable to Biogen Inc.",
              "value": 11
            },
            {
              "concept": "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings",
              "unit": "usd",
              "label": "Loss (gain) on fair value remeasurement of contingent consideration",
              "value": -62700000
            },
            {
              "concept": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
              "unit": "usd",
              "label": "Income before income tax expense and equity in loss of investee, net of tax",
              "value": 5128800000
            },
            {
              "concept": "us-gaap_IncomeLossFromEquityMethodInvestments",
              "unit": "usd",
              "label": "Equity in loss of investee, net of tax",
              "value": 0
            },
            {
              "concept": "us-gaap_IncomeTaxExpenseBenefit",
              "unit": "usd",
              "label": "Income tax expense",
              "value": 2458700000
            },
            {
              "concept": "us-gaap_LitigationSettlementExpense",
              "unit": "usd",
              "label": "TECFIDERA litigation settlement charge",
              "value": 0
            },
            {
              "concept": "us-gaap_NetIncomeLoss",
              "unit": "usd",
              "label": "Net income attributable to Biogen Inc.",
              "value": 2539100000
            },
            {
              "concept": "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest",
              "unit": "usd",
              "label": "Net income (loss) attributable to noncontrolling interests, net of tax",
              "value": 131000000
            },
            {
              "concept": "us-gaap_NonoperatingIncomeExpense",
              "unit": "usd",
              "label": "Other income (expense), net",
              "value": -215400000
            },
            {
              "concept": "us-gaap_OperatingIncomeLoss",
              "unit": "usd",
              "label": "Income from operations",
              "value": 5344200000
            },
            {
              "concept": "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax",
              "unit": "usd",
              "label": "Unrealized gains (losses) on securities available for sale, net of tax",
              "value": 9200000
            },
            {
              "concept": "us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax",
              "unit": "usd",
              "label": "Unrealized gains (losses) on cash flow hedges, net of tax",
              "value": -162300000
            },
            {
              "concept": "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
              "unit": "usd",
              "label": "Currency translation adjustment",
              "value": 158700000
            },
            {
              "concept": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
              "unit": "usd",
              "label": "Other comprehensive income (loss), net of tax",
              "value": 1500000
            },
            {
              "concept": "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax",
              "unit": "usd",
              "label": "Unrealized gains (losses) on pension benefit obligation, net of tax",
              "value": 4100000
            },
            {
              "concept": "us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax",
              "unit": "usd",
              "label": "Less: reclassification adjustment for (gains) losses included in net income, net of tax",
              "value": -12700000
            },
            {
              "concept": "us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesNetOfTax",
              "unit": "usd",
              "label": "Less: reclassification adjustment for (gains) losses included in net income, net of tax",
              "value": -31500000
            },
            {
              "concept": "us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax",
              "unit": "usd",
              "label": "Unrealized gains (losses) recognized during the period, net of tax",
              "value": -193800000
            },
            {
              "concept": "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
              "unit": "usd",
              "label": "Unrealized gains (losses) recognized during the period, net of tax",
              "value": -3500000
            },
            {
              "concept": "us-gaap_OtherSalesRevenueNet",
              "unit": "usd",
              "label": "Other revenues",
              "value": 360000000
            },
            {
              "concept": "us-gaap_ProfitLoss",
              "unit": "usd",
              "label": "Net income",
              "value": 2670100000
            },
            {
              "concept": "us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
              "unit": "usd",
              "label": "Research and development",
              "value": 2253600000
            },
            {
              "concept": "us-gaap_ResearchAndDevelopmentInProcess",
              "unit": "usd",
              "label": "Acquired in-process research and development",
              "value": 120000000
            },
            {
              "concept": "us-gaap_RestructuringCharges",
              "unit": "usd",
              "label": "Restructuring charges",
              "value": 900000
            },
            {
              "concept": "us-gaap_Revenues",
              "unit": "usd",
              "label": "Total revenues",
              "value": 12273900000
            },
            {
              "concept": "us-gaap_SalesRevenueGoodsNet",
              "unit": "usd",
              "label": "Revenue on sales in the rest of world for RITUXAN",
              "value": 10354700000
            },
            {
              "concept": "us-gaap_SellingGeneralAndAdministrativeExpense",
              "unit": "usd",
              "label": "Selling, general and administrative",
              "value": 1935500000
            },
            {
              "concept": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
              "unit": "shares",
              "label": "Shares used in calculating diluted earnings per share",
              "value": 213000000
            },
            {
              "concept": "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic",
              "unit": "shares",
              "label": "Weighted average number of common shares outstanding",
              "value": 212600000
            }
          ],
          "cf": [
            {
              "concept": "us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease",
              "unit": "usd",
              "label": "Net increase in cash and cash equivalents",
              "value": -792100000
            },
            {
              "concept": "us-gaap_DeferredIncomeTaxExpenseBenefit",
              "unit": "usd",
              "label": "Deferred income taxes",
              "value": 91700000
            },
            {
              "concept": "us-gaap_DepreciationDepletionAndAmortization",
              "unit": "usd",
              "label": "Depreciation and amortization",
              "value": 1081000000
            },
            {
              "concept": "us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents",
              "unit": "usd",
              "label": "Effect of exchange rate changes on cash and cash equivalents",
              "value": 39400000
            },
            {
              "concept": "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings",
              "unit": "usd",
              "label": "Loss (gain) on fair value remeasurement of contingent consideration",
              "value": -62700000
            },
            {
              "concept": "us-gaap_IncreaseDecreaseInAccountsReceivable",
              "unit": "usd",
              "label": "Accounts receivable",
              "value": 435600000
            },
            {
              "concept": "us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable",
              "unit": "usd",
              "label": "Income tax assets and liabilities",
              "value": 1303900000
            },
            {
              "concept": "us-gaap_IncreaseDecreaseInAccruedLiabilities",
              "unit": "usd",
              "label": "Accrued expenses and other current liabilities",
              "value": -227400000
            },
            {
              "concept": "us-gaap_IncreaseDecreaseInInventories",
              "unit": "usd",
              "label": "Inventory",
              "value": 94500000
            },
            {
              "concept": "us-gaap_IncreaseDecreaseInOtherOperatingAssets",
              "unit": "usd",
              "label": "Other assets",
              "value": 76600000
            },
            {
              "concept": "us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet",
              "unit": "usd",
              "label": "Due from anti-CD20 therapeutic programs",
              "value": 232000000
            },
            {
              "concept": "us-gaap_IncreaseDecreaseInOtherOperatingLiabilities",
              "unit": "usd",
              "label": "Other liabilities",
              "value": -2400000
            },
            {
              "concept": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
              "unit": "usd",
              "label": "Net cash flows provided by (used in) financing activities",
              "value": -2380000000
            },
            {
              "concept": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
              "unit": "usd",
              "label": "Net cash flows used in investing activities",
              "value": -2963100000
            },
            {
              "concept": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
              "unit": "usd",
              "label": "Net cash flows provided by operating activities",
              "value": 4551000000
            },
            {
              "concept": "us-gaap_OtherNoncashIncomeExpense",
              "unit": "usd",
              "label": "Other",
              "value": -162100000
            },
            {
              "concept": "us-gaap_PaymentsForProceedsFromOtherInvestingActivities",
              "unit": "usd",
              "label": "Other",
              "value": 11000000
            },
            {
              "concept": "us-gaap_PaymentsForRepurchaseOfCommonStock",
              "unit": "usd",
              "label": "Payments for repurchase of common stock",
              "value": 1365400000
            },
            {
              "concept": "us-gaap_PaymentsOfCapitalDistribution",
              "unit": "usd",
              "label": "Net cash contribution to Bioverativ, Inc.",
              "value": 302700000
            },
            {
              "concept": "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation",
              "unit": "usd",
              "label": "Payments related to issuance of stock for share-based compensation arrangements, net",
              "value": 5300000
            },
            {
              "concept": "us-gaap_PaymentsToAcquireAvailableForSaleSecurities",
              "unit": "usd",
              "label": "Purchases of marketable securities",
              "value": 5355200000
            },
            {
              "concept": "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired",
              "unit": "usd",
              "label": "Acquisitions of businesses, net of cash acquired",
              "value": 0
            },
            {
              "concept": "us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment",
              "unit": "usd",
              "label": "Payments to Acquire in Process Research and Development",
              "value": 120000000
            },
            {
              "concept": "us-gaap_PaymentsToAcquireIntangibleAssets",
              "unit": "usd",
              "label": "Acquisitions of intangible assets",
              "value": 975400000
            },
            {
              "concept": "us-gaap_PaymentsToAcquireOtherProductiveAssets",
              "unit": "usd",
              "label": "Contingent consideration related to Fumapharm AG acquisition",
              "value": 1200000000
            },
            {
              "concept": "us-gaap_PaymentsToAcquireProductiveAssets",
              "unit": "usd",
              "label": "Contingent consideration payments",
              "value": 3000000
            },
            {
              "concept": "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment",
              "unit": "usd",
              "label": "Purchases of property, plant and equipment",
              "value": 867400000
            },
            {
              "concept": "us-gaap_PaymentsToMinorityShareholders",
              "unit": "usd",
              "label": "Payment to Neurimmune",
              "value": 134100000
            },
            {
              "concept": "us-gaap_ProceedsFromNotesPayable",
              "unit": "usd",
              "label": "Proceeds from borrowings",
              "value": 0
            },
            {
              "concept": "us-gaap_ProceedsFromPaymentsForOtherFinancingActivities",
              "unit": "usd",
              "label": "Other",
              "value": -8600000
            },
            {
              "concept": "us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities",
              "unit": "usd",
              "label": "Proceeds from sales and maturities of marketable securities",
              "value": 5565900000
            },
            {
              "concept": "us-gaap_ProfitLoss",
              "unit": "usd",
              "label": "Net income",
              "value": 2670100000
            },
            {
              "concept": "us-gaap_RepaymentsOfDebt",
              "unit": "usd",
              "label": "Repayments of borrowings",
              "value": 560900000
            },
            {
              "concept": "us-gaap_ResearchAndDevelopmentInProcess",
              "unit": "usd",
              "label": "Acquired in-process research and development",
              "value": 120000000
            },
            {
              "concept": "us-gaap_ShareBasedCompensation",
              "unit": "usd",
              "label": "Share-based compensation",
              "value": 128000000
            }
          ]
        }
      },
      {
        "accessNumber": "0000875045-17-000009",
        "symbol": "BIIB",
        "cik": "875045",
        "year": 2016,
        "quarter": 0,
        "form": "10-K",
        "startDate": "2016-01-01 00:00:00",
        "endDate": "2016-12-31 00:00:00",
        "filedDate": "2017-02-02 00:00:00",
        "acceptedDate": "2017-02-02 16:24:00",
        "report": {
          "bs": [
            {
              "concept": "biib_DueFromUnconsolidatedJointBusiness",
              "unit": "usd",
              "label": "Due from anti-CD20 therapeutic programs, net",
              "value": 300600000
            },
            {
              "concept": "us-gaap_AccountsPayableCurrent",
              "unit": "usd",
              "label": "Accounts payable",
              "value": 279800000
            },
            {
              "concept": "us-gaap_AccountsReceivableNetCurrent",
              "unit": "usd",
              "label": "Accounts receivable, net",
              "value": 1441600000
            },
            {
              "concept": "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax",
              "unit": "usd",
              "label": "Accumulated other comprehensive loss",
              "value": -319900000
            },
            {
              "concept": "us-gaap_AdditionalPaidInCapital",
              "unit": "usd",
              "label": "Additional paid-in capital",
              "value": 0
            },
            {
              "concept": "us-gaap_Assets",
              "unit": "usd",
              "label": "Total assets",
              "value": 22876800000
            },
            {
              "concept": "us-gaap_AssetsCurrent",
              "unit": "usd",
              "label": "Total current assets",
              "value": 8732200000
            },
            {
              "concept": "us-gaap_AvailableForSaleSecuritiesCurrent",
              "unit": "usd",
              "label": "Marketable securities",
              "value": 2568600000
            },
            {
              "concept": "us-gaap_AvailableForSaleSecuritiesNoncurrent",
              "unit": "usd",
              "label": "Marketable securities",
              "value": 2829400000
            },
            {
              "concept": "us-gaap_CashAndCashEquivalentsAtCarryingValue",
              "unit": "usd",
              "label": "Cash and cash equivalents",
              "value": 2326500000
            },
            {
              "concept": "us-gaap_CommonStockValue",
              "unit": "usd",
              "label": "Common stock, par value $0.0005 per share",
              "value": 100000
            },
            {
              "concept": "us-gaap_DebtCurrent",
              "unit": "usd",
              "label": "Current portion of notes payable and other financing arrangements",
              "value": 4700000
            },
            {
              "concept": "us-gaap_DeferredTaxLiabilitiesNoncurrent",
              "unit": "usd",
              "label": "Deferred tax liability",
              "value": 93100000
            },
            {
              "concept": "us-gaap_Goodwill",
              "unit": "usd",
              "label": "Goodwill",
              "value": 3669300000
            },
            {
              "concept": "us-gaap_IntangibleAssetsNetExcludingGoodwill",
              "unit": "usd",
              "label": "Intangible assets, net",
              "value": 3808300000
            },
            {
              "concept": "us-gaap_InventoryNet",
              "unit": "usd",
              "label": "Inventory",
              "value": 1001600000
            },
            {
              "concept": "us-gaap_Liabilities",
              "unit": "usd",
              "label": "Total liabilities",
              "value": 10748200000
            },
            {
              "concept": "us-gaap_LiabilitiesAndStockholdersEquity",
              "unit": "usd",
              "label": "Total liabilities and equity",
              "value": 22876800000
            },
            {
              "concept": "us-gaap_LiabilitiesCurrent",
              "unit": "usd",
              "label": "Total current liabilities",
              "value": 3419900000
            },
            {
              "concept": "us-gaap_LongTermDebt",
              "unit": "usd",
              "label": "Notes payable and other financing arrangements",
              "value": 6512700000
            },
            {
              "concept": "us-gaap_MinorityInterest",
              "unit": "usd",
              "label": "Noncontrolling interests",
              "value": -11500000
            },
            {
              "concept": "us-gaap_OtherAssetsCurrent",
              "unit": "usd",
              "label": "Other current assets",
              "value": 1093300000
            },
            {
              "concept": "us-gaap_OtherAssetsNoncurrent",
              "unit": "usd",
              "label": "Investments and other assets",
              "value": 1335800000
            },
            {
              "concept": "us-gaap_OtherLiabilitiesCurrent",
              "unit": "usd",
              "label": "Accrued expenses and other",
              "value": 2903500000
            },
            {
              "concept": "us-gaap_OtherLiabilitiesNoncurrent",
              "unit": "usd",
              "label": "Accrued expenses and other long-term deferred revenue",
              "value": 722500000
            },
            {
              "concept": "us-gaap_PreferredStockValue",
              "unit": "usd",
              "label": "Preferred stock, par value $0.001 per share",
              "value": 0
            },
            {
              "concept": "us-gaap_PropertyPlantAndEquipmentNet",
              "unit": "usd",
              "label": "Property, plant and equipment, net",
              "value": 2501800000
            },
            {
              "concept": "us-gaap_RetainedEarningsAccumulatedDeficit",
              "unit": "usd",
              "label": "Retained earnings",
              "value": 15071600000
            },
            {
              "concept": "us-gaap_StockholdersEquity",
              "unit": "usd",
              "label": "Total Biogen Inc. shareholders\u2019 equity",
              "value": 12140100000
            },
            {
              "concept": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
              "unit": "usd",
              "label": "Total equity",
              "value": 12128600000
            },
            {
              "concept": "us-gaap_TaxesPayableCurrent",
              "unit": "usd",
              "label": "Taxes payable",
              "value": 231900000
            },
            {
              "concept": "us-gaap_TreasuryStockValue",
              "unit": "usd",
              "label": "Treasury stock, at cost; 22.6 million shares, respectively",
              "value": 2611700000
            }
          ],
          "ic": [
            {
              "concept": "biib_CollaborationProfitSharing",
              "unit": "usd",
              "label": "Collaboration profit (loss) sharing",
              "value": 10200000
            },
            {
              "concept": "biib_GainOnSaleOfRights",
              "unit": "usd",
              "label": "Gain on sale of rights",
              "value": 0
            },
            {
              "concept": "biib_RevenuesfromantiCD20therapeuticprograms",
              "unit": "usd",
              "label": "Revenues from anti-CD20 therapeutic programs",
              "value": 1314500000
            },
            {
              "concept": "us-gaap_AmortizationOfIntangibleAssets",
              "unit": "usd",
              "label": "Amortization of acquired intangible assets",
              "value": 385600000
            },
            {
              "concept": "us-gaap_ComprehensiveIncomeNetOfTax",
              "unit": "usd",
              "label": "Comprehensive income attributable to Biogen Inc.",
              "value": 3606900000
            },
            {
              "concept": "us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest",
              "unit": "usd",
              "label": "Comprehensive income (loss) attributable to noncontrolling interests, net of tax",
              "value": 7100000
            },
            {
              "concept": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
              "unit": "usd",
              "label": "Comprehensive income",
              "value": 3599800000
            },
            {
              "concept": "us-gaap_CostOfGoodsSold",
              "unit": "usd",
              "label": "Cost of sales, excluding amortization of acquired intangible assets",
              "value": 1478700000
            },
            {
              "concept": "us-gaap_CostsAndExpenses",
              "unit": "usd",
              "label": "Total cost and expenses",
              "value": 6298400000
            },
            {
              "concept": "us-gaap_EarningsPerShareBasic",
              "unit": "usd/share",
              "label": "Basic earnings per share attributable to Biogen Inc.",
              "value": 16
            },
            {
              "concept": "us-gaap_EarningsPerShareDiluted",
              "unit": "usd/share",
              "label": "Diluted earnings per share attributable to Biogen Inc.",
              "value": 16
            },
            {
              "concept": "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings",
              "unit": "usd",
              "label": "Loss (gain) on fair value remeasurement of contingent consideration",
              "value": -14800000
            },
            {
              "concept": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
              "unit": "usd",
              "label": "Income before income tax expense and equity in loss of investee, net of tax",
              "value": 4933000000
            },
            {
              "concept": "us-gaap_IncomeLossFromEquityMethodInvestments",
              "unit": "usd",
              "label": "Income (Loss) from Equity Method Investments",
              "value": 0
            },
            {
              "concept": "us-gaap_IncomeTaxExpenseBenefit",
              "unit": "usd",
              "label": "Total income tax expense",
              "value": 1237300000
            },
            {
              "concept": "us-gaap_LitigationSettlementExpense",
              "unit": "usd",
              "label": "TECFIDERA litigation settlement and license charges",
              "value": 454800000
            },
            {
              "concept": "us-gaap_NetIncomeLoss",
              "unit": "usd",
              "label": "Net income attributable to Biogen Idec Inc",
              "value": 3702800000
            },
            {
              "concept": "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest",
              "unit": "usd",
              "label": "Net (loss) income attributable to noncontrolling interests, net of tax",
              "value": -7100000
            },
            {
              "concept": "us-gaap_OperatingIncomeLoss",
              "unit": "usd",
              "label": "Income from operations",
              "value": 5150400000
            },
            {
              "concept": "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax",
              "unit": "usd",
              "label": "Unrealized gains (losses) on securities available for sale, net of tax",
              "value": -10000000
            },
            {
              "concept": "us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax",
              "unit": "usd",
              "label": "Unrealized gains (losses) on cash flow hedges, net of tax",
              "value": 47600000
            },
            {
              "concept": "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
              "unit": "usd",
              "label": "Currency translation adjustment",
              "value": -138600000
            },
            {
              "concept": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
              "unit": "usd",
              "label": "Net current period other comprehensive income (loss)",
              "value": -95900000
            },
            {
              "concept": "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax",
              "unit": "usd",
              "label": "Unrealized gains (losses) on pension benefit obligation",
              "value": -5100000
            },
            {
              "concept": "us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax",
              "unit": "usd",
              "label": "Less: reclassification adjustment for (gains) losses included in net income, net of tax",
              "value": -600000
            },
            {
              "concept": "us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesNetOfTax",
              "unit": "usd",
              "label": "Less: reclassification adjustment for (gains) losses included in net income, net of tax",
              "value": 4000000
            },
            {
              "concept": "us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax",
              "unit": "usd",
              "label": "Unrealized gains (losses) recognized during the period, net of tax",
              "value": 51600000
            },
            {
              "concept": "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
              "unit": "usd",
              "label": "Unrealized gains (losses) recognized during the period, net of tax",
              "value": -10600000
            },
            {
              "concept": "us-gaap_OtherNonoperatingIncomeExpense",
              "unit": "usd",
              "label": "Total other income (expense), net",
              "value": -217400000
            },
            {
              "concept": "us-gaap_OtherSalesRevenueNet",
              "unit": "usd",
              "label": "Other revenues from external customers",
              "value": 316400000
            },
            {
              "concept": "us-gaap_ProfitLoss",
              "unit": "usd",
              "label": "Net income",
              "value": 3695700000
            },
            {
              "concept": "us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
              "unit": "usd",
              "label": "Research and development",
              "value": 1973300000
            },
            {
              "concept": "us-gaap_RestructuringCharges",
              "unit": "usd",
              "label": "Restructuring charges",
              "value": 33100000
            },
            {
              "concept": "us-gaap_Revenues",
              "unit": "usd",
              "label": "Total revenues",
              "value": 11448800000
            },
            {
              "concept": "us-gaap_SalesRevenueGoodsNet",
              "unit": "usd",
              "label": "Product, net",
              "value": 9817900000
            },
            {
              "concept": "us-gaap_SellingGeneralAndAdministrativeExpense",
              "unit": "usd",
              "label": "Selling, general and administrative",
              "value": 1947900000
            },
            {
              "concept": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
              "unit": "shares",
              "label": "Shares used in calculating diluted earnings per share",
              "value": 218800000
            },
            {
              "concept": "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic",
              "unit": "shares",
              "label": "Weighted average number of common shares outstanding",
              "value": 218400000
            }
          ],
          "cf": [
            {
              "concept": "us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease",
              "unit": "usd",
              "label": "Net increase in cash and cash equivalents",
              "value": 1049800000
            },
            {
              "concept": "us-gaap_DeferredIncomeTaxExpenseBenefit",
              "unit": "usd",
              "label": "Total",
              "value": -175000000
            },
            {
              "concept": "us-gaap_DepreciationDepletionAndAmortization",
              "unit": "usd",
              "label": "Depreciation and amortization",
              "value": 682700000
            },
            {
              "concept": "us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents",
              "unit": "usd",
              "label": "Effect of exchange rate changes on cash and cash equivalents",
              "value": -31300000
            },
            {
              "concept": "us-gaap_ExcessTaxBenefitFromShareBasedCompensationFinancingActivities",
              "unit": "usd",
              "label": "Excess tax benefit from share-based compensation",
              "value": 12600000
            },
            {
              "concept": "us-gaap_IncreaseDecreaseInAccountsReceivable",
              "unit": "usd",
              "label": "Accounts receivable",
              "value": 241400000
            },
            {
              "concept": "us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable",
              "unit": "usd",
              "label": "Income tax assets and liabilities",
              "value": -232600000
            },
            {
              "concept": "us-gaap_IncreaseDecreaseInAccruedLiabilities",
              "unit": "usd",
              "label": "Accrued expenses and other current liabilities",
              "value": 570100000
            },
            {
              "concept": "us-gaap_IncreaseDecreaseInInventories",
              "unit": "usd",
              "label": "Inventory",
              "value": 165600000
            },
            {
              "concept": "us-gaap_IncreaseDecreaseInOtherOperatingAssets",
              "unit": "usd",
              "label": "Other assets",
              "value": -59100000
            },
            {
              "concept": "us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet",
              "unit": "usd",
              "label": "Due from anti-CD20 therapeutic programs",
              "value": -13900000
            },
            {
              "concept": "us-gaap_IncreaseDecreaseInOtherOperatingLiabilities",
              "unit": "usd",
              "label": "Other liabilities",
              "value": 69500000
            },
            {
              "concept": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
              "unit": "usd",
              "label": "Net cash flows provided by (used in) financing activities",
              "value": -987800000
            },
            {
              "concept": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
              "unit": "usd",
              "label": "Net cash flows used in investing activities",
              "value": -2484800000
            },
            {
              "concept": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
              "unit": "usd",
              "label": "Net cash flows provided by operating activities",
              "value": 4522400000
            },
            {
              "concept": "us-gaap_OtherNoncashIncomeExpense",
              "unit": "usd",
              "label": "Other",
              "value": -91200000
            },
            {
              "concept": "us-gaap_PaymentsForProceedsFromOtherInvestingActivities",
              "unit": "usd",
              "label": "Other",
              "value": 22800000
            },
            {
              "concept": "us-gaap_PaymentsForRepurchaseOfCommonStock",
              "unit": "usd",
              "label": "Purchases of treasury stock",
              "value": 1000000000.0
            },
            {
              "concept": "us-gaap_PaymentsToAcquireAvailableForSaleSecurities",
              "unit": "usd",
              "label": "Purchases of marketable securities",
              "value": 7913200000
            },
            {
              "concept": "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired",
              "unit": "usd",
              "label": "Acquisitions of businesses, net of cash acquired",
              "value": 0
            },
            {
              "concept": "us-gaap_PaymentsToAcquireIntangibleAssets",
              "unit": "usd",
              "label": "Acquisitions of intangible assets",
              "value": 111600000
            },
            {
              "concept": "us-gaap_PaymentsToAcquireOtherProductiveAssets",
              "unit": "usd",
              "label": "Contingent consideration related to Fumapharm AG acquisition",
              "value": 1200000000
            },
            {
              "concept": "us-gaap_PaymentsToAcquireProductiveAssets",
              "unit": "usd",
              "label": "Contingent consideration payments",
              "value": 38600000
            },
            {
              "concept": "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment",
              "unit": "usd",
              "label": "Purchases of property, plant and equipment",
              "value": 616100000
            },
            {
              "concept": "us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions",
              "unit": "usd",
              "label": "Proceeds from issuance of stock for share-based compensation arrangements",
              "value": 43700000
            },
            {
              "concept": "us-gaap_ProceedsFromNotesPayable",
              "unit": "usd",
              "label": "Proceeds from borrowings",
              "value": 0
            },
            {
              "concept": "us-gaap_ProceedsFromPaymentsForOtherFinancingActivities",
              "unit": "usd",
              "label": "Other",
              "value": -2800000
            },
            {
              "concept": "us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities",
              "unit": "usd",
              "label": "Proceeds from maturities and sales",
              "value": 7378900000
            },
            {
              "concept": "us-gaap_ProfitLoss",
              "unit": "usd",
              "label": "Net income",
              "value": 3695700000
            },
            {
              "concept": "us-gaap_RepaymentsOfDebt",
              "unit": "usd",
              "label": "Repayments of borrowings",
              "value": 2700000
            },
            {
              "concept": "us-gaap_ShareBasedCompensation",
              "unit": "usd",
              "label": "Share-based compensation",
              "value": 154800000
            }
          ]
        }
      },
      {
        "accessNumber": "0000875045-16-000042",
        "symbol": "BIIB",
        "cik": "875045",
        "year": 2015,
        "quarter": 0,
        "form": "10-K",
        "startDate": "2015-01-01 00:00:00",
        "endDate": "2015-12-31 00:00:00",
        "filedDate": "2016-02-03 00:00:00",
        "acceptedDate": "2016-02-03 16:25:52",
        "report": {
          "bs": [
            {
              "concept": "biib_DueFromUnconsolidatedJointBusiness",
              "unit": "usd",
              "label": "Due from unconsolidated joint business, net",
              "value": 314500000
            },
            {
              "concept": "us-gaap_AccountsPayableCurrent",
              "unit": "usd",
              "label": "Accounts payable",
              "value": 267400000
            },
            {
              "concept": "us-gaap_AccountsReceivableNetCurrent",
              "unit": "usd",
              "label": "Accounts receivable, net",
              "value": 1227000000
            },
            {
              "concept": "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax",
              "unit": "usd",
              "label": "Accumulated other comprehensive income (loss), net of tax ending balance",
              "value": -224000000
            },
            {
              "concept": "us-gaap_AdditionalPaidInCapital",
              "unit": "usd",
              "label": "Additional paid-in capital",
              "value": 0
            },
            {
              "concept": "us-gaap_Assets",
              "unit": "usd",
              "label": "Total assets",
              "value": 19504800000
            },
            {
              "concept": "us-gaap_AssetsCurrent",
              "unit": "usd",
              "label": "Total current assets",
              "value": 6700300000
            },
            {
              "concept": "us-gaap_AvailableForSaleSecuritiesCurrent",
              "unit": "usd",
              "label": "Marketable securities",
              "value": 2120500000
            },
            {
              "concept": "us-gaap_AvailableForSaleSecuritiesNoncurrent",
              "unit": "usd",
              "label": "Marketable securities",
              "value": 2760400000
            },
            {
              "concept": "us-gaap_CashAndCashEquivalentsAtCarryingValue",
              "unit": "usd",
              "label": "Cash and cash equivalents, end of the year",
              "value": 1308000000
            },
            {
              "concept": "us-gaap_CommonStockValue",
              "unit": "usd",
              "label": "Common stock, par value $0.0005 per share",
              "value": 100000
            },
            {
              "concept": "us-gaap_DebtCurrent",
              "unit": "usd",
              "label": "Current portion of notes payable and other financing arrangements",
              "value": 4800000
            },
            {
              "concept": "us-gaap_DeferredTaxLiabilitiesNoncurrent",
              "unit": "usd",
              "label": "Long-term deferred tax liability",
              "value": 124900000
            },
            {
              "concept": "us-gaap_Goodwill",
              "unit": "usd",
              "label": "Goodwill",
              "value": 2663800000
            },
            {
              "concept": "us-gaap_IntangibleAssetsNetExcludingGoodwill",
              "unit": "usd",
              "label": "Intangible assets, net",
              "value": 4085100000
            },
            {
              "concept": "us-gaap_InventoryNet",
              "unit": "usd",
              "label": "Inventory",
              "value": 893400000
            },
            {
              "concept": "us-gaap_Liabilities",
              "unit": "usd",
              "label": "Total liabilities",
              "value": 10129900000
            },
            {
              "concept": "us-gaap_LiabilitiesAndStockholdersEquity",
              "unit": "usd",
              "label": "Total liabilities and equity",
              "value": 19504800000
            },
            {
              "concept": "us-gaap_LiabilitiesCurrent",
              "unit": "usd",
              "label": "Total current liabilities",
              "value": 2577700000
            },
            {
              "concept": "us-gaap_LongTermDebt",
              "unit": "usd",
              "label": "Notes payable and other financing arrangements",
              "value": 6521500000
            },
            {
              "concept": "us-gaap_MinorityInterest",
              "unit": "usd",
              "label": "Noncontrolling interests",
              "value": 2100000
            },
            {
              "concept": "us-gaap_OtherAssetsCurrent",
              "unit": "usd",
              "label": "Other current assets",
              "value": 836900000
            },
            {
              "concept": "us-gaap_OtherAssetsNoncurrent",
              "unit": "usd",
              "label": "Investments and other assets",
              "value": 1107600000
            },
            {
              "concept": "us-gaap_OtherLiabilitiesCurrent",
              "unit": "usd",
              "label": "Accrued expenses and other",
              "value": 2096800000
            },
            {
              "concept": "us-gaap_OtherLiabilitiesNoncurrent",
              "unit": "usd",
              "label": "Total other long-term liabilities",
              "value": 905800000
            },
            {
              "concept": "us-gaap_PreferredStockValue",
              "unit": "usd",
              "label": "Preferred stock, par value $0.001 per share",
              "value": 0
            },
            {
              "concept": "us-gaap_PropertyPlantAndEquipmentNet",
              "unit": "usd",
              "label": "Property, plant and equipment, net",
              "value": 2187600000
            },
            {
              "concept": "us-gaap_RetainedEarningsAccumulatedDeficit",
              "unit": "usd",
              "label": "Retained earnings",
              "value": 12208400000
            },
            {
              "concept": "us-gaap_StockholdersEquity",
              "unit": "usd",
              "label": "Total Biogen Inc. shareholders\u2019 equity",
              "value": 9372800000
            },
            {
              "concept": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
              "unit": "usd",
              "label": "Total equity",
              "value": 9374900000
            },
            {
              "concept": "us-gaap_TaxesPayableCurrent",
              "unit": "usd",
              "label": "Taxes payable",
              "value": 208700000
            },
            {
              "concept": "us-gaap_TreasuryStockValue",
              "unit": "usd",
              "label": "Treasury stock, at cost; 22.6 million shares, respectively",
              "value": 2611700000
            }
          ],
          "ic": [
            {
              "concept": "biib_CollaborationProfitSharing",
              "unit": "usd",
              "label": "Collaboration profit sharing",
              "value": 0
            },
            {
              "concept": "biib_GainOnSaleOfRights",
              "unit": "usd",
              "label": "Gain on sale of rights",
              "value": 0
            },
            {
              "concept": "biib_UnconsolidatedJointBusiness",
              "unit": "usd",
              "label": "Total unconsolidated joint business revenues",
              "value": 1339200000
            },
            {
              "concept": "us-gaap_AmortizationOfIntangibleAssets",
              "unit": "usd",
              "label": "Amortization of acquired intangible assets",
              "value": 382600000
            },
            {
              "concept": "us-gaap_ComprehensiveIncomeNetOfTax",
              "unit": "usd",
              "label": "Comprehensive income attributable to Biogen Inc.",
              "value": 3382500000
            },
            {
              "concept": "us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest",
              "unit": "usd",
              "label": "Comprehensive income attributable to noncontrolling interests, net of tax",
              "value": -46200000
            },
            {
              "concept": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
              "unit": "usd",
              "label": "Comprehensive income",
              "value": 3428700000
            },
            {
              "concept": "us-gaap_CostOfGoodsSold",
              "unit": "usd",
              "label": "Cost of sales, excluding amortization of acquired intangible assets",
              "value": 1240400000
            },
            {
              "concept": "us-gaap_CostsAndExpenses",
              "unit": "usd",
              "label": "Total cost and expenses",
              "value": 5872800000
            },
            {
              "concept": "us-gaap_EarningsPerShareBasic",
              "unit": "usd/share",
              "label": "Basic earnings per share attributable to Biogen Inc.",
              "value": 15
            },
            {
              "concept": "us-gaap_EarningsPerShareDiluted",
              "unit": "usd/share",
              "label": "Diluted earnings per share attributable to Biogen Inc.",
              "value": 15
            },
            {
              "concept": "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings",
              "unit": "usd",
              "label": "(Gain) loss on fair value remeasurement of contingent consideration",
              "value": -30500000
            },
            {
              "concept": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
              "unit": "usd",
              "label": "Income before income tax expense and equity in loss of investee, net of tax",
              "value": 4767300000
            },
            {
              "concept": "us-gaap_IncomeLossFromEquityMethodInvestments",
              "unit": "usd",
              "label": "Equity in loss of investee, net of tax",
              "value": -12500000
            },
            {
              "concept": "us-gaap_IncomeTaxExpenseBenefit",
              "unit": "usd",
              "label": "Total income tax expense",
              "value": 1161600000
            },
            {
              "concept": "us-gaap_NetIncomeLoss",
              "unit": "usd",
              "label": "Net income attributable to Biogen Inc.",
              "value": 3547000000
            },
            {
              "concept": "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest",
              "unit": "usd",
              "label": "Net income attributable to noncontrolling interests, net of tax",
              "value": 46200000
            },
            {
              "concept": "us-gaap_OperatingIncomeLoss",
              "unit": "usd",
              "label": "Income from operations",
              "value": 4891000000
            },
            {
              "concept": "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax",
              "unit": "usd",
              "label": "Unrealized gains (losses) on securities available for sale, net of tax",
              "value": -400000
            },
            {
              "concept": "us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax",
              "unit": "usd",
              "label": "Unrealized gains (losses) on cash flow hedges, net of tax",
              "value": -61500000
            },
            {
              "concept": "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
              "unit": "usd",
              "label": "Currency translation adjustment",
              "value": -96400000
            },
            {
              "concept": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
              "unit": "usd",
              "label": "Total other comprehensive income (loss), net of tax",
              "value": -164500000
            },
            {
              "concept": "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax",
              "unit": "usd",
              "label": "Unrealized gains (losses) on pension benefit obligation",
              "value": 6200000
            },
            {
              "concept": "us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax",
              "unit": "usd",
              "label": "Less: reclassification adjustment for (gains) losses included in net income, net of tax",
              "value": -1300000
            },
            {
              "concept": "us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesNetOfTax",
              "unit": "usd",
              "label": "Less: reclassification adjustment for (gains) losses included in net income, net of tax",
              "value": 172300000
            },
            {
              "concept": "us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax",
              "unit": "usd",
              "label": "Unrealized gains (losses) recognized during the period, net of tax",
              "value": 110800000
            },
            {
              "concept": "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
              "unit": "usd",
              "label": "Unrealized gains (losses) recognized during the period, net of tax",
              "value": -1700000
            },
            {
              "concept": "us-gaap_OtherNonoperatingIncomeExpense",
              "unit": "usd",
              "label": "Total other income (expense), net",
              "value": -123700000
            },
            {
              "concept": "us-gaap_OtherSalesRevenueNet",
              "unit": "usd",
              "label": "Other",
              "value": 236100000
            },
            {
              "concept": "us-gaap_ProfitLoss",
              "unit": "usd",
              "label": "Net income",
              "value": 3593200000
            },
            {
              "concept": "us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
              "unit": "usd",
              "label": "Research and development",
              "value": 2012800000
            },
            {
              "concept": "us-gaap_RestructuringCharges",
              "unit": "usd",
              "label": "Restructuring charges",
              "value": 93400000
            },
            {
              "concept": "us-gaap_Revenues",
              "unit": "usd",
              "label": "Total revenues",
              "value": 10763800000
            },
            {
              "concept": "us-gaap_SalesRevenueGoodsNet",
              "unit": "usd",
              "label": "Product, net",
              "value": 9188500000
            },
            {
              "concept": "us-gaap_SellingGeneralAndAdministrativeExpense",
              "unit": "usd",
              "label": "Selling, general and administrative",
              "value": 2113100000
            },
            {
              "concept": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
              "unit": "shares",
              "label": "Diluted earnings per share attributable to Biogen Inc.",
              "value": 231200000
            },
            {
              "concept": "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic",
              "unit": "shares",
              "label": "Basic earnings per share attributable to Biogen Inc.",
              "value": 230700000
            }
          ],
          "cf": [
            {
              "concept": "us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease",
              "unit": "usd",
              "label": "Net increase in cash and cash equivalents",
              "value": 148900000
            },
            {
              "concept": "us-gaap_DeferredIncomeTaxExpenseBenefit",
              "unit": "usd",
              "label": "Deferred income taxes",
              "value": -145600000
            },
            {
              "concept": "us-gaap_DepreciationDepletionAndAmortization",
              "unit": "usd",
              "label": "Depreciation and amortization",
              "value": 600400000
            },
            {
              "concept": "us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents",
              "unit": "usd",
              "label": "Effect of exchange rate changes on cash and cash equivalents",
              "value": -45800000
            },
            {
              "concept": "us-gaap_ExcessTaxBenefitFromShareBasedCompensationFinancingActivities",
              "unit": "usd",
              "label": "Excess tax benefit from share-based compensation",
              "value": 78200000
            },
            {
              "concept": "us-gaap_IncreaseDecreaseInAccountsReceivable",
              "unit": "usd",
              "label": "Accounts receivable",
              "value": -29000000
            },
            {
              "concept": "us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable",
              "unit": "usd",
              "label": "Current taxes payable",
              "value": -410200000
            },
            {
              "concept": "us-gaap_IncreaseDecreaseInAccruedLiabilities",
              "unit": "usd",
              "label": "Accrued expenses and other current liabilities",
              "value": 74200000
            },
            {
              "concept": "us-gaap_IncreaseDecreaseInInventories",
              "unit": "usd",
              "label": "Inventory",
              "value": 174400000
            },
            {
              "concept": "us-gaap_IncreaseDecreaseInOtherOperatingAssets",
              "unit": "usd",
              "label": "Other assets",
              "value": 156600000
            },
            {
              "concept": "us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet",
              "unit": "usd",
              "label": "Due from unconsolidated joint business",
              "value": 31100000
            },
            {
              "concept": "us-gaap_IncreaseDecreaseInOtherOperatingLiabilities",
              "unit": "usd",
              "label": "Other long-term liabilities and taxes payable",
              "value": 93600000
            },
            {
              "concept": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
              "unit": "usd",
              "label": "Net cash flows provided by (used in) financing activities",
              "value": 986400000
            },
            {
              "concept": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
              "unit": "usd",
              "label": "Net cash flows used in investing activities",
              "value": -4553600000
            },
            {
              "concept": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
              "unit": "usd",
              "label": "Net cash flows provided by operating activities",
              "value": 3716100000
            },
            {
              "concept": "us-gaap_OtherNoncashIncomeExpense",
              "unit": "usd",
              "label": "Other",
              "value": -82200000
            },
            {
              "concept": "us-gaap_PaymentsForProceedsFromOtherInvestingActivities",
              "unit": "usd",
              "label": "Other",
              "value": 59900000
            },
            {
              "concept": "us-gaap_PaymentsForRepurchaseOfCommonStock",
              "unit": "usd",
              "label": "Purchase of treasury stock",
              "value": 5000000000
            },
            {
              "concept": "us-gaap_PaymentsToAcquireAvailableForSaleSecurities",
              "unit": "usd",
              "label": "Purchases of marketable securities",
              "value": 6864900000
            },
            {
              "concept": "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired",
              "unit": "usd",
              "label": "Acquisitions of businesses",
              "value": 198800000
            },
            {
              "concept": "us-gaap_PaymentsToAcquireIntangibleAssets",
              "unit": "usd",
              "label": "Acquisition of TYSABRI rights",
              "value": 0
            },
            {
              "concept": "us-gaap_PaymentsToAcquireOtherProductiveAssets",
              "unit": "usd",
              "label": "Contingent consideration related to Fumapharm AG acquisition",
              "value": 850000000
            },
            {
              "concept": "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment",
              "unit": "usd",
              "label": "Purchases of property, plant and equipment",
              "value": 643000000
            },
            {
              "concept": "us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions",
              "unit": "usd",
              "label": "Proceeds from issuance of stock for share-based compensation arrangements",
              "value": 54200000
            },
            {
              "concept": "us-gaap_ProceedsFromNotesPayable",
              "unit": "usd",
              "label": "Proceeds from borrowings",
              "value": 5930500000
            },
            {
              "concept": "us-gaap_ProceedsFromPaymentsForOtherFinancingActivities",
              "unit": "usd",
              "label": "Other",
              "value": -74400000
            },
            {
              "concept": "us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities",
              "unit": "usd",
              "label": "Proceeds from sales and maturities of marketable securities",
              "value": 4063000000
            },
            {
              "concept": "us-gaap_ProfitLoss",
              "unit": "usd",
              "label": "Net income",
              "value": 3593200000
            },
            {
              "concept": "us-gaap_RepaymentsOfDebt",
              "unit": "usd",
              "label": "Repayments of borrowings",
              "value": 2100000
            },
            {
              "concept": "us-gaap_ShareBasedCompensation",
              "unit": "usd",
              "label": "Share-based compensation",
              "value": 161400000
            }
          ]
        }
      },
      {
        "accessNumber": "0000875045-15-000005",
        "symbol": "BIIB",
        "cik": "875045",
        "year": 2014,
        "quarter": 0,
        "form": "10-K",
        "startDate": "2014-01-01 00:00:00",
        "endDate": "2014-12-31 00:00:00",
        "filedDate": "2015-02-04 00:00:00",
        "acceptedDate": "2015-02-04 16:39:52",
        "report": {
          "bs": [
            {
              "concept": "biib_DueFromUnconsolidatedJointBusiness",
              "unit": "usd",
              "label": "Due from unconsolidated joint business, net",
              "value": 283360000
            },
            {
              "concept": "us-gaap_AccountsPayableCurrent",
              "unit": "usd",
              "label": "Accounts payable",
              "value": 229178000
            },
            {
              "concept": "us-gaap_AccountsReceivableNetCurrent",
              "unit": "usd",
              "label": "Current balance included within accounts receivable, net",
              "value": 1292445000
            },
            {
              "concept": "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax",
              "unit": "usd",
              "label": "Accumulated other comprehensive loss",
              "value": -59488000
            },
            {
              "concept": "us-gaap_AdditionalPaidInCapital",
              "unit": "usd",
              "label": "Additional paid-in capital",
              "value": 4196156000
            },
            {
              "concept": "us-gaap_Assets",
              "unit": "usd",
              "label": "Total assets",
              "value": 14316559000
            },
            {
              "concept": "us-gaap_AssetsCurrent",
              "unit": "usd",
              "label": "Total current assets",
              "value": 4672673000
            },
            {
              "concept": "us-gaap_AvailableForSaleSecuritiesCurrent",
              "unit": "usd",
              "label": "Marketable securities",
              "value": 640460000
            },
            {
              "concept": "us-gaap_AvailableForSaleSecuritiesNoncurrent",
              "unit": "usd",
              "label": "Marketable securities",
              "value": 1470652000
            },
            {
              "concept": "us-gaap_CashAndCashEquivalentsAtCarryingValue",
              "unit": "usd",
              "label": "Cash and cash equivalents, end of the year",
              "value": 1204924000
            },
            {
              "concept": "us-gaap_CommonStockValue",
              "unit": "usd",
              "label": "Common stock, par value $0.0005 per share",
              "value": 129000
            },
            {
              "concept": "us-gaap_DebtCurrent",
              "unit": "usd",
              "label": "Current portion of notes payable",
              "value": 3136000
            },
            {
              "concept": "us-gaap_DeferredTaxLiabilitiesNoncurrent",
              "unit": "usd",
              "label": "Long-term deferred tax liability",
              "value": 50656000
            },
            {
              "concept": "us-gaap_Goodwill",
              "unit": "usd",
              "label": "Goodwill, end of period",
              "value": 1760249000
            },
            {
              "concept": "us-gaap_IntangibleAssetsNetExcludingGoodwill",
              "unit": "usd",
              "label": "Intangible assets, net",
              "value": 4028507000
            },
            {
              "concept": "us-gaap_InventoryNet",
              "unit": "usd",
              "label": "Total inventory",
              "value": 804022000
            },
            {
              "concept": "us-gaap_Liabilities",
              "unit": "usd",
              "label": "Total liabilities",
              "value": 3502519000
            },
            {
              "concept": "us-gaap_LiabilitiesAndStockholdersEquity",
              "unit": "usd",
              "label": "Total liabilities and equity",
              "value": 14316559000
            },
            {
              "concept": "us-gaap_LiabilitiesCurrent",
              "unit": "usd",
              "label": "Total current liabilities",
              "value": 2219706000
            },
            {
              "concept": "us-gaap_LongTermDebt",
              "unit": "usd",
              "label": "Non-current portion of notes payable",
              "value": 582061000
            },
            {
              "concept": "us-gaap_MinorityInterest",
              "unit": "usd",
              "label": "Noncontrolling interests",
              "value": 5030000
            },
            {
              "concept": "us-gaap_OtherAssetsCurrent",
              "unit": "usd",
              "label": "Other current assets",
              "value": 447462000
            },
            {
              "concept": "us-gaap_OtherAssetsNoncurrent",
              "unit": "usd",
              "label": "Investments and other assets",
              "value": 618795000
            },
            {
              "concept": "us-gaap_OtherLiabilitiesCurrent",
              "unit": "usd",
              "label": "Accrued expenses and other",
              "value": 1819334000
            },
            {
              "concept": "us-gaap_OtherLiabilitiesNoncurrent",
              "unit": "usd",
              "label": "Total other long-term liabilities",
              "value": 650096000
            },
            {
              "concept": "us-gaap_PreferredStockValue",
              "unit": "usd",
              "label": "Preferred stock, par value $0.001 per share",
              "value": 0
            },
            {
              "concept": "us-gaap_PropertyPlantAndEquipmentNet",
              "unit": "usd",
              "label": "Total property, plant and equipment, net",
              "value": 1765683000
            },
            {
              "concept": "us-gaap_RetainedEarningsAccumulatedDeficit",
              "unit": "usd",
              "label": "Retained earnings",
              "value": 9283919000
            },
            {
              "concept": "us-gaap_StockholdersEquity",
              "unit": "usd",
              "label": "Total Biogen Idec Inc. shareholders\u2019 equity",
              "value": 10809010000
            },
            {
              "concept": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
              "unit": "usd",
              "label": "Ending Balance",
              "value": 10814040000
            },
            {
              "concept": "us-gaap_TaxesPayableCurrent",
              "unit": "usd",
              "label": "Taxes payable",
              "value": 168058000
            },
            {
              "concept": "us-gaap_TreasuryStockValue",
              "unit": "usd",
              "label": "Treasury stock, at cost; 22,562 shares and 19,641 shares, respectively",
              "value": 2611706000
            }
          ],
          "ic": [
            {
              "concept": "biib_CollaborationProfitSharing",
              "unit": "usd",
              "label": "Collaboration profit sharing",
              "value": 0
            },
            {
              "concept": "biib_GainOnSaleOfRights",
              "unit": "usd",
              "label": "Gain on sale of rights",
              "value": 16758000
            },
            {
              "concept": "biib_UnconsolidatedJointBusiness",
              "unit": "usd",
              "label": "Unconsolidated joint business",
              "value": 1195389000
            },
            {
              "concept": "us-gaap_AmortizationOfIntangibleAssets",
              "unit": "usd",
              "label": "Amortization of acquired intangible assets",
              "value": 489761000
            },
            {
              "concept": "us-gaap_ComprehensiveIncomeNetOfTax",
              "unit": "usd",
              "label": "Comprehensive income attributable to Biogen Idec Inc.",
              "value": 2903041000
            },
            {
              "concept": "us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest",
              "unit": "usd",
              "label": "Comprehensive income attributable to noncontrolling interests, net of tax",
              "value": -6781000
            },
            {
              "concept": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
              "unit": "usd",
              "label": "Comprehensive income",
              "value": 2909822000
            },
            {
              "concept": "us-gaap_CostOfGoodsSold",
              "unit": "usd",
              "label": "Cost of sales, excluding amortization of acquired intangible assets",
              "value": 1171036000
            },
            {
              "concept": "us-gaap_CostsAndExpenses",
              "unit": "usd",
              "label": "Total cost and expenses",
              "value": 5747668000
            },
            {
              "concept": "us-gaap_EarningsPerShareBasic",
              "unit": "usd/share",
              "label": "Basic earnings per share attributable to Biogen Idec Inc.",
              "value": 12
            },
            {
              "concept": "us-gaap_EarningsPerShareDiluted",
              "unit": "usd/share",
              "label": "Diluted earnings per share attributable to Biogen Idec Inc.",
              "value": 12
            },
            {
              "concept": "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings",
              "unit": "usd",
              "label": "Changes in fair value",
              "value": 38893000
            },
            {
              "concept": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
              "unit": "usd",
              "label": "Income before income tax expense and equity in loss of investee, net of tax",
              "value": 3946633000
            },
            {
              "concept": "us-gaap_IncomeLossFromEquityMethodInvestments",
              "unit": "usd",
              "label": "Equity in loss of investee, net of tax",
              "value": -15126000
            },
            {
              "concept": "us-gaap_IncomeTaxExpenseBenefit",
              "unit": "usd",
              "label": "Income tax expense",
              "value": 989942000
            },
            {
              "concept": "us-gaap_NetIncomeLoss",
              "unit": "usd",
              "label": "Net income attributable to Biogen Idec Inc.",
              "value": 2934784000
            },
            {
              "concept": "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest",
              "unit": "usd",
              "label": "Net income attributable to noncontrolling interests, net of tax",
              "value": 6781000
            },
            {
              "concept": "us-gaap_OperatingIncomeLoss",
              "unit": "usd",
              "label": "Income from operations",
              "value": 3972414000
            },
            {
              "concept": "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax",
              "unit": "usd",
              "label": "Unrealized gains (losses) on securities available for sale, net of tax of $3,542, $818 and $2,454",
              "value": -6018000
            },
            {
              "concept": "us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax",
              "unit": "usd",
              "label": "Unrealized gains (losses) on foreign currency forward contracts, net of tax of $260, $1,187 and $4,756",
              "value": 95443000
            },
            {
              "concept": "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
              "unit": "usd",
              "label": "Currency translation adjustment",
              "value": -109218000
            },
            {
              "concept": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
              "unit": "usd",
              "label": "Total other comprehensive income (loss), net of tax",
              "value": -31743000
            },
            {
              "concept": "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax",
              "unit": "usd",
              "label": "Unrealized gains (losses) on pension benefit obligation",
              "value": 11950000
            },
            {
              "concept": "us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax",
              "unit": "usd",
              "label": "Less: reclassification adjustment for (gains) losses included in net income, net of tax of $3,462, $5,576 and $486",
              "value": 6429000
            },
            {
              "concept": "us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesNetOfTax",
              "unit": "usd",
              "label": "Less: reclassification adjustment for (gains) losses included in net income, net of tax of $500, $533 and $3,360",
              "value": 6349000
            },
            {
              "concept": "us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax",
              "unit": "usd",
              "label": "Unrealized gains (losses) recognized during the period, net of tax of $760, $1,721 and $1,396",
              "value": 101792000
            },
            {
              "concept": "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
              "unit": "usd",
              "label": "Unrealized gains (losses) recognized during the period, net of tax of $80, $6,394 and $2,940",
              "value": 411000
            },
            {
              "concept": "us-gaap_OtherNonoperatingIncomeExpense",
              "unit": "usd",
              "label": "Other income (expense), net",
              "value": -25781000
            },
            {
              "concept": "us-gaap_OtherSalesRevenueNet",
              "unit": "usd",
              "label": "Other revenues from external customers",
              "value": 304531000
            },
            {
              "concept": "us-gaap_ProfitLoss",
              "unit": "usd",
              "label": "Net income",
              "value": 2941565000
            },
            {
              "concept": "us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
              "unit": "usd",
              "label": "Research and development",
              "value": 1893422000
            },
            {
              "concept": "us-gaap_RestructuringCharges",
              "unit": "usd",
              "label": "Restructuring charges",
              "value": 0
            },
            {
              "concept": "us-gaap_Revenues",
              "unit": "usd",
              "label": "Total revenues",
              "value": 9703324000
            },
            {
              "concept": "us-gaap_SalesRevenueGoodsNet",
              "unit": "usd",
              "label": "Revenue on sales in the rest of world for RITUXAN",
              "value": 8203404000
            },
            {
              "concept": "us-gaap_SellingGeneralAndAdministrativeExpense",
              "unit": "usd",
              "label": "Selling, general and administrative",
              "value": 2232342000
            },
            {
              "concept": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
              "unit": "shares",
              "label": "Shares used in calculating diluted earnings per share",
              "value": 237176000
            },
            {
              "concept": "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic",
              "unit": "shares",
              "label": "Weighted average number of common shares outstanding",
              "value": 236359000
            }
          ],
          "cf": [
            {
              "concept": "us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease",
              "unit": "usd",
              "label": "Net increase (decrease) in cash and cash equivalents",
              "value": 643266000
            },
            {
              "concept": "us-gaap_DeferredIncomeTaxExpenseBenefit",
              "unit": "usd",
              "label": "Total",
              "value": -308222000
            },
            {
              "concept": "us-gaap_DepreciationDepletionAndAmortization",
              "unit": "usd",
              "label": "Depreciation and amortization",
              "value": 688150000
            },
            {
              "concept": "us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents",
              "unit": "usd",
              "label": "Effect of exchange rate changes on cash and cash equivalents",
              "value": -40904000
            },
            {
              "concept": "us-gaap_ExcessTaxBenefitFromShareBasedCompensationFinancingActivities",
              "unit": "usd",
              "label": "Excess tax benefit from share-based compensation",
              "value": 96376000
            },
            {
              "concept": "us-gaap_IncreaseDecreaseInAccountsReceivable",
              "unit": "usd",
              "label": "Accounts receivable",
              "value": 512389000
            },
            {
              "concept": "us-gaap_IncreaseDecreaseInAccruedLiabilities",
              "unit": "usd",
              "label": "Accrued expenses and other current liabilities",
              "value": 244378000
            },
            {
              "concept": "us-gaap_IncreaseDecreaseInInventories",
              "unit": "usd",
              "label": "Inventory",
              "value": 185917000
            },
            {
              "concept": "us-gaap_IncreaseDecreaseInOtherOperatingAssets",
              "unit": "usd",
              "label": "Other assets",
              "value": 94514000
            },
            {
              "concept": "us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet",
              "unit": "usd",
              "label": "Other",
              "value": 30697000
            },
            {
              "concept": "us-gaap_IncreaseDecreaseInOtherOperatingLiabilities",
              "unit": "usd",
              "label": "Other liabilities and taxes payable",
              "value": 94779000
            },
            {
              "concept": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
              "unit": "usd",
              "label": "Net cash flows used in financing activities",
              "value": -755873000
            },
            {
              "concept": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
              "unit": "usd",
              "label": "Net cash flows used in investing activities",
              "value": -1542976000
            },
            {
              "concept": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
              "unit": "usd",
              "label": "Net cash flows provided by operating activities",
              "value": 2942115000
            },
            {
              "concept": "us-gaap_OtherNoncashIncomeExpense",
              "unit": "usd",
              "label": "Other",
              "value": 50320000
            },
            {
              "concept": "us-gaap_PaymentsForProceedsFromOtherInvestingActivities",
              "unit": "usd",
              "label": "Other",
              "value": 15998000
            },
            {
              "concept": "us-gaap_PaymentsForRepurchaseOfCommonStock",
              "unit": "usd",
              "label": "Repurchase of common stock, value",
              "value": 886779000
            },
            {
              "concept": "us-gaap_PaymentsToAcquireAvailableForSaleSecurities",
              "unit": "usd",
              "label": "Purchases of marketable securities",
              "value": 3583150000
            },
            {
              "concept": "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired",
              "unit": "usd",
              "label": "Acquisitions of businesses",
              "value": 0
            },
            {
              "concept": "us-gaap_PaymentsToAcquireIntangibleAssets",
              "unit": "usd",
              "label": "Acquisition of TYSABRI rights",
              "value": 0
            },
            {
              "concept": "us-gaap_PaymentsToAcquireOtherProductiveAssets",
              "unit": "usd",
              "label": "Contingent consideration related to Fumapharm AG acquisition",
              "value": 375000000
            },
            {
              "concept": "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment",
              "unit": "usd",
              "label": "Purchases of property, plant and equipment",
              "value": 287751000
            },
            {
              "concept": "us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions",
              "unit": "usd",
              "label": "Proceeds from issuance of stock for share-based compensation arrangements",
              "value": 54887000
            },
            {
              "concept": "us-gaap_ProceedsFromPaymentsForOtherFinancingActivities",
              "unit": "usd",
              "label": "Other",
              "value": -17683000
            },
            {
              "concept": "us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities",
              "unit": "usd",
              "label": "Proceeds from sales and maturities of marketable securities",
              "value": 2718923000
            },
            {
              "concept": "us-gaap_ProfitLoss",
              "unit": "usd",
              "label": "Net income",
              "value": 2941565000
            },
            {
              "concept": "us-gaap_RepaymentsOfDebt",
              "unit": "usd",
              "label": "Repayments of borrowings",
              "value": 2674000
            },
            {
              "concept": "us-gaap_ShareBasedCompensation",
              "unit": "usd",
              "label": "Share-based compensation",
              "value": 155302000
            }
          ]
        }
      },
      {
        "accessNumber": "0000875045-14-000004",
        "symbol": "BIIB",
        "cik": "875045",
        "year": 2013,
        "quarter": 0,
        "form": "10-K",
        "startDate": "2013-01-01 00:00:00",
        "endDate": "2013-12-31 00:00:00",
        "filedDate": "2014-02-06 00:00:00",
        "acceptedDate": "2014-02-06 17:28:12",
        "report": {
          "bs": [
            {
              "unit": "usd",
              "label": "Cash and cash equivalents",
              "value": 602562000,
              "concept": "CashAndCashEquivalentsAtCarryingValue"
            },
            {
              "unit": "usd",
              "label": "Marketable securities",
              "value": 620167000,
              "concept": "AvailableForSaleSecuritiesCurrent"
            },
            {
              "unit": "usd",
              "label": "Accounts receivable, net",
              "value": 824406000,
              "concept": "AccountsReceivableNetCurrent"
            },
            {
              "unit": "usd",
              "label": "Due from unconsolidated joint business, net",
              "value": 252662000,
              "concept": "biib:DueFromUnconsolidatedJointBusiness"
            },
            {
              "unit": "usd",
              "label": "Inventory",
              "value": 659003000,
              "concept": "InventoryNet"
            },
            {
              "unit": "usd",
              "label": "Other current assets",
              "value": 226134000,
              "concept": "OtherAssetsCurrent"
            },
            {
              "unit": "usd",
              "label": "Current assets:",
              "value": 3184934000,
              "concept": "AssetsCurrent"
            },
            {
              "unit": "usd",
              "label": "Marketable securities",
              "value": 625772000,
              "concept": "AvailableForSaleSecuritiesNoncurrent"
            },
            {
              "unit": "usd",
              "label": "Property, plant and equipment, net",
              "value": 1750710000,
              "concept": "PropertyPlantAndEquipmentNet"
            },
            {
              "unit": "usd",
              "label": "Intangible assets",
              "value": 4474653000,
              "concept": "IntangibleAssetsNetExcludingGoodwill"
            },
            {
              "unit": "usd",
              "label": "Goodwill and Intangible Assets Disclosure [Abstract]",
              "value": 1232916000,
              "concept": "Goodwill"
            },
            {
              "unit": "usd",
              "label": "Investments and other assets",
              "value": 594350000,
              "concept": "OtherAssetsNoncurrent"
            },
            {
              "unit": "usd",
              "label": "ASSETS",
              "value": 11863335000,
              "concept": "Assets"
            },
            {
              "unit": "usd",
              "label": "Current portion of notes payable and line of credit",
              "value": 3494000,
              "concept": "DebtCurrent"
            },
            {
              "unit": "usd",
              "label": "Taxes payable",
              "value": 179685000,
              "concept": "TaxesPayableCurrent"
            },
            {
              "unit": "usd",
              "label": "Accounts payable",
              "value": 219913000,
              "concept": "AccountsPayableCurrent"
            },
            {
              "unit": "usd",
              "label": "Accrued expenses and other",
              "value": 1355187000,
              "concept": "OtherLiabilitiesCurrent"
            },
            {
              "unit": "usd",
              "label": "Current liabilities:",
              "value": 1758279000,
              "concept": "LiabilitiesCurrent"
            },
            {
              "unit": "usd",
              "label": "Notes payable and other financing arrangements",
              "value": 592433000,
              "concept": "LongTermDebt"
            },
            {
              "unit": "usd",
              "label": "Long-term deferred tax liability",
              "value": 232554000,
              "concept": "DeferredTaxLiabilitiesNoncurrent"
            },
            {
              "unit": "usd",
              "label": "Other long-term liabilities",
              "value": 659231000,
              "concept": "OtherLiabilitiesNoncurrent"
            },
            {
              "unit": "usd",
              "label": "LIABILITIES AND EQUITY",
              "value": 3242497000,
              "concept": "Liabilities"
            },
            {
              "unit": "usd",
              "label": "Commitments and Contingencies Disclosure [Abstract]",
              "value": "N/A",
              "concept": "CommitmentsAndContingencies"
            },
            {
              "unit": "usd",
              "label": "Preferred stock, par value $0.001 per share",
              "value": 0,
              "concept": "PreferredStockValue"
            },
            {
              "unit": "usd",
              "label": "Common stock, par value $0.0005 per share",
              "value": 128000,
              "concept": "CommonStockValue"
            },
            {
              "unit": "usd",
              "label": "Additional paid-in capital",
              "value": 4023651000,
              "concept": "AdditionalPaidInCapital"
            },
            {
              "unit": "usd",
              "label": "Accumulated other comprehensive loss",
              "value": -27745000,
              "concept": "AccumulatedOtherComprehensiveIncomeLossNetOfTax"
            },
            {
              "unit": "usd",
              "label": "Retained earnings",
              "value": 6349135000,
              "concept": "RetainedEarningsAccumulatedDeficit"
            },
            {
              "unit": "usd",
              "label": "Treasury stock, at cost; 19,641 shares and 17,655 shares, respectively",
              "value": 1724927000,
              "concept": "TreasuryStockValue"
            },
            {
              "unit": "usd",
              "label": "Equity:",
              "value": 8620242000,
              "concept": "StockholdersEquity"
            },
            {
              "unit": "usd",
              "label": "Noncontrolling interests",
              "value": 596000,
              "concept": "MinorityInterest"
            },
            {
              "unit": "usd",
              "label": "Equity:",
              "value": 8620838000,
              "concept": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"
            },
            {
              "unit": "usd",
              "label": "LIABILITIES AND EQUITY",
              "value": 11863335000,
              "concept": "LiabilitiesAndStockholdersEquity"
            }
          ],
          "cf": [
            {
              "unit": "usd",
              "label": "Net income",
              "value": 1862341000,
              "concept": "ProfitLoss"
            },
            {
              "unit": "usd",
              "label": "Depreciation and amortization of property, plant and equipment, and intangible assets",
              "value": 531740000,
              "concept": "DepreciationDepletionAndAmortization"
            },
            {
              "unit": "usd",
              "label": "Share-based Compensation Arrangements by Share-based Payment Award, Award Type and Plan Name [Domain]",
              "value": 136293000,
              "concept": "ShareBasedCompensation"
            },
            {
              "unit": "usd",
              "label": "Deferred income taxes",
              "value": -245077000,
              "concept": "DeferredIncomeTaxExpenseBenefit"
            },
            {
              "unit": "usd",
              "label": "Other",
              "value": 27612000,
              "concept": "OtherNoncashIncomeExpense"
            },
            {
              "unit": "usd",
              "label": "Accounts receivable",
              "value": 126753000,
              "concept": "IncreaseDecreaseInAccountsReceivable"
            },
            {
              "unit": "usd",
              "label": "Inventory",
              "value": 243960000,
              "concept": "IncreaseDecreaseInInventories"
            },
            {
              "unit": "usd",
              "label": "Other assets",
              "value": 160188000,
              "concept": "IncreaseDecreaseInOtherOperatingAssets"
            },
            {
              "unit": "usd",
              "label": "Accrued expenses and other current liabilities",
              "value": 284049000,
              "concept": "IncreaseDecreaseInAccruedLiabilities"
            },
            {
              "unit": "usd",
              "label": "Other liabilities and taxes payable",
              "value": 318512000,
              "concept": "IncreaseDecreaseInOtherOperatingLiabilities"
            },
            {
              "unit": "usd",
              "label": "Other",
              "value": -15733000,
              "concept": "IncreaseDecreaseInOtherOperatingCapitalNet"
            },
            {
              "unit": "usd",
              "label": "Cash flows from operating activities:",
              "value": 2345078000,
              "concept": "NetCashProvidedByUsedInOperatingActivities"
            },
            {
              "unit": "usd",
              "label": "Proceeds from sales and maturities of marketable securities",
              "value": 5190052000,
              "concept": "ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities"
            },
            {
              "unit": "usd",
              "label": "Purchases of marketable securities",
              "value": 3278091000,
              "concept": "PaymentsToAcquireAvailableForSaleSecurities"
            },
            {
              "unit": "usd",
              "label": "Acquisition of TYSABRI rights",
              "value": 3262719000,
              "concept": "PaymentsToAcquireIntangibleAssets"
            },
            {
              "unit": "usd",
              "label": "Acquisitions of businesses and variable interest entities, net of cash acquired",
              "value": 15000000,
              "concept": "PaymentsToAcquireBusinessesNetOfCashAcquired"
            },
            {
              "unit": "usd",
              "label": "Purchases of property, plant and equipment",
              "value": 246281000,
              "concept": "PaymentsToAcquirePropertyPlantAndEquipment"
            },
            {
              "unit": "usd",
              "label": "Other",
              "value": -7371000,
              "concept": "PaymentsForProceedsFromOtherInvestingActivities"
            },
            {
              "unit": "usd",
              "label": "Cash flows from investing activities:",
              "value": -1604668000,
              "concept": "NetCashProvidedByUsedInInvestingActivities"
            },
            {
              "unit": "usd",
              "label": "Repurchase of common stock, value",
              "value": 400309000,
              "concept": "PaymentsForRepurchaseOfCommonStock"
            },
            {
              "unit": "usd",
              "label": "Proceeds from issuance of stock for share-based compensation arrangements",
              "value": 66770000,
              "concept": "ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions"
            },
            {
              "unit": "usd",
              "label": "Excess tax benefit from share-based compensation",
              "value": 73467000,
              "concept": "ExcessTaxBenefitFromShareBasedCompensationFinancingActivities"
            },
            {
              "unit": "usd",
              "label": "Acquisition of noncontrolling interests",
              "value": 0,
              "concept": "biib:PaymentsForAcquisitionOfNoncontrollingInterest"
            },
            {
              "unit": "usd",
              "label": "Repayments of borrowings",
              "value": 452340000,
              "concept": "RepaymentsOfDebt"
            },
            {
              "unit": "usd",
              "label": "Other",
              "value": -4116000,
              "concept": "ProceedsFromPaymentsForOtherFinancingActivities"
            },
            {
              "unit": "usd",
              "label": "Cash flows from financing activities:",
              "value": -716528000,
              "concept": "NetCashProvidedByUsedInFinancingActivities"
            },
            {
              "unit": "usd",
              "label": "Net increase (decrease) in cash and cash equivalents",
              "value": 23882000,
              "concept": "CashAndCashEquivalentsPeriodIncreaseDecrease"
            },
            {
              "unit": "usd",
              "label": "Effect of exchange rate changes on cash and cash equivalents",
              "value": 7959000,
              "concept": "EffectOfExchangeRateOnCashAndCashEquivalents"
            }
          ],
          "ic": [
            {
              "unit": "usd",
              "label": "Net income attributable to Biogen Idec Inc",
              "value": 1862341000,
              "concept": "NetIncomeLoss"
            },
            {
              "unit": "usd",
              "label": "Unrealized gains (losses) recognized during the period, net of tax of $6,394, $2,940 and $133",
              "value": 11770000,
              "concept": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"
            },
            {
              "unit": "usd",
              "label": "Less: reclassification adjustment for (gains) losses included in net income, net of tax of $5,576, $486 and $7,155",
              "value": 10355000,
              "concept": "OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax"
            },
            {
              "unit": "usd",
              "label": "Unrealized gains (losses) on securities available for sale, net of tax of $818, $2,454 and $7,288",
              "value": 1415000,
              "concept": "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"
            },
            {
              "unit": "usd",
              "label": "Unrealized gains (losses) recognized during the period, net of tax of $1,721, $1,396 and $3,647",
              "value": -26679000,
              "concept": "OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax"
            },
            {
              "unit": "usd",
              "label": "Less: reclassification adjustment for (gains) losses included in net income, net of tax of $533, $3,360 and $1,268",
              "value": -13716000,
              "concept": "OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesNetOfTax"
            },
            {
              "unit": "usd",
              "label": "Unrealized gains (losses) on foreign currency forward contracts, net of tax of $1,187, $4,756 and $4,915",
              "value": -12963000,
              "concept": "OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax"
            },
            {
              "unit": "usd",
              "label": "Unrealized gains (losses) on pension benefit obligation",
              "value": -2096000,
              "concept": "OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax"
            },
            {
              "unit": "usd",
              "label": "Currency translation adjustment",
              "value": 37012000,
              "concept": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"
            },
            {
              "unit": "usd",
              "label": "Other comprehensive income:",
              "value": 27560000,
              "concept": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"
            },
            {
              "unit": "usd",
              "label": "Comprehensive income attributable to Biogen Idec Inc.",
              "value": 1889901000,
              "concept": "ComprehensiveIncomeNetOfTax"
            },
            {
              "unit": "usd",
              "label": "Comprehensive income attributable to noncontrolling interests, net of tax",
              "value": 0,
              "concept": "ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest"
            },
            {
              "unit": "usd",
              "label": "Comprehensive income",
              "value": 1889901000,
              "concept": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"
            },
            {
              "unit": "usd",
              "label": "Product, net",
              "value": 5542331000,
              "concept": "SalesRevenueGoodsNet"
            },
            {
              "unit": "usd",
              "label": "Unconsolidated joint business revenues",
              "value": 1126017000,
              "concept": "biib:UnconsolidatedJointBusiness"
            },
            {
              "unit": "usd",
              "label": "Other",
              "value": 263851000,
              "concept": "OtherSalesRevenueNet"
            },
            {
              "unit": "usd",
              "label": "Total revenues",
              "value": 6932199000,
              "concept": "Revenues"
            },
            {
              "unit": "usd",
              "label": "Cost of sales, excluding amortization of acquired intangible assets",
              "value": 857726000,
              "concept": "CostOfGoodsSold"
            },
            {
              "unit": "usd",
              "label": "Research and development",
              "value": 1444053000,
              "concept": "ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"
            },
            {
              "unit": "usd",
              "label": "Selling, general and administrative",
              "value": 1712051000,
              "concept": "SellingGeneralAndAdministrativeExpense"
            },
            {
              "unit": "usd",
              "label": "Amortization of acquired intangible assets",
              "value": 342948000,
              "concept": "AmortizationOfIntangibleAssets"
            },
            {
              "unit": "usd",
              "label": "Collaboration profit sharing",
              "value": 85357000,
              "concept": "biib:CollaborationProfitSharing"
            },
            {
              "unit": "usd",
              "label": "(Gain) loss on fair value remeasurement of contingent consideration",
              "value": 547000,
              "concept": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"
            },
            {
              "unit": "usd",
              "label": "Restructuring charges",
              "value": 0,
              "concept": "RestructuringCharges"
            },
            {
              "unit": "usd",
              "label": "Cost and expenses:",
              "value": 4441588000,
              "concept": "CostsAndExpenses"
            },
            {
              "unit": "usd",
              "label": "Gain on Sale of Rights [Abstract]",
              "value": 24898000,
              "concept": "biib:GainOnSaleOfRights"
            },
            {
              "unit": "usd",
              "label": "Income from operations",
              "value": 2515509000,
              "concept": "OperatingIncomeLoss"
            },
            {
              "unit": "usd",
              "label": "Other income (expense), net",
              "value": -34930000,
              "concept": "OtherNonoperatingIncomeExpense"
            },
            {
              "unit": "usd",
              "label": "Income before income tax expense and equity in loss of investee, net of tax",
              "value": 2480579000,
              "concept": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"
            },
            {
              "unit": "usd",
              "label": "Income tax expense",
              "value": 601014000,
              "concept": "IncomeTaxExpenseBenefit"
            },
            {
              "unit": "usd",
              "label": "Equity in loss of investee, net of tax",
              "value": -17224000,
              "concept": "IncomeLossFromEquityMethodInvestments"
            },
            {
              "unit": "usd",
              "label": "Net income",
              "value": 1862341000,
              "concept": "ProfitLoss"
            },
            {
              "unit": "usd",
              "label": "Net income attributable to noncontrolling interests, net of tax",
              "value": 0,
              "concept": "NetIncomeLossAttributableToNoncontrollingInterest"
            },
            {
              "unit": "usd/shares",
              "label": "Basic earnings per share attributable to Biogen Idec Inc.",
              "value": 7.86,
              "concept": "EarningsPerShareBasic"
            },
            {
              "unit": "usd/shares",
              "label": "Diluted earnings per share attributable to Biogen Idec Inc.",
              "value": 7.81,
              "concept": "EarningsPerShareDiluted"
            },
            {
              "unit": "shares",
              "label": "Basic earnings per share attributable to Biogen Idec Inc.",
              "value": 236919000,
              "concept": "WeightedAverageNumberOfSharesOutstandingBasic"
            },
            {
              "unit": "shares",
              "label": "Diluted earnings per share attributable to Biogen Idec Inc.",
              "value": 238308000,
              "concept": "WeightedAverageNumberOfDilutedSharesOutstanding"
            }
          ]
        }
      },
      {
        "accessNumber": "0000875045-13-000006",
        "symbol": "BIIB",
        "cik": "875045",
        "year": 2012,
        "quarter": 0,
        "form": "10-K",
        "startDate": "2012-01-01 00:00:00",
        "endDate": "2012-12-31 00:00:00",
        "filedDate": "2013-02-05 00:00:00",
        "acceptedDate": "2013-02-05 06:42:21",
        "report": {
          "bs": [
            {
              "unit": "usd",
              "label": "Cash and cash equivalents, beginning of the period",
              "value": 570721000,
              "concept": "CashAndCashEquivalentsAtCarryingValue"
            },
            {
              "unit": "usd",
              "label": "Marketable securities",
              "value": 1134989000,
              "concept": "MarketableSecuritiesCurrent"
            },
            {
              "unit": "usd",
              "label": "Current balance included within accounts receivable, net",
              "value": 686848000,
              "concept": "AccountsReceivableNetCurrent"
            },
            {
              "unit": "usd",
              "label": "Due from unconsolidated joint business",
              "value": 268395000,
              "concept": "biib:DueFromUnconsolidatedJointBusiness"
            },
            {
              "unit": "usd",
              "label": "Total inventory",
              "value": 447373000,
              "concept": "InventoryNet"
            },
            {
              "unit": "usd",
              "label": "Other current assets",
              "value": 136011000,
              "concept": "OtherAssetsCurrent"
            },
            {
              "unit": "usd",
              "label": "Current assets:",
              "value": 3244337000,
              "concept": "AssetsCurrent"
            },
            {
              "unit": "usd",
              "label": "Marketable securities",
              "value": 2036658000,
              "concept": "MarketableSecuritiesNoncurrent"
            },
            {
              "unit": "usd",
              "label": "Total property, plant and equipment, net",
              "value": 1742226000,
              "concept": "PropertyPlantAndEquipmentNet"
            },
            {
              "unit": "usd",
              "label": "Intangible assets",
              "value": 1631547000,
              "concept": "IntangibleAssetsNetExcludingGoodwill"
            },
            {
              "unit": "usd",
              "label": "Goodwill and Intangible Assets Disclosure [Abstract]",
              "value": 1201296000,
              "concept": "Goodwill"
            },
            {
              "unit": "usd",
              "label": "Investments and other assets",
              "value": 274054000,
              "concept": "OtherAssetsNoncurrent"
            },
            {
              "unit": "usd",
              "label": "Assets:",
              "value": 10130118000,
              "concept": "Assets"
            },
            {
              "unit": "usd",
              "label": "Current portion of notes payable and line of credit",
              "value": 453379000,
              "concept": "NotesPayableCurrent"
            },
            {
              "unit": "usd",
              "label": "Taxes payable",
              "value": 20066000,
              "concept": "TaxesPayableCurrent"
            },
            {
              "unit": "usd",
              "label": "Accounts payable",
              "value": 203999000,
              "concept": "AccountsPayableCurrent"
            },
            {
              "unit": "usd",
              "label": "Total accrued expenses and other",
              "value": 979945000,
              "concept": "OtherLiabilitiesCurrent"
            },
            {
              "unit": "usd",
              "label": "Current liabilities:",
              "value": 1657389000,
              "concept": "LiabilitiesCurrent"
            },
            {
              "unit": "usd",
              "label": "Notes payable, line of credit and other financing arrangements",
              "value": 687396000,
              "concept": "LongTermNotesPayable"
            },
            {
              "unit": "usd",
              "label": "Long-term deferred tax liability",
              "value": 217272000,
              "concept": "DeferredTaxLiabilitiesNoncurrent"
            },
            {
              "unit": "usd",
              "label": "Other long-term liabilities",
              "value": 604266000,
              "concept": "OtherLiabilitiesNoncurrent"
            },
            {
              "unit": "usd",
              "label": "Liabilities:",
              "value": 3166323000,
              "concept": "Liabilities"
            },
            {
              "unit": "usd",
              "label": "Contingencies",
              "value": "N/A",
              "concept": "CommitmentsAndContingencies"
            },
            {
              "unit": "usd",
              "label": "Preferred stock, par value $0.001 per share",
              "value": 0,
              "concept": "PreferredStockValue"
            },
            {
              "unit": "usd",
              "label": "Common stock, par value $0.0005 per share",
              "value": 127000,
              "concept": "CommonStockValue"
            },
            {
              "unit": "usd",
              "label": "Additional paid-in capital",
              "value": 3854525000,
              "concept": "AdditionalPaidInCapital"
            },
            {
              "unit": "usd",
              "label": "Accumulated other comprehensive income (loss)",
              "value": -55305000,
              "concept": "AccumulatedOtherComprehensiveIncomeLossNetOfTax"
            },
            {
              "unit": "usd",
              "label": "Retained earnings",
              "value": 4486794000,
              "concept": "RetainedEarningsAccumulatedDeficit"
            },
            {
              "unit": "usd",
              "label": "Repurchase of common stock for Treasury pursuant to the 2011, 2010 and 2009 share repurchase plans, at cost",
              "value": 1324618000,
              "concept": "TreasuryStockValue"
            },
            {
              "unit": "usd",
              "label": "Equity",
              "value": 6961523000,
              "concept": "StockholdersEquity"
            },
            {
              "unit": "usd",
              "label": "Distributions to noncontrolling interests",
              "value": 2272000,
              "concept": "MinorityInterest"
            },
            {
              "unit": "usd",
              "label": "Beginning Balance",
              "value": 6963795000,
              "concept": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"
            },
            {
              "unit": "usd",
              "label": "LIABILITIES AND EQUITY",
              "value": 10130118000,
              "concept": "LiabilitiesAndStockholdersEquity"
            }
          ],
          "cf": [
            {
              "unit": "usd",
              "label": "Net income",
              "value": 1380033000,
              "concept": "ProfitLoss"
            },
            {
              "unit": "usd",
              "label": "Depreciation and amortization of property, plant and equipment, and intangible assets",
              "value": 365648000,
              "concept": "DepreciationAndAmortization"
            },
            {
              "unit": "usd",
              "label": "Acquired research and development in process",
              "value": 0,
              "concept": "ResearchAndDevelopmentInProcess"
            },
            {
              "unit": "usd",
              "label": "Share-based Compensation Arrangements by Share-based Payment Award, Award Type and Plan Name [Domain]",
              "value": 118566000,
              "concept": "ShareBasedCompensation"
            },
            {
              "unit": "usd",
              "label": "Fair value adjustment of contingent consideration",
              "value": 27202000,
              "concept": "biib:FairValueAdjustmentOfContingentConsideration"
            },
            {
              "unit": "usd",
              "label": "Excess tax benefit from share-based compensation",
              "value": 54738000,
              "concept": "ExcessTaxBenefitFromShareBasedCompensationOperatingActivities"
            },
            {
              "unit": "usd",
              "label": "Deferred",
              "value": -116900000,
              "concept": "DeferredIncomeTaxExpenseBenefit"
            },
            {
              "unit": "usd",
              "label": "Write-downs on excess, obsolete or unmarketable inventory",
              "value": 24821000,
              "concept": "InventoryWriteDown"
            },
            {
              "unit": "usd",
              "label": "Other",
              "value": -31537000,
              "concept": "OtherNoncashIncomeExpense"
            },
            {
              "unit": "usd",
              "label": "Accounts receivable",
              "value": -3571000,
              "concept": "IncreaseDecreaseInAccountsReceivable"
            },
            {
              "unit": "usd",
              "label": "Due from unconsolidated joint business",
              "value": 39671000,
              "concept": "biib:IncreaseDecreaseInDueFromUnconsolidatedJointBusiness"
            },
            {
              "unit": "usd",
              "label": "Inventory",
              "value": 140309000,
              "concept": "IncreaseDecreaseInInventories"
            },
            {
              "unit": "usd",
              "label": "Other assets",
              "value": 27347000,
              "concept": "IncreaseDecreaseInOtherOperatingAssets"
            },
            {
              "unit": "usd",
              "label": "Accrued expenses and other current liabilities",
              "value": 273372000,
              "concept": "IncreaseDecreaseInAccruedLiabilities"
            },
            {
              "unit": "usd",
              "label": "Other liabilities and taxes payable",
              "value": 34112000,
              "concept": "IncreaseDecreaseInOtherOperatingLiabilities"
            },
            {
              "unit": "usd",
              "label": "Cash flows from operating activities:",
              "value": 1879897000,
              "concept": "NetCashProvidedByUsedInOperatingActivities"
            },
            {
              "unit": "usd",
              "label": "Proceeds from maturities and sales",
              "value": 2749558000,
              "concept": "ProceedsFromSaleAndMaturityOfMarketableSecurities"
            },
            {
              "unit": "usd",
              "label": "Purchases of marketable securities",
              "value": 3334434000,
              "concept": "PaymentsToAcquireMarketableSecurities"
            },
            {
              "unit": "usd",
              "label": "Acquisitions of businesses and variable interest entities, net of cash acquired",
              "value": 72401000,
              "concept": "biib:AcquisitionsOfBusinessesAndVariableInterestEntitiesNetOfCashAcquired"
            },
            {
              "unit": "usd",
              "label": "Purchases of property, plant and equipment",
              "value": 254548000,
              "concept": "PaymentsToAcquirePropertyPlantAndEquipment"
            },
            {
              "unit": "usd",
              "label": "Proceeds from the sale of strategic investments and long-lived assets",
              "value": 10058000,
              "concept": "biib:ProceedsFromSaleOfStrategicInvestmentsAndLongLivedAssets"
            },
            {
              "unit": "usd",
              "label": "Purchases of intangible assets",
              "value": 6634000,
              "concept": "PaymentsToAcquireIntangibleAssets"
            },
            {
              "unit": "usd",
              "label": "Purchases of other investments",
              "value": 41941000,
              "concept": "PaymentsToAcquireOtherInvestments"
            },
            {
              "unit": "usd",
              "label": "Cash flows from investing activities:",
              "value": -950342000,
              "concept": "NetCashProvidedByUsedInInvestingActivities"
            },
            {
              "unit": "usd",
              "label": "Purchase of treasury stock",
              "value": 984715000,
              "concept": "PaymentsForRepurchaseOfCommonStock"
            },
            {
              "unit": "usd",
              "label": "Proceeds from issuance of stock for share-based compensation arrangements",
              "value": 67493000,
              "concept": "ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans"
            },
            {
              "unit": "usd",
              "label": "Excess tax benefit from share-based compensation",
              "value": 54738000,
              "concept": "ExcessTaxBenefitFromShareBasedCompensationFinancingActivities"
            },
            {
              "unit": "usd",
              "label": "Acquisition of noncontrolling interests",
              "value": 0,
              "concept": "biib:PaymentsForAcquisitionOfNoncontrollingInterest"
            },
            {
              "unit": "usd",
              "label": "Net distributions to noncontrolling interests",
              "value": 2726000,
              "concept": "PaymentsToMinorityShareholders"
            },
            {
              "unit": "usd",
              "label": "Repayments of borrowings",
              "value": 2428000,
              "concept": "RepaymentsOfShortTermDebt"
            },
            {
              "unit": "usd",
              "label": "Cash payments for contingent consideration",
              "value": 2500000,
              "concept": "biib:BusinessAcquisitionContingentConsiderationCashPayment"
            },
            {
              "unit": "usd",
              "label": "Net proceeds from financing arrangement for the sale of the San Diego facility",
              "value": 0,
              "concept": "biib:NetProceedsFromFinancingArrangementForSaleOfFacility"
            },
            {
              "unit": "usd",
              "label": "Other",
              "value": -7340000,
              "concept": "ProceedsFromPaymentsForOtherFinancingActivities"
            },
            {
              "unit": "usd",
              "label": "Cash flows from financing activities:",
              "value": -877478000,
              "concept": "NetCashProvidedByUsedInFinancingActivities"
            },
            {
              "unit": "usd",
              "label": "Net decrease in cash and cash equivalents",
              "value": 52077000,
              "concept": "CashAndCashEquivalentsPeriodIncreaseDecrease"
            },
            {
              "unit": "usd",
              "label": "Effect of exchange rate changes on cash and cash equivalents",
              "value": 4102000,
              "concept": "EffectOfExchangeRateOnCashAndCashEquivalents"
            }
          ],
          "ic": [
            {
              "unit": "usd",
              "label": "Net income",
              "value": 1380033000,
              "concept": "NetIncomeLoss"
            },
            {
              "unit": "usd",
              "label": "Unrealized gains (losses) recognized during the period, net of tax of $2,940, $133 and $6,345",
              "value": 5080000,
              "concept": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"
            },
            {
              "unit": "usd",
              "label": "Less: reclassification adjustment for gains (losses) included in net income, net of tax of $486, $7,155 and $5,656",
              "value": -903000,
              "concept": "OtherComprehensiveIncomeLossReclassificationAdjustmentForSaleOfSecuritiesIncludedInNetIncomeNetOfTax"
            },
            {
              "unit": "usd",
              "label": "Unrealized gains (losses) on securities available for sale, net of tax of $2,454, $7,288 and $689",
              "value": 4177000,
              "concept": "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"
            },
            {
              "unit": "usd",
              "label": "Unrealized gains (losses) recognized during the period, net of tax of $1,396, $3,647 and $1,268",
              "value": -11808000,
              "concept": "OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax"
            },
            {
              "unit": "usd",
              "label": "Less: reclassification adjustment for gains (losses) included in net income, net of tax of $3,360, $1,268 and $304",
              "value": -31713000,
              "concept": "OtherComprehensiveIncomeLossReclassificationAdjustmentOnDerivativesIncludedInNetIncomeNetOfTax"
            },
            {
              "unit": "usd",
              "label": "Unrealized gains (losses) on foreign currency forward contracts, net of tax of $4,756, $4,915 and $964",
              "value": -43521000,
              "concept": "OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax"
            },
            {
              "unit": "usd",
              "label": "Unrealized gains (losses) on pension benefit obligation, net of tax",
              "value": 12656000,
              "concept": "OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax"
            },
            {
              "unit": "usd",
              "label": "Currency translation adjustment",
              "value": 23230000,
              "concept": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"
            },
            {
              "unit": "usd",
              "label": "Other comprehensive income:",
              "value": -28770000,
              "concept": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"
            },
            {
              "unit": "usd",
              "label": "Comprehensive income",
              "value": 1351263000,
              "concept": "ComprehensiveIncomeNetOfTax"
            },
            {
              "unit": "usd",
              "label": "Comprehensive income attributable to noncontrolling interests, net of tax",
              "value": -65000,
              "concept": "ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest"
            },
            {
              "unit": "usd",
              "label": "Comprehensive income attributable to Biogen Idec Inc.",
              "value": 1351328000,
              "concept": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"
            },
            {
              "unit": "usd",
              "label": "Revenue by product",
              "value": 4166074000,
              "concept": "SalesRevenueGoodsNet"
            },
            {
              "unit": "usd",
              "label": "Unconsolidated joint business revenues",
              "value": 1137923000,
              "concept": "biib:UnconsolidatedJointBusiness"
            },
            {
              "unit": "usd",
              "label": "Other revenues from external customers",
              "value": 212464000,
              "concept": "OtherSalesRevenueNet"
            },
            {
              "unit": "usd",
              "label": "Total revenues",
              "value": 5516461000,
              "concept": "Revenues"
            },
            {
              "unit": "usd",
              "label": "Cost of sales, excluding amortization of acquired intangible assets",
              "value": 545494000,
              "concept": "CostOfRevenue"
            },
            {
              "unit": "usd",
              "label": "Research and development",
              "value": 1334919000,
              "concept": "ResearchAndDevelopmentExpense"
            },
            {
              "unit": "usd",
              "label": "Selling, General and Administrative Expenses",
              "value": 1277465000,
              "concept": "SellingGeneralAndAdministrativeExpense"
            },
            {
              "unit": "usd",
              "label": "Collaboration profit sharing",
              "value": 317895000,
              "concept": "biib:CollaborationProfitSharing"
            },
            {
              "unit": "usd",
              "label": "Amortization of acquired intangible assets",
              "value": 202204000,
              "concept": "AmortizationOfIntangibleAssets"
            },
            {
              "unit": "usd",
              "label": "Fair value adjustment of contingent consideration",
              "value": 27202000,
              "concept": "biib:FairValueAdjustmentOfContingentConsideration"
            },
            {
              "unit": "usd",
              "label": "Restructuring Charges",
              "value": 2225000,
              "concept": "RestructuringCharges"
            },
            {
              "unit": "usd",
              "label": "Acquired in-process research and development",
              "value": 0,
              "concept": "biib:AcquiredInProcessResearchAndDevelopment"
            },
            {
              "unit": "usd",
              "label": "Cost and expenses:",
              "value": 3707404000,
              "concept": "CostsAndExpenses"
            },
            {
              "unit": "usd",
              "label": "Gain on Sale of Rights [Abstract]",
              "value": 46792000,
              "concept": "biib:GainOnSaleOfRights"
            },
            {
              "unit": "usd",
              "label": "Income from operations",
              "value": 1855849000,
              "concept": "OperatingIncomeLoss"
            },
            {
              "unit": "usd",
              "label": "Total other income (expense), net",
              "value": -744000,
              "concept": "OtherNonoperatingIncomeExpense"
            },
            {
              "unit": "usd",
              "label": "Income before income taxes (benefit):",
              "value": 1855105000,
              "concept": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"
            },
            {
              "unit": "usd",
              "label": "Income tax expense (benefit):",
              "value": 470554000,
              "concept": "IncomeTaxExpenseBenefit"
            },
            {
              "unit": "usd",
              "label": "Income (Loss) from Equity Method Investments",
              "value": -4518000,
              "concept": "IncomeLossFromEquityMethodInvestments"
            },
            {
              "unit": "usd",
              "label": "Net income",
              "value": 1380033000,
              "concept": "ProfitLoss"
            },
            {
              "unit": "usd",
              "label": "Net income (loss) attributable to noncontrolling interests, net of tax",
              "value": 0,
              "concept": "NetIncomeLossAttributableToNoncontrollingInterest"
            },
            {
              "unit": "usd/shares",
              "label": "Basic earnings per share attributable to Biogen Idec Inc.",
              "value": 5.8,
              "concept": "EarningsPerShareBasic"
            },
            {
              "unit": "usd/shares",
              "label": "Diluted earnings per share attributable to Biogen Idec Inc.",
              "value": 5.76,
              "concept": "EarningsPerShareDiluted"
            },
            {
              "unit": "shares",
              "label": "Weighted average number of common shares outstanding",
              "value": 237938000,
              "concept": "WeightedAverageNumberOfSharesOutstandingBasic"
            },
            {
              "unit": "shares",
              "label": "Shares used in calculating diluted earnings per share",
              "value": 239740000,
              "concept": "WeightedAverageNumberOfDilutedSharesOutstanding"
            }
          ]
        }
      },
      {
        "accessNumber": "0001193125-12-039072",
        "symbol": "BIIB",
        "cik": "875045",
        "year": 2011,
        "quarter": 0,
        "form": "10-K",
        "startDate": "2011-01-01 00:00:00",
        "endDate": "2011-12-31 00:00:00",
        "filedDate": "2012-02-03 00:00:00",
        "acceptedDate": "2012-02-03 17:19:40",
        "report": {
          "bs": [
            {
              "unit": "usd",
              "label": "Cash and cash equivalents",
              "value": 514542000,
              "concept": "CashAndCashEquivalentsAtCarryingValue"
            },
            {
              "unit": "usd",
              "label": "Marketable securities",
              "value": 1176115000,
              "concept": "MarketableSecuritiesCurrent"
            },
            {
              "unit": "usd",
              "label": "Accounts receivable, net current",
              "value": 584603000,
              "concept": "AccountsReceivableNetCurrent"
            },
            {
              "unit": "usd",
              "label": "Due from unconsolidated joint business",
              "value": 228724000,
              "concept": "biib:DueFromUnconsolidatedJointBusiness"
            },
            {
              "unit": "usd",
              "label": "Inventory",
              "value": 326843000,
              "concept": "InventoryNet"
            },
            {
              "unit": "usd",
              "label": "Other current assets",
              "value": 144600000,
              "concept": "OtherAssetsCurrent"
            },
            {
              "unit": "usd",
              "label": "Current assets:",
              "value": 2975427000,
              "concept": "AssetsCurrent"
            },
            {
              "unit": "usd",
              "label": "Marketable securities",
              "value": 1416737000,
              "concept": "MarketableSecuritiesNoncurrent"
            },
            {
              "unit": "usd",
              "label": "Property, plant and equipment, net",
              "value": 1571387000,
              "concept": "PropertyPlantAndEquipmentNet"
            },
            {
              "unit": "usd",
              "label": "Intangible assets, net",
              "value": 1608191000,
              "concept": "IntangibleAssetsNetExcludingGoodwill"
            },
            {
              "unit": "usd",
              "label": "Goodwill",
              "value": 1146314000,
              "concept": "Goodwill"
            },
            {
              "unit": "usd",
              "label": "Investments and other assets",
              "value": 331548000,
              "concept": "OtherAssetsNoncurrent"
            },
            {
              "unit": "usd",
              "label": "ASSETS",
              "value": 9049604000,
              "concept": "Assets"
            },
            {
              "unit": "usd",
              "label": "Current portion of notes payable, line of credit and other financing arrangements",
              "value": 3292000,
              "concept": "NotesPayableCurrent"
            },
            {
              "unit": "usd",
              "label": "Taxes payable",
              "value": 45939000,
              "concept": "TaxesPayableCurrent"
            },
            {
              "unit": "usd",
              "label": "Accounts payable",
              "value": 186448000,
              "concept": "AccountsPayableCurrent"
            },
            {
              "unit": "usd",
              "label": "Accrued expenses and other",
              "value": 677210000,
              "concept": "OtherLiabilitiesCurrent"
            },
            {
              "unit": "usd",
              "label": "Current liabilities:",
              "value": 912889000,
              "concept": "LiabilitiesCurrent"
            },
            {
              "unit": "usd",
              "label": "Long-term Notes Payable",
              "value": 1060808000,
              "concept": "LongTermNotesPayable"
            },
            {
              "unit": "usd",
              "label": "Long-term deferred tax liability",
              "value": 248644000,
              "concept": "DeferredTaxLiabilitiesNoncurrent"
            },
            {
              "unit": "usd",
              "label": "Other long-term liabilities",
              "value": 400276000,
              "concept": "OtherLiabilitiesNoncurrent"
            },
            {
              "unit": "usd",
              "label": "LIABILITIES AND EQUITY",
              "value": 2622617000,
              "concept": "Liabilities"
            },
            {
              "unit": "usd",
              "label": "Commitments and Contingencies",
              "value": "N/A",
              "concept": "CommitmentsAndContingencies"
            },
            {
              "unit": "usd",
              "label": "Preferred stock, par value $0.001 per share",
              "value": "N/A",
              "concept": "PreferredStockValue"
            },
            {
              "unit": "usd",
              "label": "Common stock, par value $0.0005 per share",
              "value": 128000,
              "concept": "CommonStockValue"
            },
            {
              "unit": "usd",
              "label": "Additional paid-in capital",
              "value": 4185048000,
              "concept": "AdditionalPaidInCapital"
            },
            {
              "unit": "usd",
              "label": "Accumulated other comprehensive income (loss)",
              "value": -26535000,
              "concept": "AccumulatedOtherComprehensiveIncomeLossNetOfTax"
            },
            {
              "unit": "usd",
              "label": "Retained earnings",
              "value": 3106761000,
              "concept": "RetainedEarningsAccumulatedDeficit"
            },
            {
              "unit": "usd",
              "label": "Treasury stock, at cost",
              "value": 839903000,
              "concept": "TreasuryStockValue"
            },
            {
              "unit": "usd",
              "label": "Equity:",
              "value": 6425499000,
              "concept": "StockholdersEquity"
            },
            {
              "unit": "usd",
              "label": "Stockholders' Equity Attributable to Noncontrolling Interest",
              "value": 1488000,
              "concept": "MinorityInterest"
            },
            {
              "unit": "usd",
              "label": "Equity:",
              "value": 6426987000,
              "concept": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"
            },
            {
              "unit": "usd",
              "label": "LIABILITIES AND EQUITY",
              "value": 9049604000,
              "concept": "LiabilitiesAndStockholdersEquity"
            }
          ],
          "cf": [
            {
              "unit": "usd",
              "label": "Net income",
              "value": 1266686000,
              "concept": "ProfitLoss"
            },
            {
              "unit": "usd",
              "label": "Depreciation and Amortization",
              "value": 358933000,
              "concept": "DepreciationAndAmortization"
            },
            {
              "unit": "usd",
              "label": "Acquired in-process research and development",
              "value": 0,
              "concept": "ResearchAndDevelopmentInProcess"
            },
            {
              "unit": "usd",
              "label": "Share-based compensation",
              "value": 113005000,
              "concept": "ShareBasedCompensation"
            },
            {
              "unit": "usd",
              "label": "Fair Value Adjustment Of Contingent Consideration",
              "value": 36065000,
              "concept": "biib:FairValueAdjustmentOfContingentConsideration"
            },
            {
              "unit": "usd",
              "label": "Excess tax benefit from share-based compensation",
              "value": 50586000,
              "concept": "ExcessTaxBenefitFromShareBasedCompensationOperatingActivities"
            },
            {
              "unit": "usd",
              "label": "Deferred income taxes",
              "value": 153576000,
              "concept": "DeferredIncomeTaxExpenseBenefit"
            },
            {
              "unit": "usd",
              "label": "Inventory Write-down",
              "value": 25446000,
              "concept": "InventoryWriteDown"
            },
            {
              "unit": "usd",
              "label": "Impairment Of Investments And Other Assets",
              "value": 8619000,
              "concept": "biib:ImpairmentOfInvestmentsAndOtherAssets"
            },
            {
              "unit": "usd",
              "label": "Non-cash interest (income) expense, foreign exchange remeasurement loss (gain), net and other",
              "value": 15671000,
              "concept": "OtherNoncashExpense"
            },
            {
              "unit": "usd",
              "label": "Gain (Loss) on Investments, Total",
              "value": 15062000,
              "concept": "GainLossOnInvestments"
            },
            {
              "unit": "usd",
              "label": "Accounts receivable",
              "value": 73374000,
              "concept": "IncreaseDecreaseInAccountsReceivable"
            },
            {
              "unit": "usd",
              "label": "Increase Decrease In Due From Unconsolidated Joint Business",
              "value": 6265000,
              "concept": "biib:IncreaseDecreaseInDueFromUnconsolidatedJointBusiness"
            },
            {
              "unit": "usd",
              "label": "Inventory",
              "value": 59219000,
              "concept": "IncreaseDecreaseInInventories"
            },
            {
              "unit": "usd",
              "label": "Other assets",
              "value": 43241000,
              "concept": "IncreaseDecreaseInOtherOperatingAssets"
            },
            {
              "unit": "usd",
              "label": "Accrued expenses and other current liabilities",
              "value": 33722000,
              "concept": "IncreaseDecreaseInAccruedLiabilities"
            },
            {
              "unit": "usd",
              "label": "Other liabilities and taxes payable",
              "value": -36235000,
              "concept": "IncreaseDecreaseInOtherOperatingLiabilities"
            },
            {
              "unit": "usd",
              "label": "Cash flows from operating activities:",
              "value": 1727741000,
              "concept": "NetCashProvidedByUsedInOperatingActivities"
            },
            {
              "unit": "usd",
              "label": "Proceeds from sales and maturities of marketable securities",
              "value": 2276720000,
              "concept": "ProceedsFromSaleAndMaturityOfMarketableSecurities"
            },
            {
              "unit": "usd",
              "label": "Purchases of marketable securities",
              "value": 3696995000,
              "concept": "PaymentsToAcquireMarketableSecurities"
            },
            {
              "unit": "usd",
              "label": "Acquisitions",
              "value": 5000000,
              "concept": "PaymentsToAcquireBusinessesNetOfCashAcquired"
            },
            {
              "unit": "usd",
              "label": "Purchases of property, plant and equipment",
              "value": 208020000,
              "concept": "PaymentsToAcquirePropertyPlantAndEquipment"
            },
            {
              "unit": "usd",
              "label": "Proceeds from the sale of property, plant and equipment",
              "value": 2207000,
              "concept": "ProceedsFromSaleOfPropertyPlantAndEquipment"
            },
            {
              "unit": "usd",
              "label": "Purchases of intangible assets",
              "value": 44155000,
              "concept": "PaymentsToAcquireIntangibleAssets"
            },
            {
              "unit": "usd",
              "label": "Purchases of other investments",
              "value": 16324000,
              "concept": "PaymentsToAcquireOtherInvestments"
            },
            {
              "unit": "usd",
              "label": "Proceeds from the sale of strategic investments",
              "value": 41273000,
              "concept": "ProceedsFromSaleOfEquityMethodInvestments"
            },
            {
              "unit": "usd",
              "label": "Cash flows from investing activities:",
              "value": -1650294000,
              "concept": "NetCashProvidedByUsedInInvestingActivities"
            },
            {
              "unit": "usd",
              "label": "Purchase of treasury stock",
              "value": 497975000,
              "concept": "PaymentsForRepurchaseOfCommonStock"
            },
            {
              "unit": "usd",
              "label": "Proceeds from issuance of stock for share-based compensation arrangements",
              "value": 314650000,
              "concept": "ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans"
            },
            {
              "unit": "usd",
              "label": "Excess tax benefit from share-based compensation",
              "value": 50586000,
              "concept": "ExcessTaxBenefitFromShareBasedCompensationFinancingActivities"
            },
            {
              "unit": "usd",
              "label": "Change in cash overdraft",
              "value": 2823000,
              "concept": "ProceedsFromRepaymentsOfBankOverdrafts"
            },
            {
              "unit": "usd",
              "label": "Payments For Acquisition Of Noncontrolling Interest",
              "value": 148264000,
              "concept": "biib:PaymentsForAcquisitionOfNoncontrollingInterest"
            },
            {
              "unit": "usd",
              "label": "Net distributions to noncontrolling interests",
              "value": 27062000,
              "concept": "PaymentsToMinorityShareholders"
            },
            {
              "unit": "usd",
              "label": "Repayments of borrowings",
              "value": 11459000,
              "concept": "RepaymentsOfShortTermDebt"
            },
            {
              "unit": "usd",
              "label": "Net Proceeds From Financing Arrangement For Sale Of Facility",
              "value": 0,
              "concept": "biib:NetProceedsFromFinancingArrangementForSaleOfFacility"
            },
            {
              "unit": "usd",
              "label": "Repayments On Financing Arrangement For Sale Of Facility",
              "value": 3161000,
              "concept": "biib:RepaymentsOnFinancingArrangementForSaleOfFacility"
            },
            {
              "unit": "usd",
              "label": "Cash flows from financing activities:",
              "value": -319862000,
              "concept": "NetCashProvidedByUsedInFinancingActivities"
            },
            {
              "unit": "usd",
              "label": "Cash and Cash Equivalents, Period Increase (Decrease)",
              "value": -242415000,
              "concept": "CashAndCashEquivalentsPeriodIncreaseDecrease"
            },
            {
              "unit": "usd",
              "label": "Effect of exchange rate changes on cash and cash equivalents",
              "value": -2641000,
              "concept": "EffectOfExchangeRateOnCashAndCashEquivalents"
            }
          ],
          "ic": [
            {
              "unit": "usd",
              "label": "Sales Revenue, Goods, Net",
              "value": 3836117000,
              "concept": "SalesRevenueGoodsNet"
            },
            {
              "unit": "usd",
              "label": "Unconsolidated Joint Business",
              "value": 996597000,
              "concept": "biib:UnconsolidatedJointBusiness"
            },
            {
              "unit": "usd",
              "label": "Other",
              "value": 215920000,
              "concept": "OtherSalesRevenueNet"
            },
            {
              "unit": "usd",
              "label": "Revenues:",
              "value": 5048634000,
              "concept": "Revenues"
            },
            {
              "unit": "usd",
              "label": "Cost of sales, excluding amortization of acquired intangible assets",
              "value": 466780000,
              "concept": "CostOfRevenue"
            },
            {
              "unit": "usd",
              "label": "Research and development",
              "value": 1219602000,
              "concept": "ResearchAndDevelopmentExpense"
            },
            {
              "unit": "usd",
              "label": "Selling, general and administrative",
              "value": 1056133000,
              "concept": "SellingGeneralAndAdministrativeExpense"
            },
            {
              "unit": "usd",
              "label": "Collaboration profit sharing",
              "value": 317771000,
              "concept": "biib:CollaborationProfitSharing"
            },
            {
              "unit": "usd",
              "label": "Amortization of acquired intangible assets",
              "value": 208566000,
              "concept": "AmortizationOfIntangibleAssets"
            },
            {
              "unit": "usd",
              "label": "Restructuring Charges",
              "value": 19026000,
              "concept": "RestructuringCharges"
            },
            {
              "unit": "usd",
              "label": "Cost and expenses:",
              "value": 3323943000,
              "concept": "CostsAndExpenses"
            },
            {
              "unit": "usd",
              "label": "Income from operations",
              "value": 1724691000,
              "concept": "OperatingIncomeLoss"
            },
            {
              "unit": "usd",
              "label": "Other income (expense), net",
              "value": -13477000,
              "concept": "OtherNonoperatingIncomeExpense"
            },
            {
              "unit": "usd",
              "label": "Total",
              "value": 1711214000,
              "concept": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"
            },
            {
              "unit": "usd",
              "label": "Income tax expense",
              "value": 444528000,
              "concept": "IncomeTaxExpenseBenefit"
            },
            {
              "unit": "usd",
              "label": "Net income",
              "value": 1266686000,
              "concept": "ProfitLoss"
            },
            {
              "unit": "usd",
              "label": "Net income (loss) attributable to noncontrolling interests, net of tax",
              "value": 32258000,
              "concept": "NetIncomeLossAttributableToNoncontrollingInterest"
            },
            {
              "unit": "usd",
              "label": "Net income (loss) attributable to noncontrolling interests, net of tax",
              "value": 1234428000,
              "concept": "NetIncomeLoss"
            },
            {
              "unit": "usd/shares",
              "label": "Basic earnings per share attributable to Biogen Idec Inc.",
              "value": 5.09,
              "concept": "EarningsPerShareBasic"
            },
            {
              "unit": "usd/shares",
              "label": "Diluted earnings per share attributable to Biogen Idec Inc.",
              "value": 5.04,
              "concept": "EarningsPerShareDiluted"
            },
            {
              "unit": "shares",
              "label": "Basic earnings per share attributable to Biogen Idec Inc.",
              "value": 242395000,
              "concept": "WeightedAverageNumberOfSharesOutstandingBasic"
            },
            {
              "unit": "shares",
              "label": "Shares used in calculating diluted earnings per share",
              "value": 245033000,
              "concept": "WeightedAverageNumberOfDilutedSharesOutstanding"
            },
            {
              "unit": "usd",
              "label": "Fair Value Adjustment Of Contingent Consideration",
              "value": 36065000,
              "concept": "biib:FairValueAdjustmentOfContingentConsideration"
            }
          ]
        }
      },
      {
        "accessNumber": "0000950123-11-009300",
        "symbol": "BIIB",
        "cik": "875045",
        "year": 2010,
        "quarter": 0,
        "form": "10-K",
        "startDate": "2010-01-01 00:00:00",
        "endDate": "2010-12-31 00:00:00",
        "filedDate": "2011-02-04 00:00:00",
        "acceptedDate": "2011-02-04 17:06:26",
        "report": {
          "bs": [
            {
              "concept": "biib_DueFromUnconsolidatedJointBusiness",
              "unit": "usd",
              "label": "Due from unconsolidated joint business",
              "value": 222459000.0
            },
            {
              "concept": "biib_TotalInventory",
              "unit": "usd",
              "label": "Total Inventory",
              "value": 289066000.0
            },
            {
              "concept": "us-gaap_AccountsPayableCurrent",
              "unit": "usd",
              "label": "Accounts payable",
              "value": 162529000.0
            },
            {
              "concept": "us-gaap_AccountsReceivableNetCurrent",
              "unit": "usd",
              "label": "Accounts Receivable, Net, Current",
              "value": 605329000.0
            },
            {
              "concept": "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax",
              "unit": "usd",
              "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
              "value": -21610000.0
            },
            {
              "concept": "us-gaap_AdditionalPaidInCapital",
              "unit": "usd",
              "label": "Additional paid-in capital",
              "value": 3895103000.0
            },
            {
              "concept": "us-gaap_Assets",
              "unit": "usd",
              "label": "Total assets",
              "value": 8092493000.0
            },
            {
              "concept": "us-gaap_AssetsCurrent",
              "unit": "usd",
              "label": "Total current assets",
              "value": 2540420000.0
            },
            {
              "concept": "us-gaap_CashAndCashEquivalentsAtCarryingValue",
              "unit": "usd",
              "label": "Cash and Cash Equivalents, at Carrying Value",
              "value": 759598000.0
            },
            {
              "concept": "us-gaap_CommonStockValue",
              "unit": "usd",
              "label": "Common stock, par value $0.0005 per share",
              "value": 124000.0
            },
            {
              "concept": "us-gaap_DeferredTaxLiabilitiesNoncurrent",
              "unit": "usd",
              "label": "Long-term deferred tax liability",
              "value": 200950000.0
            },
            {
              "concept": "us-gaap_Goodwill",
              "unit": "usd",
              "label": "Goodwill",
              "value": 1146314000.0
            },
            {
              "concept": "us-gaap_IntangibleAssetsNetExcludingGoodwill",
              "unit": "usd",
              "label": "Intangible assets, net",
              "value": 1772826000.0
            },
            {
              "concept": "us-gaap_Liabilities",
              "unit": "usd",
              "label": "Total liabilities",
              "value": 2643050000.0
            },
            {
              "concept": "us-gaap_LiabilitiesAndStockholdersEquity",
              "unit": "usd",
              "label": "Liabilities and Stockholders' Equity",
              "value": 8092493000.0
            },
            {
              "concept": "us-gaap_LiabilitiesCurrent",
              "unit": "usd",
              "label": "Total current liabilities",
              "value": 1050122000.0
            },
            {
              "concept": "us-gaap_LongTermNotesPayable",
              "unit": "usd",
              "label": "Long-term Notes Payable",
              "value": 1066379000.0
            },
            {
              "concept": "us-gaap_MarketableSecuritiesCurrent",
              "unit": "usd",
              "label": "Marketable securities",
              "value": 448146000.0
            },
            {
              "concept": "us-gaap_MarketableSecuritiesNoncurrent",
              "unit": "usd",
              "label": "Marketable securities",
              "value": 743101000.0
            },
            {
              "concept": "us-gaap_MinorityInterest",
              "unit": "usd",
              "label": "Stockholders' Equity Attributable to Noncontrolling Interest",
              "value": 52937000.0
            },
            {
              "concept": "us-gaap_NotesPayableCurrent",
              "unit": "usd",
              "label": "Notes Payable, Current",
              "value": 137153000.0
            },
            {
              "concept": "us-gaap_OtherAssetsCurrent",
              "unit": "usd",
              "label": "Other current assets",
              "value": 215822000.0
            },
            {
              "concept": "us-gaap_OtherAssetsNoncurrent",
              "unit": "usd",
              "label": "Investments and other assets",
              "value": 248198000.0
            },
            {
              "concept": "us-gaap_OtherLiabilitiesCurrent",
              "unit": "usd",
              "label": "Accrued expenses and other",
              "value": 665923000.0
            },
            {
              "concept": "us-gaap_OtherLiabilitiesNoncurrent",
              "unit": "usd",
              "label": "Other long-term liabilities",
              "value": 325599000.0
            },
            {
              "concept": "us-gaap_PreferredStockValue",
              "unit": "usd",
              "label": "Preferred stock, par value $0.001 per share",
              "value": 0.0
            },
            {
              "concept": "us-gaap_PropertyPlantAndEquipmentNet",
              "unit": "usd",
              "label": "Property, Plant and Equipment, Net",
              "value": 1641634000.0
            },
            {
              "concept": "us-gaap_RetainedEarningsAccumulatedDeficit",
              "unit": "usd",
              "label": "Retained earnings",
              "value": 1872481000.0
            },
            {
              "concept": "us-gaap_StockholdersEquity",
              "unit": "usd",
              "label": "Total Biogen Idec Inc. shareholders' equity",
              "value": 5396506000.0
            },
            {
              "concept": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
              "unit": "usd",
              "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest",
              "value": 5449443000.0
            },
            {
              "concept": "us-gaap_TaxesPayableCurrent",
              "unit": "usd",
              "label": "Taxes payable",
              "value": 84517000.0
            },
            {
              "concept": "us-gaap_TreasuryStockValue",
              "unit": "usd",
              "label": "Treasury stock, at cost",
              "value": 349592000.0
            }
          ],
          "ic": [
            {
              "concept": "biib_AcquiredInProcessResearchAndDevelopment",
              "unit": "usd",
              "label": "Acquired in-process research and development",
              "value": 244976000.0
            },
            {
              "concept": "biib_CollaborationProfitSharing",
              "unit": "usd",
              "label": "Collaboration profit sharing",
              "value": 258071000.0
            },
            {
              "concept": "biib_UnconsolidatedJointBusiness",
              "unit": "usd",
              "label": "Unconsolidated joint business",
              "value": 1077244000.0
            },
            {
              "concept": "us-gaap_AmortizationOfIntangibleAssets",
              "unit": "usd",
              "label": "Amortization of acquired intangible assets",
              "value": 208928000.0
            },
            {
              "concept": "us-gaap_CostOfRevenue",
              "unit": "usd",
              "label": "Cost of sales, excluding amortization of acquired intangible assets",
              "value": 400262000.0
            },
            {
              "concept": "us-gaap_CostsAndExpenses",
              "unit": "usd",
              "label": "Costs and Expenses",
              "value": 3467534000.0
            },
            {
              "concept": "us-gaap_EarningsPerShareBasic",
              "unit": "usdeps",
              "label": "Earnings Per Share, Basic",
              "value": 3.98
            },
            {
              "concept": "us-gaap_EarningsPerShareDiluted",
              "unit": "usdeps",
              "label": "Diluted earnings per share attributable to Biogen Idec Inc.",
              "value": 3.94
            },
            {
              "concept": "us-gaap_GainsLossesOnSalesOfAssets",
              "unit": "usd",
              "label": "Gains (Losses) on Sales of Assets",
              "value": -1643000.0
            },
            {
              "concept": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
              "unit": "usd",
              "label": "Income (Loss) from Continuing Operations before Income Taxes, Minority Interest, and Income (Loss) from Equity Method Investments",
              "value": 1229906000.0
            },
            {
              "concept": "us-gaap_IncomeTaxExpenseBenefit",
              "unit": "usd",
              "label": "Income Tax Expense (Benefit)",
              "value": 331333000.0
            },
            {
              "concept": "us-gaap_NetIncomeLoss",
              "unit": "usd",
              "label": "Net income attributable to Biogen Idec Inc.",
              "value": 1005273000.0
            },
            {
              "concept": "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest",
              "unit": "usd",
              "label": "Net Income (Loss) Attributable to Noncontrolling Interest",
              "value": -106700000.0
            },
            {
              "concept": "us-gaap_OperatingIncomeLoss",
              "unit": "usd",
              "label": "Income from operations",
              "value": 1248889000.0
            },
            {
              "concept": "us-gaap_OtherNonoperatingIncomeExpense",
              "unit": "usd",
              "label": "Other Nonoperating Income (Expense)",
              "value": -18983000.0
            },
            {
              "concept": "us-gaap_OtherSalesRevenueNet",
              "unit": "usd",
              "label": "Other revenues",
              "value": 169123000.0
            },
            {
              "concept": "us-gaap_ProfitLoss",
              "unit": "usd",
              "label": "Net income",
              "value": 898573000.0
            },
            {
              "concept": "us-gaap_ResearchAndDevelopmentExpense",
              "unit": "usd",
              "label": "Research and Development Expense",
              "value": 1248604000.0
            },
            {
              "concept": "us-gaap_RestructuringCharges",
              "unit": "usd",
              "label": "Restructuring Charges",
              "value": 75153000.0
            },
            {
              "concept": "us-gaap_Revenues",
              "unit": "usd",
              "label": "Revenues",
              "value": 4716423000.0
            },
            {
              "concept": "us-gaap_SalesRevenueGoodsNet",
              "unit": "usd",
              "label": "Sales Revenue, Goods, Net",
              "value": 3470056000.0
            },
            {
              "concept": "us-gaap_SellingGeneralAndAdministrativeExpense",
              "unit": "usd",
              "label": "Selling, general and administrative",
              "value": 1031540000.0
            },
            {
              "concept": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
              "unit": "shares",
              "label": "Diluted earnings per share attributable to Biogen Idec Inc.",
              "value": 254867000.0
            },
            {
              "concept": "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic",
              "unit": "shares",
              "label": "Basic earnings per share attributable to Biogen Idec Inc.",
              "value": 252307000.0
            }
          ],
          "cf": [
            {
              "concept": "biib_AcquisitionOfVariableInterestNet",
              "unit": "usd",
              "label": "Acquisition Of Variable Interest Net",
              "value": 84952000.0
            },
            {
              "concept": "biib_ImpairmentOfInvestmentsAndOtherAssets",
              "unit": "usd",
              "label": "Impairment Of Investments And Other Assets",
              "value": 20846000.0
            },
            {
              "concept": "biib_IncreaseDecreaseInDueFromUnconsolidatedJointBusiness",
              "unit": "usd",
              "label": "Increase Decrease In Due From Unconsolidated Joint Business",
              "value": 28670000.0
            },
            {
              "concept": "biib_NetProceedsFromFinancingArrangementForSaleOfSanDiegoFacility",
              "unit": "usd",
              "label": "Net proceeds from financing arrangement for the sale of the San Diego facility",
              "value": 126980000.0
            },
            {
              "concept": "biib_RepaymentsOnFinancingArrangementForSaleOfSanDiegoFacility",
              "unit": "usd",
              "label": "Repayments On Financing Arrangement For The Sale Of The San Diego facility",
              "value": 1175000.0
            },
            {
              "concept": "us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease",
              "unit": "usd",
              "label": "Cash and Cash Equivalents, Period Increase (Decrease)",
              "value": 185079000.0
            },
            {
              "concept": "us-gaap_DeferredIncomeTaxExpenseBenefit",
              "unit": "usd",
              "label": "Deferred income taxes",
              "value": -81410000.0
            },
            {
              "concept": "us-gaap_DepreciationAndAmortization",
              "unit": "usd",
              "label": "Depreciation and amortization of fixed and intangible assets",
              "value": 354101000.0
            },
            {
              "concept": "us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents",
              "unit": "usd",
              "label": "Effect of Exchange Rate on Cash and Cash Equivalents",
              "value": -7370000.0
            },
            {
              "concept": "us-gaap_ExcessTaxBenefitFromShareBasedCompensationFinancingActivities",
              "unit": "usd",
              "label": "Excess Tax Benefit from Share-based Compensation, Financing Activities",
              "value": 13136000.0
            },
            {
              "concept": "us-gaap_ExcessTaxBenefitFromShareBasedCompensationOperatingActivities",
              "unit": "usd",
              "label": "Excess Tax Benefit from Share-based Compensation, Operating Activities",
              "value": 13136000.0
            },
            {
              "concept": "us-gaap_GainLossOnInvestments",
              "unit": "usd",
              "label": "Gain (Loss) on Investments",
              "value": 16321000.0
            },
            {
              "concept": "us-gaap_GainsLossesOnSalesOfAssets",
              "unit": "usd",
              "label": "Gains (Losses) on Sales of Assets",
              "value": -1643000.0
            },
            {
              "concept": "us-gaap_IncreaseDecreaseInAccountsReceivable",
              "unit": "usd",
              "label": "Accounts receivable",
              "value": 99227000.0
            },
            {
              "concept": "us-gaap_IncreaseDecreaseInAccruedLiabilities",
              "unit": "usd",
              "label": "Accrued expenses and other current liabilities",
              "value": 130875000.0
            },
            {
              "concept": "us-gaap_IncreaseDecreaseInInventories",
              "unit": "usd",
              "label": "Increase (Decrease) in Inventories",
              "value": 4527000.0
            },
            {
              "concept": "us-gaap_IncreaseDecreaseInOtherOperatingAssets",
              "unit": "usd",
              "label": "Other assets",
              "value": 12584000.0
            },
            {
              "concept": "us-gaap_IncreaseDecreaseInOtherOperatingLiabilities",
              "unit": "usd",
              "label": "Other liabilities and taxes payable",
              "value": 17692000.0
            },
            {
              "concept": "us-gaap_InventoryWriteDown",
              "unit": "usd",
              "label": "Write-down of inventory to net realizable value",
              "value": 11808000.0
            },
            {
              "concept": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
              "unit": "usd",
              "label": "Net Cash Provided by (Used in) Financing Activities",
              "value": -1784919000.0
            },
            {
              "concept": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
              "unit": "usd",
              "label": "Net Cash Provided by (Used in) Investing Activities",
              "value": 345325000.0
            },
            {
              "concept": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
              "unit": "usd",
              "label": "Net cash flows provided by operating activities",
              "value": 1624673000.0
            },
            {
              "concept": "us-gaap_OtherNoncashExpense",
              "unit": "usd",
              "label": "Non-cash interest (income) expense and foreign exchange remeasurement loss (gain), net",
              "value": 5808000.0
            },
            {
              "concept": "us-gaap_PaymentsForRepurchaseOfCommonStock",
              "unit": "usd",
              "label": "Purchase of treasury stock",
              "value": 2077579000.0
            },
            {
              "concept": "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired",
              "unit": "usd",
              "label": "Payments to Acquire Businesses, Net of Cash Acquired",
              "value": 72476000.0
            },
            {
              "concept": "us-gaap_PaymentsToAcquireMarketableSecurities",
              "unit": "usd",
              "label": "Purchases of marketable securities",
              "value": 1988394000.0
            },
            {
              "concept": "us-gaap_PaymentsToAcquireOtherInvestments",
              "unit": "usd",
              "label": "Purchases of other investments",
              "value": 4492000.0
            },
            {
              "concept": "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment",
              "unit": "usd",
              "label": "Purchases of property, plant and equipment",
              "value": 173055000.0
            },
            {
              "concept": "us-gaap_PaymentsToMinorityShareholders",
              "unit": "usd",
              "label": "Payments to Noncontrolling Interests",
              "value": 23475000.0
            },
            {
              "concept": "us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans",
              "unit": "usd",
              "label": "Proceeds from issuance of stock for share-based compensation arrangements",
              "value": 183486000.0
            },
            {
              "concept": "us-gaap_ProceedsFromRepaymentsOfBankOverdrafts",
              "unit": "usd",
              "label": "Change in cash overdraft",
              "value": 11781000.0
            },
            {
              "concept": "us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities",
              "unit": "usd",
              "label": "Proceeds from Sale and Maturity of Marketable Securities",
              "value": 2668694000.0
            },
            {
              "concept": "us-gaap_ProfitLoss",
              "unit": "usd",
              "label": "Net income",
              "value": 898573000.0
            },
            {
              "concept": "us-gaap_RepaymentsOfShortTermDebt",
              "unit": "usd",
              "label": "Repayments of Short-term Debt",
              "value": 18073000.0
            },
            {
              "concept": "us-gaap_ResearchAndDevelopmentInProcess",
              "unit": "usd",
              "label": "Research And Development In Process",
              "value": 271376000.0
            },
            {
              "concept": "us-gaap_ShareBasedCompensation",
              "unit": "usd",
              "label": "Share-based compensation",
              "value": 167826000.0
            }
          ]
        }
      }
    ],
    "symbol": "BIIB"
  }
}